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Throughout this project I learnt more about pregnancy and the hypertensive 
diseases associated with it; the physiology, the pathology, the potential. I had the 
privilege of working with clinical specialists and scientists, as well as many women 
experiencing pregnancy but I also became a mother myself. 
















Pre-eclampsia is a disease unique to pregnancy. Prevalence in the UK is between 5-
8% of pregnancies yet diagnosis remains challenging. The PELICAN study was a 
multi-centre, observational cohort study. The primary aim was to evaluate the 
diagnostic accuracy of plasma placental growth factor (PlGF) in the second half of 
pregnancy, in predicting the need for delivery for pre-eclampsia within 14 days of 
testing. 649 women presenting with suspected pre-eclampsia were recruited 
between January 2011 and February 2012, across seven consultant-led units within 
England and Ireland. Blood samples were taken at enrolment; PlGF measurements 
were performed but results blinded until the study was complete and diagnoses and 
pregnancy outcome known. A further 47 biomarkers were measured (using 57 
assays) to evaluate whether the diagnostic potential of PlGF could be improved 
further.  
 
Using a pre-specified cut off of <5th centile, a low (>12pg/ml < 5th centile) or very low 
(<12pg/ml) PlGF concentration was shown to have high sensitivity (0.95 CI (0.89-
0.99) in women <35 weeks’ gestation) to determine need for delivery within 14 days. 
When compared with other biologically plausible biomarkers, the area under the 
ROC curve for low or very low PlGF (0.87, standard error 0.03), was greater than all 
other commonly utilised tests either singly or in combination (range 0.58–0.76; 
p<0.001 for all comparisons). Data from 100 women were then used to perform a 
budget impact analysis. A hypothetical decision analytical model using data 
extracted from case note review and reference cost tariffs, suggested a mean cost 
saving associated with the PlGF test (in the PlGF plus management arm) of £35,087 
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(95% CI -£33,181 to -£36,992) per 1,000 women, equating to a saving of £582 (95% 
CI -£552 to -£613) per woman tested. 
 
PlGF testing could be used to risk-stratify women with suspected pre-eclampsia with 
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Hypertensive disorders of pregnancy affect around 15% of pregnant women 
(≈120,000 women per year in UK). (W or ld Heal th  Organizat ion,  2013 ) Pre-
eclampsia is characterised by hypertension and other features of multi-organ 
disease, including proteinuria, liver derangement or renal damage and complicates 
around 5% of all pregnancies. (Levine et al., 2004) Pre-eclampsia is associated with 
increased serious maternal morbidity and is the leading cause of iatrogenic preterm 
birth, responsible for substantial neonatal mortality and morbidity. 
 
Current diagnosis and risk stratification of women presenting with suspected disease 
is subject to considerable test and observer error (Conde-Agudelo et al., 2004a). 
Recent improvements in understanding of the biological roles of placentally-derived 
angiogenic/anti-angiogenic factors in pre-eclampsia and fetal growth restriction has 
led to their development as potential diagnostic biomarkers, including at point of 
care, in suspected disease. The PELICAN study was designed to test the hypothesis 
that abnormally low PlGF concentrations are associated with pre-eclampsia requiring 
delivery within 14 days and the primary findings of that study are discussed in this 
thesis. 
 
In chapter one, the need for improved clinical assessment tools is demonstrated by 
showing the scale of the problem and the impact of pre-eclampsia in both developed 
and low resource settings. Current definitions are set out and the underlying 
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pathophysiological theories are explored, to highlight the need for a point of care test 
based on disease aetiology. PlGF is compared with current surveillance tools, as 
well as other relevant biomarker targets, identified following an extensive literature 
review. 
 
The PELICAN study further provided the opportunity to supplement data from the 
literature with actual resource use to calculate the cost of current practice and to 
model the savings if PLGF were used in management decisions. A proportion of 
these women also completed a patient questionnaire-style survey, with the aim of 
producing a Patient Reported Outcome Measure, to assist clinician awareness of the 
emotional and practical difficulties that the monitoring and uncertainty of this disease 
places on women and their families. 
 
1.1.2 Pre-eclampsia: the scale of the problem 
Pre-eclampsia complicates 3-8% of all pregnancies (Redman et al., 2014) and is a 
serious complication of the second half of pregnancy, labour and the early postnatal 
period. In high-income settings, it accounts for the majority of iatrogenic pre-term 
delivery (Steegers et al., 2010b) and between 2006 and 2009, 19 women died as a 
direct consequence of the disease in the UK. (Knight et al., 2014) Up to 15% of 
pregnant women present with gestational hypertension (Hall et al., 1980) with around 
a third of those going on to develop pre-eclampsia (Saudan et al., 1998). Once in the 
antenatal day unit for assessment, most women undergo a series of blood tests 
(creatinine, liver transaminases, uric acid and platelet count) along with fetal 




Pre-eclampsia remains a global health problem. Worldwide, pre-eclampsia is the 
second commonest cause of maternal mortality (Kassebaum et al., 2014) and an 
important cause of fetal growth restriction, accounting for a quarter of very low birth 
weight infants (Shennan et al., 2001). It has been estimated that hypertensive 
diseases of pregnancy are associated with about 20% of intrapartum and 10% of 
antepartum stillbirths and 6% of neonatal deaths. (Lawn et al., 2011) The sequelae 
of pre-eclampsia lead to approximately 60,000 maternal deaths per year (Stokowski, 
2005) worldwide. In high-income countries, the risk of death is between 0% and 
1.8% whereas, in low resource settings, that figure rises to 15%. (Staff et al., 2013a) 
In addition, more than three million neonatal deaths occur as a result. (Friberg et al., 
2010). There is an obvious need for an accurate predictive test aligned with effective 
preventative treatments. 
 
In the UK, diagnostic uncertainty and imperfect risk stratification leads to treatment 
delays or over-management and high costs for an already over-stretched health 
service. In addition to adverse outcomes, our current imperfect tests for evaluating 
women with suspected pre-eclampsia lead to repeated antenatal monitoring and in-
patient admissions. This can lead to substantial emotional stress for the women involved, 
as well as placing a financial burden on pregnant women and their families because of 
hospital attendance. (Hadker et al., 2010) Pre-eclampsia is estimated to account for 
one-fifth of antenatal admissions and two-thirds of referrals to day assessment units. 
(Rosenberg and Twaddle, 1990) Improvements in confirmation of diagnosis have the 
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potential to improve clinical outcomes and significantly reduce costs, to women as 
well as the health service, by directing resources to women most at need. 
 
1.2 Associated morbidity and mortality 
1.2.1 Short-term fetal complications 
Pre-eclampsia has the potential to cause life-limiting complications for mother, baby, 
or both. (Redman and Sargent, 2009) Hypertensive disorders of pregnancy are 
associated with poor outcomes. (Sibai, 2006) Early, intrauterine risks for the baby 
include poor growth and prematurity (Sibai, 2006), leading to infants being born with 
complications of prematurity or small for gestational age and contributing to an 
increased risk of perinatal death. As a result, in low and middle income countries, 
limited access to neonatal intensive care means mortality and morbidity is 
considerably higher than in settings where such facilities are available. (Duley, 2009) 
With gestational age and weight at delivery being the most important predictors 
(Withagen et al., 2005) of adverse outcome for the baby, preterm delivery and 
growth restriction following pre-eclampsia are important causes of perinatal 
complications. 
 
Hypertension (with/ without additional features of pre-eclampsia) is the leading single 
identifiable risk factor in pregnancy associated with stillbirth (one in five stillbirths in 
otherwise viable babies) (Centre for Maternal and Child Enquiries (CMACE), 2011). 
A multinational study exploring the impact of being born premature in low and middle 
income countries reported that the relative risk of neonatal mortality was 6.82 (CI 
1.32 to 2.5). If the baby was also small for gestational age, the risk rose to 15.42 (CI 
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9.11 to 16.12). (Katz et al., 2013) Worldwide, pre-eclampsia is associated with a 
10% perinatal and neonatal death rate, (Altman et al., 2002) most commonly due to 
premature delivery, carried out to preserve the life of the mother. 
 
1.2.2 Short term maternal complications 
Over half a million women die each year from pregnancy related causes, 99% of 
whom are in low and middle income countries. (Duley, 2009) The Millennium 
Development Goals (www.un.org) have prioritised maternal health within the struggle 
against poverty and inequality, yet 10% to 15% of direct maternal deaths are 
associated with preeclampsia and eclampsia. (Duley, 2009) Most deaths are 
attributable to eclampsia, a rare but important complication associated with 
approximately 1 in 2000 deliveries in Europe. (von Dadelszen et al., 2011a) Pre-
eclampsia can affect the brain, kidneys, clotting system and liver, which can lead to 
haemolysis, elevated liver enzymes, low platelets (HELLP syndrome). Approximately 
1% of women with HELLP syndrome will die in the perinatal period, even in high 
income settings (Sibai et al., 1993) and a greater proportion will experience life 
threatening sequelae, such as disseminated intravascular coagulopathy, acute renal 
failure, retinal detachment or pulmonary oedema. 
 
1.2.3 Long term baby complications 
Placental insufficiency (associated with pre-eclampsia), places the infant at 
increased risk of being born growth restricted, which has implications for long-term 
health. Not only has it been suggested to be the highest attributable cause of 
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stillbirth in high income countries (Lawn et al., 2011) but it is also associated with 
increased incidence of respiratory distress syndrome, intraventricular haemorrhage, 
necrotising enterocolitis (McIntire et al., 1999) and seizures (Bukowski et al., 2003) 
within the perinatal period. Disadvantage also extends into childhood and later life: a 
reported increased risk of cerebral palsy, by up to seven-fold, (Jacobsson et al., 
2008) has been linked to placental disease, as well as lower intelligence, behavioural 
problems and poor social skills. (Gray et al., 1996) Several studies have also 
suggested a higher incidence of coronary heart disease and hypertension in adults 
who experienced early in utero placental deficiency or growth restriction. (Bonamy et 
al., 2011) (Huxley et al., 2000) 
 
1.2.4 Long term maternal complications 
Pre-eclampsia usually ends when the placenta is delivered but risk of long-term 
cardiovascular disease, perhaps due to a shared pathophysiology, persists in 
mothers. Approximately 20% of women with pre-eclampsia develop hypertension 
within seven years of their pregnancy, compared with only 2% of women following a 
normotensive pregnancy. (Nisell et al., 1995) A large, Norwegian study, following 
over 600,000 parents for a median of 13 years after delivery, found reduced survival 
in women who had been diagnosed with pre-eclampsia during their pregnancy (with 
no significant increase in mortality of fathers). Women who had pre-term deliveries 
with pre-eclampsia, had a 2.71 fold higher risk of death and this rose to 8.12 fold in 
those with a cardiovascular cause of death (CI 4.31 to 15.33). An increased risk of 
early mortality persisted in women who had a term pre-eclamptic delivery but was 
marginal in women with a healthy pre-term delivery. (Irgens et al., 2001) Studies in 
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other populations corroborate these findings that pre-eclampsia infers an increased 
risk of future cardiovascular disease and death in women, despite post-natal 
normotension. (Funai et al., 2005) Pre-eclampsia also predisposes women to 
develop end-stage renal disease in later life. (Vikse et al., 2006) 
 
In summary, women with previous pre-eclampsia are more likely to develop 
cardiovascular disease later in life (Mosca et al., 2011) and this association is more 
profound in women who develop the pre-eclampsia at earlier gestations (Melchiorre 
et al., 2011). However, pre-eclampsia does not only increase the risk of pervasive 
physical ill health: the combination of experiencing a serious illness, possible 
emergency intervention or unplanned delivery of a premature or disabled child has 
obvious psychological consequences for mother, including depression, tocophobia 
and post-traumatic stress disorder. (van Pampus et al., 2004) A Dutch study, 
investigating women following pre-eclampsia and/or HELLP syndrome, found that 
psychological therapy (psycho-education, eye movement desensitisation, support 
techniques) improved coping strategies in this cohort. (Poel et al., 2009) The 
researchers affirm the importance of timely diagnosis and suggest that it can shorten 
duration of required therapeutic support. 
 
1.2.5 Pre-eclampsia: historical context 
The following account of pre-eclampsia at 24 weeks’ gestation, documented in 1914, 
suggests little progress in diagnosis and management over the last century. It is 
notable that the diagnosis of pre-eclampsia was made on the findings of 
hypertension and proteinuria in 1914 and that these remain the NICE criteria for 
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diagnosis in 2015, despite the considerable amount of research into the 
pathophysiology of the disorder.  
 
 
Taken from Bonney MS, ‘A case of pre-eclampsia at the twenty-fourth week’ 
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1.3 Defining hypertensive disorders of pregnancy 
Pre-eclampsia was first described over 2000 years ago; Hippocrates warned of the 
combination of headaches, heaviness and convulsions in pregnant women 
associated with a dry uterus. At that time, treatment strategies focussed on releasing 
excess ‘humor’ through a variety of mechanisms including purging and blood-
letting.(Bell, 2010) Throughout the 19th century, more theories emerged as to the 
underlying pathophysiology, with physicians and scientists acknowledging the 
prodromal syndrome as distinct from the seizure activity of eclampsia. In the 1500s, 
Fallopius first described the female pelvic anatomy and identified the placenta was 
only found in the gravid uterus,(Bell, 2010) yet it took another century until eclampsia 
was described in the literature and primigravid women suggested to be at increased 
risk. Today, the exact mechanisms of disease remain elusive, yet the disease claims 
more than 60,000 maternal lives worldwide annually. (World Health Organization, 
2013) 
 
Classically, pre-eclampsia has been defined as new hypertension of over 140/90 
mmHg and proteinuria >0.3g/24 hours after 20 weeks’ gestation. (National Institute 
for Health and Clinical Excellence, 2010) In recent years, concerns have been raised 
that this relatively narrow definition (in which only proteinuria is the additional feature 
required to make the diagnosis of pre-eclampsia) could lead to inadequacies in 
diagnosis and risk delayed intervention. (Brown et al., 2001) For the purposes of this 
thesis, we adopted the extended definition of pre-eclampsia (American College of 
Obstetricians and Gynaecologists (ACOG)/ International Society for the Study of 
Hypertension in Pregnancy (ISSHP)) in which other multi-organ features of the 
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disease (see below) may be utilised to make a pre-eclampsia diagnosis. (Brown et 
al., 2001) The international consensus has been to adopt these definitions, as they 
appear to reflect the clinical situation more closely: 
 
American College of Obstetricians and Gynaecologists’ (ACOG) definition 
Pre-eclampsia: Raised BP (>140 systolic or 90 diastolic) after 20 weeks’ gestation 
with proteinuria (>300mg over 24 hours) or any of the following features of severe 
pre-eclampsia: 
 Severe hypertension (>160/>110) 
 Thrombocytopaenia 
 Impaired liver function or persistent right upper quadrant or epigastric pain 
 New renal insufficiency or doubling of creatinine in the absence of renal 
disease 
 Pulmonary oedema 
 New cerebral or visual disturbances 
 
Gestational hypertension: Raised BP after 20 weeks’ gestation in the absence of 
proteinuria or any features of severe pre-eclampsia 
 




Chronic hypertension with superimposed pre-eclampsia: Chronic BP in association 
with pre-eclampsia 
 
International Society for the Study of Hypertension in Pregnancy (ISSHP) 
definition 
Pre-eclampsia: de novo hypertension in the presence of proteinuria (>30mg/mmol, 
>300mg/day, >2+ on dipstick) and/or maternal organ dysfunction (renal insufficiency 
with creatinine >90umol/l, liver derangement, neurological symptoms or 
haematological complications such as thrombocytopaenia or haemolysis) and/or 
fetal growth restriction.  
 
Gestational hypertension: de novo hypertension (>140/90mmHg) after 20 weeks’ 
gestation without proteinuria, other features of pre-eclampsia or evidence of utero-
placental dysfunction (fetal growth restriction) 
 
Chronic hypertension: hypertension that pre-dates pregnancy. Practically, this may 
include hypertension recorded during the first trimester. 
 
Chronic hypertension with superimposed pre-eclampsia: Essential hypertension with 
one of the above features of pre-eclampsia 
 
National Institute of Clinical Excellence 
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Pre-eclampsia: new hypertension presenting after 20 weeks’ gestation with 
significant proteinuria. 
 
Severe pre-eclampsia: pre-eclampsia with severe hypertension and/or with 
symptoms, and/or biochemical and/or haematological impairment 
 
Gestational hypertension: new hypertension presenting after 20 weeks without 
significant proteinuria 
 
Chronic hypertension: hypertension present at the booking visit or before 20 weeks 
or if the woman is already taking anti-hypertensive medication when referred to 
maternity services. It can be primary of secondary. 
 
1.3.1 Epidemiology of pre-eclampsia 
Previous studies have reported that approximately half of multiparous women 
diagnosed with pre-eclampsia have a history of the disease. (Seed et al., 2011) Their 
risk doubles if the previous pre-eclampsia was early onset or required delivery before 
32 weeks’ gestation. (Bramham et al., 2011) Nulliparity, maternal age over 40 years 
and obesity (>80kg in first trimester) (Duckitt and Harrington, 2005) are recognised 
risk factors, which may contribute to the secular increases in chronic hypertension, 
gestational hypertension and severe pre-eclampsia in recent years. (Ananth et al., 
2013) Despite an increasing research focus on hypertensive disorders in pregnancy 
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over the last decade (including preventative strategies), pre-eclampsia rates have 
remained stable. 
 
An overall decline in eclampsia in the western world in recent years (Hutcheon et al., 
2011) likely results from improved antenatal awareness and use of prophylactic 
treatments (such as magnesium sulphate), highlighting the value of ongoing 
research in this area. A retrospective study of over 1200 women between 1931 and 
1990 suggests a 90% decline in the incidence of eclampsia (particularly antenatal 
and intra-partum) over this period, which has also resulted in a drop in associated 
mortality: perinatal death has dropped and there were no eclampsia-related maternal 
deaths after 1964. (Leitch et al., 1997) A large prospective study of over 210,000 
women diagnosed with either severe pre-eclampsia or eclampsia between 1999 and 
2003 found only 82 women had eclamptic seizures, with no maternal deaths. Over 
half of the seizures occurred antenatally, prior to hospital presentation. (Tuffnell et 
al., 2005) This study supports the use of regional clinical management guidelines to 
prevent serious adverse outcome. 
 
The figure below shows the rate of pre-eclampsia in the United States between 1980 
and 2010; total cases and number of pregnancies with mild pre-eclampsia have 
remained stable over this period, but cases of severe pre-eclampsia have risen from 






Figure 1.1: Temporal changes in rates of pre-eclampsia in the United States 1980-2010 
(taken from (Ananth et al., 2013) 
 
1.3.2 Current management 
1.3.2.1 Primary prevention 
Low dose aspirin has been shown to reduce pre-eclampsia, stillbirth and serious 
adverse outcome. A meta-analysis of over 30,000 women recruited to 31 studies 
found that women taking anti-platelet therapy had a lower relative risk (RR 0.90 
(95% CI 0.84–0.97)) of developing pre-eclampsia and of delivering prior to 34 weeks’ 
gestation (RR 0.90; 0.83–0.98). (Askie et al., 2007) This review also reported a 14% 




In a contradictory manner, exercise and rest have both been associated with 
hypertensive disease outside of pregnancy. (van Duijnhoven et al., 2010) However, 
data relating to this association within pregnancy are sparse. A Cochrane review 
suggests that rest, for up to four hours a day, can reduce pre-eclampsia developing 
in normotensive, high risk women. (Duley et al., 2006) The same review concluded 
there was no clear direction as to appropriate dietary advice to protect against pre-
eclampsia, including reduced salt intake or low fat diets. 
 
1.3.2.2 Secondary prevention 
The most recent Cochrane meta-analysis to assess the effects of antihypertensive 
drug treatments for women with mild to moderate hypertension during pregnancy 
concluded that ‘it remains unclear whether antihypertensive drug therapy for mild to 
moderate hypertension during pregnancy is worthwhile’, (Abalos et al., 2014) 
although there is consensus that antihypertensive medication should be given to 
women with severe hypertension to prevent ongoing high blood pressures. (Brown et 
al., 2000). It is unclear whether antihypertensive treatment reduces adverse outcome 
or makes a woman less likely to develop pre-eclampsia. The recent Control of 
Hypertension in Pregnancy Study (CHIPS) trial confirmed that ‘tight’ blood pressure 
control reduces episodes of severe hypertension without any adverse effects on fetal 
growth. (Magee et al., 2015). 
 
Anticonvulsants are used with the aim of preventing eclamptic seizures. The 
MAGPIE Trial included data from over 10,000 women, with blood pressure >140/90 
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and >1+ proteinuria, who were randomised to either receive magnesium sulphate or 
placebo. Women who received magnesium had a 58% lower risk of suffering 
eclampsia. (Altman et al., 2002) Maternal morbidity was also lower in this cohort. 
Overall, the trial identified a halving in the risk of developing eclampsia, with 
improved maternal outcomes, without proven risk to the baby, leading to widespread 
use of magnesium sulphate in high risk women across the United Kingdom (and 
worldwide). These findings are summarised in the forest plot below. 
 






1.4 Pathophysiology of pre-eclampsia 
Pre-eclampsia is a multi-factorial, multi-stage (Chaiworapongsa et al., 2013c) 
condition and its exact pathophysiology has been the subject of decades of 
research. We now have a better understanding of the disease syndrome and how 
this process can be used to develop improved diagnostic adjuncts. 
 
Most theories now focus on the ischaemic placenta, which is considered to release 
bioactive factors into the maternal circulation in response to hypoxia. In turn this is 
followed by multi-organ clinical manifestations of the disease. The only curative 
action remains delivery of the placenta (irrespective of the fetus). In the early 1900s, 
animal studies demonstrated seizures and liver damage in guinea pigs injected with 
placental tissue from women who had died of eclampsia.(Young, 1914) These 
studies were later supported by evidence that reducing aortic blood flow to the uterus 
of pregnant dogs produced signs of pre-eclampsia, which resolved with removal of 
the aortic clamp. Interestingly, this phenomenon was not reproduced in non-pregnant 
dogs or dogs post-hysterectomy. (Chaiworapongsa et al., 2014a) This phenomenon 





Figure 1.3: Schematic of effects of reducing uterine blood flow in pregnant and non-
pregnant dogs: Clamping of the renal artery led to hypertension in dogs, whereas 
clamping of the aorta only led to hypertension in pregnant dogs: no hypertension was 
seen in dogs without a gravid uterus or those who had undergone hysterectomy. 
Taken from (Chaiworapongsa et al., 2014a) 
 
 
1.4.1 Normal placental development 
Effective placentation necessitates fetal villous invasion into the maternal uterine 
decidua. This process is supported by the trophoblast, which consists of two layers: 
the inner single nucleated cytotrophoblast and the outer multinucleated continuous 
syncytiotrophoblast that forms the interface between the developing fetal vessels 
and the maternal circulation. This takes place between 8 and 18 weeks’ gestation, 
resulting in cytotrophoblast remodelling of the maternal spiral arteries. (Ashton et al., 
2005) This remodelling is aided by uterine natural killer cells and results in loss of 
maternal artery smooth muscle and collagen matrix and the development of new 
fibrinoid material, to allow sufficient maternal blood flow to the placenta and support 
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a developing fetus. (Redman and Sargent, 2009). Pressure and pulsatility are 
reduced to optimise maternal-fetal exchange. (Burton et al., 2009) 
 
Haemodynamic changes occur in normal pregnancy: sodium and water retention 
increases plasma volume by nearly 50%, (Faupel-Badger et al., 2007) raising 
cardiac output and stroke volume. Despite this, in a healthy pregnancy, reduced 
peripheral vascular resistance means blood pressure drops by the first trimester and 
often remains lowered throughout (relative to the non-pregnant state). This process 
is reversed in pre-eclampsia; a generally vasoconstricted state leads to increased 
arterial blood pressure and low cardiac output. (Maynard and Karumanchi, 2011) 
The plasma-extended state is dependent on the normal functioning of maternal 
endothelium and immune interactions. Measuring blood pressure is a non-invasive 
screening test, used antenatally and during labour, to alert clinicians of the possibility 
of pre-eclampsia. However, Doppler studies suggest (Noori et al., 2010) that uterine 
vascular resistance is significantly raised before a measureable increase in blood 
pressure can be detected by the clinician. 
 
1.4.2 Poor placentation 
In pre-eclampsia, inadequate trophoblast invasion leads to diminished dilatation of 
spiral arteries and an inadequately perfused placenta. Smooth muscle cells persist 
within the spiral arteries (Lim et al., 1997) causing impaired blood flow and reduced 
maternal acceptance of the fetal trophoblast. (Redman et al., 2014) These poorly 
adapted spiral arteries may develop atherosclerosis, causing impaired blood flow 
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and thombus formation (Staff et al., 2014) which further compromises placental 
blood supply and, therefore, impedes fetal growth. The figure below shows a healthy, 
dilated spiral artery, with trophoblasts extending into the myometrium, in comparison 
with a narrowed, poorly developed artery of pre-eclampsia, with inadequate 
trophoblast invasion. 
 
Figure 1.4: Figure showing altered modelling of spiral arteries in pre-eclampsia 
Taken from (Chaiworapongsa et al., 2014a) 
 
Such disruption of flow leads to oxidative stress (Burton and Jauniaux, 2011) and a 
generalised systemic inflammatory response, causing abnormal cellular 
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development (Staff et al., 2013c) consistent with hypoxic injury. Reactive oxygen 
species can overwhelm mammalian natural defences. Resultant oxidative stress 
occurs due to increased production of superoxides in the presence of reduced anti-
oxidants. (Chappell et al., 1999) Additional evidence of inadequate antioxidant 
defence in women with pre-eclampsia includes reduced blood mRNA encoding 
haemoxygenases, catalase and superoxide dismutase (antioxidant enzymes) in 
women with pre-eclampsia compared with healthy controls. (Nakamura et al., 2009) 
An overview of the mechanism underlying the placental contribution to pre-eclampsia 
is shown in the figure below. 
 





In summary, the placenta plays a vital role in the development of pre-eclampsia but 
the process is complex. The underlying pathophysiology takes place before the 
outward clinical features develop. In the first trimester, inadequate fetal villous 
invasion sets up compromised maternal-fetal blood flow and inadequate spiral artery 
remodelling. This leads to laminar flow, artery atherosclerosis and 
hypoxia/reperfusion injury. The combined effect is a poorly functioning placenta, an 
inflammatory oxidative stress response and systemic effects of pre-eclampsia. 
(Walker, 2000) Poor placental invasion can, however, exist in the absence of any 
features of pre-eclampsia, (Brosens, 2011) meaning additional factors must 
contribute to the development of the maternal syndrome. Indeed, inappropriate 
placentation and maladapted spiral arteries can be seen in women with placental 
abruption (Tikkanen, 2011) and fetal growth restriction. (Redline, 2008) This two 




Figure 1.6: The two-stage development of pre-eclampsia (Redman et al., 2014) 
 
1.4.3 Angiogenesis 
As discussed above, the development of a healthy pregnancy requires adequate 
invasion of fetal vasculature into the spiral arteries, to set up an effective low 
resistance circulation. Angiogenesis is the term used to describe the development of 
new vessels and is an active and important part of this process. Pregnancy has been 
reported in a PlGF knock-out mouse experiment, implying pregnancy can continue in 
the absence of PlGF in the mouse model (Carmeliet et al., 2001) but its role in 
activating pro-angiogenic genes when it binds to the tyrosine kinase receptor VEGF-
R1 (also known as soluble Flt-1) (Maynard and Karumanchi, 2011, Chaiworapongsa 
et al., 2011b) has been demonstrated to promote vasodilatation and vascular 
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permeability. This process is depicted below and the angiogenic factors are 




Figure 1.7: PlGF binds to VEGFR-1 to promote angiogenesis, Taken from (Tammela et 
al., 2005) 
 
The pre-eclamptic placenta is now thought to secrete (although not exclusively) 
bioactive factors, such as PlGF, vascular endothelial growth factors, tyrosine kinases 
and other biological debris into the maternal circulation. The resulting imbalance of 
angiogenic and anti-angiogenic factors accounts for the widespread clinical 
manifestation of the disease. (Redman and Sargent, 2005) A growing body of 
42 
 
research has now targeted these markers as a possible aid to the risk stratification 
and classification of pre-eclampsia. A later table demonstrates the role of a variety of 
implicated biomarkers and their maternal blood concentrations in pre-eclampsia. 
 
1.4.4 Inflammatory response to pre-eclampsia 
In pre-eclampsia, the inflammatory changes associated with normal pregnancy, are 
exaggerated; pre-eclampsia is less distinct from normal pregnancy than from the 
non-pregnant state. (Johansen et al., 1999) In a healthy pregnancy, there is an 
immune reaction between maternal natural killer cells and the fetal cytotrophoblast, 
such that, by the second half of pregnancy, it is the main immune interface between 
mother and fetus. (Germain and Nelson-Piercy, 2006) The precise stimulus for this 
exaggerated inflammatory response remains unclear but theories include 
alloimmune interaction (Tan et al., 2008) or innate systemic inflammatory activation. 
Research in this area implies specific cytokine targets in the excessive inflammatory 
pathways linked to pre-eclampsia: TNF-α, IL-12, IL-18 and IFN-ƴ (Redman and 
Sargent, 2003) and suggests this inflammatory response increases with advancing 
gestation, (Brewster et al., 2008) possibly accounting for the incidence late onset 
pre-eclampsia without placental disease. 
 
Successful pregnancy requires the maternal immune system to accept the 
trophoblast; trophoblastic HLA-C molecules, regulatory T cells and maternal natural 
killer cells have been implicated in this complex interaction. (Sargent et al., 2007) 
The uterine natural killer cells release cytokines that promote appropriate 
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placentation when they bind with HLA-C1 molecules. It has been proposed that 
inappropriate binding with HLA-C2 could influence a woman’s likelihood of 
developing pre-eclampsia. (Moffett and Hiby, 2007) The high resistance system and 
subsequent hypoxic conditions of the utero-placental bed of pre-eclamptic women 
places the cellular endoplasmic reticulum under stress and suspends protein folding 
(the ‘unfolded protein response’) (Chaiworapongsa et al., 2014a). If severe, this 
leads to trophoblast apoptosis and can cause a generalised intravascular 
inflammatory response. 
 
1.4.5 Oxidative stress 
Oxidative stress occurs when the reactive oxygen species overwhelm the body’s 
innate anti-oxidant defences. (Chaiworapongsa et al., 2014a) This process is 
relevant to the pathogenesis of pre-eclampsia because it generates an exaggerated 
release of pro-inflammatory mediators. Once in the maternal circulation, they trigger 
widespread cellular activation, which alters the concentrations of acute phase 
proteins seen in the pre-eclamptic mother. The outcome is maternal endothelial 
dysfunction. (Conway et al., 2009) In healthy humans, bilirubin and biliverdin 
(breakdown products converted from red blood cells by haem oxidases) provide 
antioxidant protection. Mice deficient in a haem oxidase isoform develop 
hypertension, small placentas and elevated sFlt-1. (Zhao et al., 2009) 
 
1.4.6 Endothelial dysfunction 
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Maternal endothelial activation has been shown to be induced by syncytiotrophoblast 
microvesicles (Cockell and Poston, 1997) and other microparticles including 
neutrophils, (Mellembakken et al., 2001) angiotensin II receptor agonist antibodies 
(Herse et al., 2009) and angiogenic factors. (Levine et al., 2004) Endothelial 
dysfunction has been assessed by measuring flow in the brachial artery, which is 
impaired in women with pre-eclampsia compared with healthy controls, even before 
the onset of clinical features (Savvidou et al., 2003) especially in women with early-
onset disease. (Noori et al., 2010) 
 
1.5 Biomarkers of placental disease 
Despite pre-eclampsia being well known as a ‘disease of the placenta’, evidence is 
emerging to suggest most of its damaging effects are due to maternal endothelial 
insult (Maynard and Karumanchi, 2011) and downstream organ damage of 
associated ischaemia. This has led to suggestions that circulating markers in the 
maternal blood could be responsible for the systemic effects of the disease. The 
International Programme on Chemical Safety, led by the World Health Organisation 
defined a biomarker as “any substance, structure or process that can be measured 
in bio specimens and may be associated with health-related outcomes.” (Strimbu 
and Tavel, 2010) By definition, they are an objective measure of a medical state that 
can be identified, recorded accurately and therefore, reproduced. Their use has now 
become commonplace in medical practice and they are an accepted endpoint in 




Biomarkers relating to specific cellular and molecular events can inform of early 
biological mechanisms often prior to clinical manifestation of disease. Careful 
selection of appropriate biomarker, or panel of biomarkers, is required. Selection is 
usually based upon disease aetiology: complex diseases may require multiple 
biomarkers. Evidence has been emerging over the last decade as to clinically 
appropriate biomarkers for the diagnosis and prediction of adverse outcome in pre-
eclampsia. This next section will discuss some of the main placentally-derived 
biomarkers that contribute to the studies later described in this thesis. 
 
1.5.1 Placental Growth Factor (PlGF) 
PlGF was first identified in 1991 and has four isoforms (PlGF 1-4) made up of amino 
acids. PlGF-2 and -4 have heparin binding domains, whereas PlGF-1 and -3 do not. 
(Hauser and Weich, 1993). PlGF is a potent angiogenic glycoprotein, secreted by the 
placenta and increases in healthy pregnancy from eight weeks’ gestation, with peak 
concentrations at 29 to 32 weeks being up to ten-fold higher than those of the first 
trimester, followed by a fall towards delivery. (Benton et al., 2012b) It has a role in 
endothelial cell activation and proliferation. In vitro studies have shown that 
trophoblastic expression of PlGF reduces in hypoxic conditions, leading to the 
hypothesis that PlGF would be low in women with pre-eclampsia. 
 
This theory was explored via a case-control study by Torry and colleagues. (Torry et 
al., 1998) Serum PlGF concentrations in pre-eclamptic women were compared with 
age matched normotensive participants. Results showed that PlGF concentrations 
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fluctuate according to gestation, even in healthy pregnancy, rising in the second 
trimester and dropping at term. Despite a small sample size (30 women with pre-
eclampsia versus 30 controls), PlGF concentrations were consistently low in women 
with diagnosed pre-eclampsia and significantly higher in women with healthy 
pregnancies. Moreover, concentrations were noted to be lowest in women with the 
most severe phenotypes, despite there being no difference in placental mass. (Torry 
et al., 1998)  
 
A subsequent paper reported a prospective case-control study of women at risk of 
pre-eclampsia, designed to explore the behaviour of biochemical variables in the 
serum of women from 20 weeks’ gestation to delivery. The researchers suggested 
PlGF to be predictive of pre-eclampsia. The figure below shows that PlGF was 
lowest in women who developed pre-eclampsia (triangles). 
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Figure 1.8: Graph showing change in PlGF concentrations, according to gestational 
age and disease status. (Chappell et al., 2002) The closed squares show results from 
low risk women. The closed triangles show concentrations in high risk women. The 
results represented by closed circles were from women who did not develop pre-
eclampsia but went on to develop small for gestational age babies. 
 
Other case control studies also describe PlGF concentrations to be lower in women 
with severe early onset pre-eclampsia compared with severe late onset disease 
(Levine et al., 2004) and lower in women with severe pre-eclampsia compared with 
mild pre-eclampsia. (Robinson et al., 2006) Eclampsia is associated with serum 
PlGF concentrations comparable to women with severe pre-eclampsia, suggesting a 
common underlying disease pathway. (Vaisbuch et al., 2011) Despite this, there is 
evidence to suggest that PlGF is a marker of placental pathology but not specific to 
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pre-eclampsia: low concentrations of PlGF have also been shown to be associated 
with small for gestational age babies, even in mothers without pre-eclampsia. 
(Benton et al., 2012a) It is important to identify a biomarker capable of predicting pre-
eclampsia at earlier gestations, as this is when the disease poses the greatest 
management challenge and potential harm. PlGF is a placentally derived biomarker, 
present in normal pregnancy, but which has markedly different concentrations in pre-
eclamptic pregnancies, with the difference greatest prior to 37 weeks’ gestation. 
 
1.5.2 Vascular endothelial growth factors (VEGF) 
Vascular endothelial growth factors play an important role in angiogenesis, by 
contributing to endothelial relaxation via the nitric oxide pathway. VEGF-A was 
initially discovered in 1989 when it was known as vascular permeability factor. (Keck 
et al., 1989) Since then, many more have been identified and are seen in high 
quantities in highly angiogenic organs such as the placenta. 
 
1.5.3 Soluble fms-like tyrosine kinase 1 (sFlt-1) 
Soluble Flt-1, (also known as vascular endothelial growth factor R1 or VEGF-R1), 
binds to PlGF and stimulates angiogenesis. PlGF is up-regulated in many 
pathological conditions and displaces VEGF-A from sFlt-1, activating an amplified 
VEGFA-driven angiogenesis. Concentrations of sFlt-1 are high in the serum and 















Figure 1.9: sFlt and its ligands: direct stimulation of angiogenesis through sFlt-1 and 
indirect stimulation of pathological angiogenesis via enhancement of VEGF-A 
(Fischer et al., 2008) 
 
Administration of exogenous sFlt-1 in rats produced hypertension and proteinuria. 
(Maynard et al., 2003) Similarly, reduced VEGF concentration in a murine model has 
been associated with significant proteinuria. (Levine et al., 2004) These findings 
suggest that excess sFlt-1 could be linked to the pathogenesis of pre-eclampsia, by 
binding to circulating VEGF and PlGF molecules. Increased sFlt-1 concentrations 




eclampsia: twin pregnancy has been shown to yield sFlt-1 concentrations double that 
of singleton pregnancy (Bdolah et al., 2008) and in pregnancies with a trisomy 13 
(the gene location of sFlt-1) fetus. (Steinberg et al., 2009) It has been proposed that 
the low sFlt-1 concentrations in pregnant smokers may partly explain the protective 
effects of smoking against pre-eclampsia.(Jeyabalan et al., 2008) 
 
1.5.4 Soluble Endoglin (S Eng) 
Endoglin is a co-receptor responsible for transforming growth factor ß1 and ß3. It is 
found on endothelial cell membranes and syncytiotrophoblasts (Levine et al., 2006b) 
but in pre-eclampsia is upregulated, leading to release of soluble endoglin into the 
maternal circulation. (Venkatesha et al., 2006) Venkatesha and colleagues went on 
to show that over expression of endoglin caused hypertension in rodents. When sFlt-
1 was included in the adenoviral mediated over-expression, this was associated with 
severe hypertension with proteinuria and features of HELLP syndrome, supporting 
the theory that soluble endoglin behaves as a powerful anti-angiogenic agent and 
plays a part in the pathogenesis of pre-eclampsia. 
 
The Calcium for the Prevention of Pre-eclampsia trial (CPEP) was a randomised 
double blind trial, (Levine et al., 2006) investigating the effect of calcium 
supplementation on over 3500 women. A random selection of participants, with and 
without hypertensive disease, was tested in a nested case-control analysis. The 
study identified significant elevations in soluble endoglin (sEng) concentrations in 
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women with pre-eclampsia, particularly those with pre-term disease, but calcium 
supplementation did not impact on circulating markers of pro-angiogenesis. 
 
The graph below shows sEng across cohorts of pregnant women: concentrations 




Figure 1.10: Soluble endoglin concentrations are higher in women with pre-eclampsia, 
taken from (Levine et al., 2006a) 
 
1.5.5 Other biomarkers 
A far-reaching range of other potential biomarker targets were also included in the 
secondary analysis of the PELICAN study, selected on biological plausibility and 
their availability on a commercial platform. The table at the end of this section lists 
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the biomarkers tested (the results of which are discussed in chapter 4). The 
biomarkers have been grouped under biologically relevant headings below.  
 
1.5.5.1 Podocyte proteins 
Glomerular podocytes are highly specialised cells that function to prevent renal 
protein loss. Cellular damage following glomerular disease can lead to shedding into 
the urine. Evidence suggests that the quantities of four podocyte markers (podocin, 
podocalyxin, synaptopodin, and nephrin) found in the urine of proteinuric pre-
eclamptics were not found in the urine of non-proteinuric normotensive controls. 
(Karumanchi and Lindheimer, 2007) However, podocyturia is not pathognomonic of 
pre-eclampsia and glomerular endotheliosis has been demonstrated in up to 40% of 
normotensive pregnant women. (Strevens et al., 2003) 
 
1.5.5.2 Endothelial markers 
Several biomarkers released by the endothelium have been proposed as potential 
diagnostic tools for pre-eclampsia, including endothelin and Neutrophil gelatinase-
associated lipocalin (NGAL). Endothelin is a potent vasoconstrictor, which may 
contribute to the hypertension observed in pre-eclampsia. (Chaiworapongsa et al., 
2014a) NGAL is released in response to ischaemic damage and elevated plasma 
concentrations have been linked with the presence and severity of pre-eclampsia. 
(Kim et al., 2013) Arginase, also released by the endothelium, reduces nitric oxide 




1.5.5.3 Metabolic markers 
Pregnancy associated plasma protein A (PAPP-A) is a metalloprotease produced by 
the syncytiotrophoblast and promotes fetal growth. Multiple studies have investigated 
the role of PAPP-A, mainly when measured in the first trimester to determine 
pregnancies at risk of placental dysfunction. Reduced maternal concentrations have 
been reported in pre-eclampsia (Smith et al., 2007) but large-scale meta-analysis 
has found low predictive accuracy. (Morris et al., 2008) 
 
1.5.5.4 Natriuretic peptides 
The association between placental and cardiovascular disease has already been 
discussed and provides the basis for suggested promise of cardiovascular 
biomarkers holding diagnostic potential in pre-eclampsia. Brain Natriuretic Peptide 
(BNP) has been seen in high concentrations in pre-eclamptic women (Szabo et al., 
2011) although concentrations usually rise in response to volume expansion. For this 




Table 1.1: Angiogenic biomarkers and their biological action* in placental disease 
Biomarker Biomarker full name Mechanism of action  or  * 
PlGF Placental Growth Factor  Angiogenic marker produced by trophoblastic tissues  
VEGF-C Vascular endothelial growth factor C Angiogenic marker produced by trophoblastic tissues  
sFlt-1 (VEGFR1) Soluble fms-like tyrosine kinase-1 Binds to VEGF causing reducing plasma concentrations   
Endoglin Endoglin Anti-angiogenic cell surface glycoprotein  
Angiogenin Angiogenin  Potent angiogenic factor which interacts with endothelial cells   
C-Met Tyrosine kinase  Proto-oncogene which promotes angiogenesis   
 
Table 1.2: Endothelial biomarkers and their biological action 
Biomarkers Biomarker full name Mechanism of action  or   
Arginase-1 Arginase 1 Enzyme which compete with nitric oxide synthase (NOS)   
Endothelin Endothelin Potent vasoconstricting peptide produced by the endothelium  
NGAL Neutrophil gelatinase-associated lipocalin Protein released post ischaemic damage or sepsis  
HIF Hypoxia inducible factor 1-alpha inhibitor Inhibits transcription factor HIF-1alpha, which mediates cellular responses 
to hypoxia, preventing tissue repair 
 
PODXL Podocalyxin Renal marker expressed in glomerular podocytes and vascular 





Table 1.3: Cell adhesion biomarkers and their biological action 
Biomarkers Biomarker full name Mechanism of action  or   
ADAM 9 Disintegrin and metalloproteinase domain-
containing protein 9 
Modulates cell-cell interactions possibly affecting trophoblast invasion and 
spiral artery formation. Role in angiogenesis. Marker in renal and prostate 
cancers 
 
CPA-4 Carboxypeptidase A4 Cleaves angiotensin-1, a potent vasoconstrictor. Low concentrations in 
normal tissue 
 
ESAM-1 Endothelial Cell-selective adhesion molecule Cellular adhesion molecule expressed by vascular endothelium  
ICAM-1 Intercellular adhesion molecule 1 SIgnalling protein involved in immune activation  
VCAM Vascular cell adhesion molecule SIgnalling protein involved in immune activatio.  
Kunitz-2 (HAI-2)  Kunitz-type protease inhibitor 2  Inhibits clotting factors  
MMP-9 Matrix metalloproteinase-9 Expressed by cytotrophoblast, to aid trophoblast invasion and remodeling 















Table 1.4: Inflammatory biomarkers and their biological action 
 
Biomarkers Biomarker full name Mechanism of action  or   
CRP C reactive protein Non-specific inflammatory marker raised in the acute phase response  
CXCL10 CXC motif chemokine 10 Immune activator released by endothelial cells  
Elafin Elafin Protease inhibitor involved in inflammation  
IL-1ra  Interleukin 1 receptor antagonist Activates inflammatory response with release of prostaglandins  
MIF Macrophage migration inhibitory factor  Pro-inflammatory cytokine  
PCT Procalcitonin Involved in calcium homeostasis ( plasma [calcium]) and raised in 
inflammation 
 
ST2 Interleukin-1 receptor-like 1  Detected in liver, kidney, pancreas, prostate, spleen, small intestine and 
placenta. Activation produces modulatory cytokines. 
 








Table 1.5: Coagulation/metabolic biomarkers and their biological action 
Biomarkers Biomarker full name Mechanism of action  or   
PAI-1 and -2  Plasminogen activator inhibitor 1 and 2 Produced by trophoblasts, inhibits fibrinolysis  
Pentraxin-3 Pentraxin-related protein PTX3  Involved in the activation of the complement system  
PAPP-A  Pregnancy specific plasma protein A Produced by the syncytiotrophoblast, promotes fetal and placental growth  
IGF-1 Insulin growth factor 1 IGF-1 suppresses catabolism in fetal tissues  
Leptin Leptin Released by the placenta, stimulates growth and inhibits apoptosis. 






Table 1.6: Renal and cardiovascular biomarkers and their biological action 
Biomarkers Biomarker full name Mechanism of action  or   
ANP  Natriuretic peptide A Cardiac hormone causing vasodilatation. Released by the atria in response 
to stretch 
 
BNP Natriuretic peptide B Cardiac hormone causing vasodilatation, and inhibition of renin and 
aldosterone. Synthesised in ventricle in response to volume expansion and 
pressure overload. 
 
Nephrin Nephrin Renal marker essential for normal glomerular function and cardiovascular 
development.  
 






1.6 Classification of pre-eclampsia 
The range of pre-eclamptic phenotypes (including gestational age at onset and 
disease severity) is likely to be influenced by maternal individual differences, 
including co-morbidities, physical characteristics, obstetric history, recreational 
behaviours and genetic factors, and the resultant impact these may have on a 
developing placenta. 
 
With improved understanding of pre-eclampsia pathophysiology, two phenotypes 
have been described, but with over-lapping clinical features: 
 Placental pre-eclampsia: driven by inadequate placental development, and 
associated with fetal growth restriction, usually requiring early pre-term 
delivery 
 Maternal pre-eclampsia: associated with pre-existing maternal disease with 
vascular dysfunction which is exaggerated by the inflammatory burden of 
pregnancy 
 
1.6.1 Maternal pre-disposition 
Maternal chronic conditions, such as essential hypertension, renal disease, diabetes 
mellitus, systemic lupus erythematous, obesity and antiphospholipid syndrome are 
associated with an increased risk of developing pre-eclampsia, mainly due to 
impaired placental function. (Yogev et al., 2004) (Duckitt and Harrington, 2005) 
(Steegers et al., 2010b) Increasing age is a risk factor for developing pre-eclampsia, 
with women over the age of 40 years being at twice the risk of those who are 
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younger at conception (Duckitt and Harrington, 2005); data from the United States 
suggest a 30% increased risk for every year past the age of 34. (Saftlas et al., 1990) 
A body mass index (BMI) over 35 doubled the risk of developing pre-eclampsia 
(Sibai et al., 1997) and a BMI less than 20 reduced the risk. (Sebire et al., 2001). 
 
1.6.2 Placental contribution to pre-eclampsia 
Pre-eclampsia is a multifactorial condition, but placental dysfunction, exacerbated by 
maternal disease is the underlying pathological process in the majority of cases. 
Improvements in the understanding of the pathophysiological processes underlying 
placental disease has aided the identification of upstream markers altered early in 
the pathological process allowing earlier detection and targeted intervention. These 





Figure 1.11: Diagrammatic representation of pre-eclamptic phenotypes, taken from 
(Staff et al., 2010) 
 
Recent research compares placental invasion in humans with other primates. Some 
primates, including lemurs and lorises, do not exhibit pre-eclamptic phenotypes; 
perhaps due to a more shallow trophoblastic invasion in these species. (Carter et al., 
2015) (Pijnenborg et al., 2011) There is an apparent tendency towards deeper 
invasion during primate evolution, such that gorillas, great apes and humans get pre-
eclampsia, suggesting that pre-eclampsia represents a failure in deep endovascular 
trophoblast invasion. In the second half of pregnancy, it is the cytotrophoblast that 
accounts for this process and is responsible for remodelling the spiral arteries. 
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Deeper invasion into the endometrium and inner myometrium is seen in gorillas, 
chimps and humans. 
 
It is thought defective deep placentation is associated with a range of adverse 
syndromes of pregnancy: placental abruption, preterm labour, fetal growth restriction 
and spontaneous miscarriage. It is hypothesised that poor placentation restricts 
transformation of the spiral arteries and that this defective process is of a greater 
severity at the peripheries of the placental bed, as shown in the diagram below: 
 
 
Figure 1.12: A-normal pregnancy, B-Defective deep placentation, characterized by 
non-transformation of the myometrial spiral arteries reducing the central area with 




1.7 The need for a new test 
As discussed, pre-eclampsia is a complex, multi-factorial disease that is challenging 
to detect and diagnose, particularly in its early stages. Assessment is usually 
initiated by routine detection of signs that could indicate evolving disease (such as 
proteinuria or raised blood pressure) during antenatal monitoring in the community. 
(North et al., 2011) With one in 10 pregnant women developing symptoms 
suggestive of pre-eclampsia (headache, abdominal pain) but only 20% of these 
reaching a diagnosis of pre-eclampsia, there is a clear need for improved testing at 
time of presentation with suspected disease. (Chaiworapongsa et al., 2013c) NICE 
recommends evaluation of risk factors, such as first pregnancy, BMI, previous pre-
eclampsia, more than 10 years between pregnancies, age over 40 years and 
physical co-morbidity at the time of booking (National Institute for Health and Clinical 
Excellence, 2010) but, as yet, a robust means of accurately attributing risk does not 
exist. It is possible to test prediction, in the first trimester of pregnancy or test to 
diagnose disease at the time of presentation with symptoms. 
 
1.7.1 First trimester prediction 
The SCOPE (Screening for Pregnancy Endpoints) study aimed to develop and 
evaluate screening tests to predict pre-eclampsia in the first half of pregnancy. The 
study ran over four years, across five international units (UK, Ireland, Australia and 
New Zealand) and recruited over 3500 women. An extensive range of variables were 
explored including dietary intake, lifestyle, mental health questionnaires, physical 
measurements, blood pressure, family history, early pregnancy complications such 
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as hyperemesis and vaginal bleeding and blood sampling. Participants were then 
followed up throughout pregnancy and delivery. (North et al., 2011) Results 
suggested promise for the development of an individual risk algorithm to which 
biomarker analysis could be added. Guidance exists to promote early detection and 
timely specialist input (Milne et al., 2005) for women at greatest risk. It is suggested 
that appropriate surveillance and intervention has the potential to improve adverse 
perinatal outcomes associated with pre-eclampsia and superimposed pre-eclampsia. 
(Chappell et al., 2008) 
 
Screening risk in the first trimester is useful but the management options of proven 
value in terms of outcome for mother and baby are largely limited to aspirin (Duley et 
al., 2007) and an increased surveillance strategy (currently of uncertain value). Using 
this information to better predict the women that will go on to experience 
complications associated with their disease could better define risk and direct 
resources to reduce morbidity (Duckitt and Harrington, 2005), at a time when 
medication or iatrogenic delivery can alleviate disease. In a study designed to 
develop a predictive tool, based on data from over 3500 nulliparous women, based 
on individual clinical characteristics, only modest predictive potential was reported. 
Assessment of both risk factors and protective factors included personal 
characteristics (smoking, maternal birth weight, body mass index and obstetric 
history) as well as family history (cardiovascular disease, pre-eclampsia). The 
researchers conclude that risk profiling in this way could gain improved validity if 
added to biomarker analysis. No improvement was found by adding uterine artery 
Doppler (area under curve remained 0.71). The figure below shows how a risk 
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prediction model of this kind could be used to identify the high risk cohort of women 
who would require specialist care. (North et al., 2011) 
 
 
Figure 1.13: Framework of care pathway according to estimated risk, showing 
specialist referral if presumed risk of pre-eclampsia >15%. Taken from (North et al., 
2011) 
 
1.7.2 Diagnostic tests 
Studies have explored the role of PlGF in both making the diagnosis of pre-
eclampsia, usually in the third trimester and in determining disease prognosis in 
women already diagnosed, or of adverse outcome at a fixed point in the second half 
of pregnancy. For the purposes of this thesis, a predictive test is defined as one 
capable of detecting disease in asymptomatic women (e.g. in the first trimester) and 
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a diagnostic test as one used in women presenting at time of suspected disease, 
(such as those recruited to the PELICAN study in the third trimester). 
 
In women with a viable fetus, decisions around delivery are challenging and often 
made to save the mother, resulting in complications of prematurity in the fetus. The 
identification of bioactive proteins in the maternal circulation, which hold diagnostic 
and prognostic potential in pre-eclampsia, hold potential to allow intervention prior to 
the onset of fulminant disease. Fulminant pre-eclampsia is a multi-organ disorder, 
causing derangement of renal, liver, clotting and cerebral functioning and 
contributing to sudden infant death, still birth and haemorrhage. Delivery of the fetus, 
and crucially, its poorly functioning placenta, remains the only means of ameliorating 
the clinical manifestation of the disease. While a variety of biomarkers and imaging 
techniques have been evaluated for improving detection, to date none has adequate 
sensitivity, specificity, and convenience for the diagnosis or prediction of pre-
eclampsia. Development of a test using a biomarker implicated in its 
pathophysiology, such as PlGF, has attraction over the traditional measurement of 
blood pressure and urinary protein which are consequences of established disease. 
 
In a retrospective study of over 500 women, Anumba and colleagues explored the 
validity of frequently used serum tests in identifying adverse outcome. (Anumba et 
al., 2010) Their work suggested the use of laboratory ‘cut-offs’ and subsequent 
interpretation of blood results varied across units and could be improved. The 
sample sizes for each diagnostic group were small, but indicated that platelet count 
and alanine transaminase had low sensitivity for adverse outcomes. Other markers 
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(creatinine, blood pressure and early gestational presentation) were predictive of 
development of pre-eclampsia, early delivery or fetal growth restriction; however the 
researchers recorded that a third of women referred were normotensive at day unit 
assessment yet 16% of this cohort still went on to develop pre-eclampsia, suggesting 
a latent disease phase. Anumba’s study adds to the notion that current assessment 
practices are disparate and poorly predict disease outcome. 
 
Anumba and colleagues’ work is supported by other research into the parameters 
currently used as aids both to diagnosis of pre-eclampsia and predictors of adverse 
outcome. A systematic review, including 13 studies involving over 3000 women with 
diagnosed pre-eclampsia, into the utility of liver function derangement as a predictor 
of maternal adverse outcome suggested a higher probability of complications with 
raised liver enzymes but reported poor test sensitivity. (Thangaratinam et al., 2011b). 
Raised uric acid concentrations were also found to be a poor predictor of any 
complication associated with pre-eclampsia. (Thangaratinam et al., 2006b) The 
same research group also explored other indicators of imminent complications and 
found similarly disappointing study statistics. Reported maternal symptoms of 
headache, epigastric pain and visual disturbance did correlate to a higher incidence 
of maternal poor outcome, yet a lack of symptoms did not enable convincing rule-out 
for adverse outcomes. (Thangaratinam et al., 2011a)  
 
Proteinuria is one of the defining features of pre-eclampsia, with dipstick testing 
being performed regularly throughout the antenatal period and included as a 
screening tool in asymptomatic women. Once in hospital, more accurate protein 
68 
 
measurement is usually carried out (24 hour urinary protein collection or spot 
random protein:creatinine ratio). It has been hypothesised that the severity of protein 
loss may be linked to worst outcomes. (Chan et al., 2005) However, a large 
systematic review including over 6000 participants found proteinuria to be a poor 
determinant of adverse maternal or fetal outcomes, including perinatal death and to 
be of ‘very little clinical value.’ (Thangaratinam et al., 2009b) The review included two 
test accuracy studies conducted thirty years earlier and studies involving a range of 
test methods, leading to heterogeneity of comparators, yet its findings highlight the 
diversity of test methodology and proteinuria interpretation across units, (Chappell 
and Shennan, 2008) and raise questions as to the usefulness of proteinuria as an 
essential diagnostic criterion.(Hofmeyr and Belfort, 2009) It is notable that the newer 
extended definitions of pre-eclampsia from the ISSHP and ACOG make proteinuria 
one of the multi-organ features that defines the disease, rather than the sole 
additional criterion (to hypertension) as previously given. 
 
1.7.3 Prognostic testing 
Once a woman has a diagnosis of confirmed pre-eclampsia, a test may then become 
prognostic, in that it aims to identify those who will go on to develop adverse 
outcome (as defined by the PROGRESS series of papers on prognostic research). 
(Hemingway et al., 2013) A 2004 systematic review of 87 cohort or cross-sectional 
studies found only questionable clinical utility of screening tests for pre-eclampsia. 
(Conde-Agudelo et al., 2004a) Similar results were found by a 2013 systematic 
review and meta-analysis exploring the value of 37 novel biomarkers for the 
prediction of growth restricted babies; none gave sufficient predictive power. (Conde-
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Agudelo et al., 2013) The test performance statistics, taken from this systematic 
review, of commonly researched biomarkers and uterine artery assessments are 
shown, in graphical form, below. 
 
Figure 1.14: ROC curves for a) PlGF/sEng and b) PlGF/VEGFR-1. (Conde-Agudelo et 
al., 2013) 
Tests have been used in this way, in each trimester, to predict certain downstream 
events. In the PELICAN study, PlGF was tested as to its ability to predict women 
requiring delivery within 14 days of testing. When the PELICAN study was conceived 
and designed, in 2010, there were no prospective observational cohort studies 
published reporting diagnostic accuracy. However, the table below shows some of 





Author, year No. of 
participants (n) 











Development of mild PE, 
severe PE requiring pre-
term delivery (<34 weeks) 
Rana, 2012 616 Suspected PE 28-38 weeks PlGF/sFlt Diagnosed hypertensive 
disease 
Verlohren, 2012 630 Confirmed PE 24-34 weeks sFlt/PlGF ratio Imminent delivery: time 
from test to delivery 
Chaiworapongsa, 
2013 
1269 Normal pregnancy at time 
of first enrolment (6-22 
weeks) 
30-34 weeks PlGF, VEGFR Stillbirth, late PE, SGA 
Nicolaides, 2013 300 50 with PE, 250 normal 
pregnancy 
30-33 weeks PlGF, BhcG, PAPP-A Development of PE 
Table 1.7: Summary of studies investigating third trimester PlGF testing on pregnancy outcome 
sEng: soluble endoglin, VEGFR: vascular endothelial growth factor receptor, BhcG: beta human chorionic gonadotrophin, PAPP-A: pregnancy associated 




Author, year No. of 
participants (n) 





Meler, 2014 84 Confirmed PE 20-37 weeks PlGF Prediction of maternal 
complication  
Chappell, 2013 625 Suspected PE 20-40 weeks PlGF PE requiring delivery in 14 
days 
Droge, 2015 341 Twin pregnancies with 
suspected or confirmed PE, 
compared with matched 
singleton pregnancies 
>25 weeks sFlt/PlGF Diagnosis of PE/normal 
outcome 






Identifying a test close to the usual onset of symptoms has merit for women 
presenting in the third trimester but there is an obvious need also to find a means of 
predicting pre-eclampsia early, to allow timely intervention. A meta-analysis of 
studies involving pregnant women in the first and second trimesters showed low 
PlGF concentrations, and high sFlt-1 and sEng concentrations in women with pre-
eclampsia (Kleinrouweler et al., 2012). These changes occurred below 16 weeks, as 
well as above 19 weeks but did not reach significance, and test sensitivity and 
specificity did not reach a level that could allow recommendation for introduction into 
clinical use. 
 
1.7.4 PlGF as a marker of disease 
In 2011, PlGF and other biomarkers were found in significantly different 
concentrations in women with an eventual diagnosis of pre-eclampsia that required 
imminent delivery, compared with those who delivered at term. (Chaiworapongsa et 
al., 2011b) It is hypothesised that testing of this kind could enable accurate diagnosis 
of pre-eclampsia during pregnancy, at a time when expedition of delivery is required, 
due to disease severity, but delayed if possible, to optimise fetal outcome. (Rana et 
al., 2012b) It is possible that biomarker testing may provide improved evidence of 
disease status, in women with atypical presentations of pre-eclampsia, who may 





The potential of sFlt/PlGF ratio has also been investigated as a means of diagnosing 
and risk stratifying women with pre-eclampsia and HELLP syndrome. A study 
including 630 women found a significantly increased ratio in women with pre-
eclampsia compared with controls. The ratio was higher in women presenting before 
34 weeks’ gestation and in women at greatest risk of requiring imminent delivery. 
(Verlohren et al., 2012) This ratio is also higher in twin pregnancies complicated by 
pre-eclampsia (and PlGF lower) compared with singleton pregnancy. (Droge et al., 
2015) Theories to justify these findings include increased placental mass or maternal 
blood volume associated with twin pregnancy, but this is still under debate. 
 
Chaiworapongsa and colleagues explored the role of PlGF in predicting stillbirth or 
late severe pre-eclampsia in women in the third trimester, via a prospective cohort 
study. (Chaiworapongsa et al., 2014b) This was the first study of its kind, looking at 
predictive properties of anti/angiogenic factors at a fixed time-point at later 
gestations. Reduced concentrations of PlGF/sEng at 30-34 weeks’ gestation were 
associated with severe late pre-eclampsia. Similar results were reported at earlier 
gestations and the test appeared to work best at 30-34 weeks. (Chaiworapongsa et 
al., 2013a) A low PlGF/sFlt-1 ratio was associated with an increased likelihood of 
stillbirth. However, it remains a limitation of these studies that test accuracy statistics 
were not reported, making it difficult to compare against other studies or extrapolate 
into other populations with varying prevalence of disease. 
 
Results of a recent study (Sibiude et al., 2012) showed that, despite a small sample 
size, PlGF was notably lower, not only in women who went on to develop pre-
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eclampsia but also those who experienced adverse outcome and severe adverse 
outcome. The graph below, taken from this study, shows that higher PlGF 
concentrations are associated with a lack of adverse outcome (blue squares), 
particularly in women <35 weeks’ gestation. 
 
Figure 1.15: PlGF concentrations according to gestation and pregnancy outcome, 
taken from (Sibiude et al., 2012) 
 
However, Meler and colleagues question the test’s role in clinical practice, due to a 
65.5% false positive rate in their recent prospective cohort study. (Meler et al., 2014) 
Despite a small cohort size (84 women), a low plasma PlGF concentration did 
predict maternal complications with a sensitivity of 76.9% (Meler et al., 2014) and a 
very low PlGF concentration was associated with pre-eclampsia, particularly in 




In summary, a variety of tests have been evaluated, and reviewed in clinical practice: 
antenatal assessment of blood pressure and proteinuria, serum assessment of liver 
and renal function and Doppler ultrasound (Conde-Agudelo et al., 2004a) as well as 
novel biomarker analysis. There is potential to develop a two-stage screening 
process that may yield improved risk stratification in high risk women and reduce 
perinatal complications. (Lai et al., 2013b) Further research is necessary to translate 
findings into clinically relevant testing. 
 
1.7.5 Combined potential of biomarkers 
The complex aetiological basis of pre-eclampsia implies that a combination of clinical 
parameters and biomarkers could improve predictive accuracy; a prognostic model 
in pre-eclampsia including gestational age, serum creatinine, platelet count, 
aspartate aminotransferase, oxygen saturation and chest pain or dyspnoea had an 
area under the curve of 0.88 for adverse maternal outcomes within 48 hours. (von 
Dadelszen et al., 2011a) Whilst none of the parameters discussed so far have, in 
isolation, been recommended for use in clinical practice as a means of identifying the 
pregnancy at risk of pre-eclampsia, promising combinations are being explored. The 
findings of a systematic review evaluating the predictive capabilities of combinations 
of serum biomarkers measured in the late first and early second trimesters report low 
test performance. (Hui et al., 2012) Despite a ten-fold increase in soluble endoglin 
being associated with growth restriction (Rana et al., 2012a), the addition of other 




Chapter 4 of this thesis discusses the basis of this research in more detail and 
describes a planned secondary analysis on samples from the PELICAN study, 
comparing the predictive performance of PlGF and other selected serum biomarkers. 
 
1.7.6 Point of care testing 
Tests capable of predicting downstream complications, such as the need for preterm 
delivery, have the potential to direct resources and on-going intervention 
appropriately, including transfer to tertiary units with neonatal intensive care facilities, 
if required.  
 
1.8 Health economic implications of diagnostic testing 
Diagnostic tests are required to: identify women with the disease (sensitivity), identify 
women without the disease (specificity) and perform adequately in practice, perhaps 
in combination with other clinical assessments or testing strategies. Most 
importantly, the test results need to translate into patient benefit or improved 
decision making. (Ferrante di Ruffano et al., 2012) It is clear that further testing is 
required to assure the feasibility and diagnostic yield of PlGF in clinical practice but 
there are also more unpredictable aspects, including the perceptions of both clinician 
and patient. (Ferrante di Ruffano et al., 2012) PlGF is a minimally invasive, bedside 
blood test, likely to be carried in secondary care, so may yield additive placebo 






1.8.1 Health economic implications of PlGF 
Before any diagnostic test can become a clinical reality, cost effectiveness should be 
demonstrated. Previous decision analytical models of diagnostic tests for pre-
eclampsia have demonstrated cost-savings as a result of better identification of true 
positives and negatives (Hadker et al., 2010) (Schnettler et al., 2013b). The later 
chapters in this thesis provide additional information about the potential costs and 
cost savings of implementing the Triage® PLGF test, as a result of improved 
identification and clinical management of pregnant women with suspected pre-
eclampsia. A hypothetical clinical algorithm was developed, comparing current 
assessment of women with suspected pre-eclampsia (National Institute for Health 
and Clinical Excellence, 2010) with a pathway incorporating PlGF. This analysis, is 
explained in chapter 5. 
 
1.9 Patient reported outcome measures 
Patient reported outcome measures assess the self-reported health and quality of 
life of an individual patient, via questionnaires or surveys and have become more 
commonplace in clinical practice, (2009b) since their recommendation in The 
Department of Health’s Next Stage Review in 2009. There are an extensive number 
of surveys now available to assess cost effectiveness (Appleby et al., 2013), to 
assess the impact of disease or surgical intervention (Snyder and Aaronson, 2009) 
or to measure healthcare provider performance. Within maternity care, patient 
reported outcome measures are of increasing interest to Service Commissioners 
(Tyler S, 2012) and as a measure of patient perceived outcome in practice.(Ismail et 
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al., 2013) However, surveys validated for pregnancy or diseases of pregnancy are 
not readily available for use. 
 
Assessment of qualitative variables, such as quality of life, mood and functional 
status, is an increasingly recognised means of recording the impact of medical 
intervention. (Black, 2013) Unlike patient reported experience measures (PREMs), 
they do not focus on national standards of patient care (Black, 2013) but on the 
patient’s perspective and self-reported health status. As well as being of use in 
economic evaluation, the King’s Fund suggest Patient Reported Outcome Measures 
(PROMs) promote improved patient choice, better clinical decision making and 
enhanced regulation of healthcare services. (Devlin NJ and Appleby J, 2010) Their 
use is supported by Clinical Commissioning Groups (Health and Social Care 
Information Centre, 2013) and patient support groups alike.(Arthritis Research UK, 
2013) 
 
PROMs are now used routinely in orthopaedic surgery (Browne et al., 2013, Hunt 
and Hurwit, 2013) and have modified service delivery. (Keurentjes et al., 2013) They 
are recognised to be of benefit in assessing competing interventions in terms of 
clinical effectiveness as well as cost;(Suk et al., 2008) for example, in the calculation 
of quality adjusted life years following joint replacement. (Appleby et al., 2013) 
PROMs have also been used in paediatric intensive care,(Andersen et al., 2013) 
gastroenterology,(Bodger et al., 2013), psychiatry (Hunter et al., 2009) and 
urogynaecology (Nilsson et al., 2012, Srikrishna et al., 2010, Bjelic-Radisic et al., 
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2011) but uncertainty exists as to whether these surveys perform equitably when 
translated and used in patients across cultural groups.(Treszezamsky et al., 2013) 
 
The PEARLS (Perineal Assessment and Repair Longitudinal Study) used PROMs to 
assess its primary outcome; pain reduction. It could be argued that highly subjective, 
retrospective variables, such as pain, should not be compared in this way. However, 
evidence exists to support the role of patient surveys to inform appropriate types of 
pain relief for labouring women. (Jimenez et al., 2012, Ahmad Shirvani and Ganji, 
2013) At the time of study design, there were no other PROMs in use within pre-
eclampsia. Many current pre-eclampsia studies focus exclusively on outcomes 
chosen by researchers, without reference to measures that pregnant women may 
rate as important. Chapter 6 describes the first stage in the design of a PROM for 

























The overall aim of this thesis is to address the following research questions: in 
women presenting with suspected pre-eclampsia, what is the diagnostic accuracy of 
PlGF in determining pre-eclampsia requiring delivery within 14 days; how does the 
test performance of PlGF compare with other candidate biomarkers, suggested in 
literature as potential targets; what would the economic impact be of introducing 
PlGF testing as a diagnostic adjunct within NHS antenatal triage units; and what 
alternative patient reported outcome measures might be developed in hypertensive 
diseases of pregnancy? 
 
2.1.2 Objectives 
1. To evaluate the diagnostic accuracy of plasma PlGF concentration in women 
presenting with suspected preeclampsia between 20 and 35 weeks of 
gestation (with women recruited up to 40+6 weeks as a secondary analysis) in 
determining need for delivery for preeclampsia within 14 days of testing 
(preeclampsia-D14). 
2. To determine how the predictive power of PlGF compares with other currently 
used biological tests and with other selected biomarkers, or combined 
biomarker targets, in recent medical literature. 
3. To determine whether the introduction of PlGF as a point of care test in high 
risk women represents a realistic, cost effective strategy. 
4. To explore the development of a patient reported outcome measure for 











Diagnostic accuracy of Placental Growth 








3.1 Diagnostic accuracy of Placental Growth Factor in women with 
suspected preeclampsia: a prospective multicentre study. 
 
This chapter discusses the methodology, results and main conclusions from the 
PELICAN study, a prospective observational study designed to investigate the 
diagnostic accuracy of PlGF in high risk women. 
 
3.1.1 Introduction 
Preeclampsia is characterised by placental and maternal vascular dysfunction and 
associated adverse outcomes. (Steegers et al., 2010b) Diagnosis is based on 
traditional but unreliable and nonspecific clinical markers, most commonly blood 
pressure and urinary protein excretion; both are subject to observer error and poor 
test accuracy for identifying women and infants at risk of adverse outcome. (Menzies 
et al., 2007b) This clinical uncertainty leads to over-utilisation of ancillary testing and 
intervention, with associated expense of antenatal monitoring and in-patient 
admissions, placing considerable burden on pregnant women and their families. In 
the US, preeclampsia is the most common reason for iatrogenic preterm delivery. 
(Meis et al., 1998a) While biomarkers and imaging techniques have been evaluated, 
none have adequate sensitivity, specificity, and convenience for diagnosis or 
prediction of preeclampsia or its complications, (Meads et al., 2008, Menzies et al., 





Recent advances in understanding of preeclampsia and fetal growth restriction have 
elucidated important biological roles for placentally-derived angiogenic and anti-
angiogenic factors. (Maynard and Karumanchi, 2011) In normal pregnancy, placental 
growth factor (PlGF), synthesised by placental syncytiotrophoblast, (Shore et al., 
1997) increases with gestation in the maternal circulation, with concentrations 
peaking at 26-30 weeks (Knudsen et al., 2011) and declining towards term. PlGF is 
abnormally low in women with preeclampsia compared to gestational age-matched 
controls (Levine et al., 2004) and is reduced further in severe preeclampsia. 
(Robinson et al., 2006) 
 
Development of a test for preeclampsia using a pathophysiologically relevant 
biomarker, such as PlGF, may have advantages over the traditional measurement of 
blood pressure and urinary protein which are consequences of established disease. 
As earlier gestation of preeclampsia onset is associated with greater maternal and 
perinatal risks, (Steegers et al., 2010b) and the difference in PlGF concentrations 
between normal and preeclamptic pregnancies is most marked prior to 35 weeks, 
PlGF has the potential to aid diagnosis of hypertensive disorders of pregnancy at 
gestations critical to clinical outcome. 
 
The most useful test for health professionals would identify women with 
preeclampsia associated with clinically relevant and deteriorating disease requiring 
iatrogenic delivery. As women with suspected hypertensive disease are routinely 
monitored two-weekly, a clinically useful test should be applicable for a subsequent 






The PELICAN study was a prospective observational study, undertaken between 
January 2011 and February 2012 in seven consultant-led maternity units in the 
United Kingdom and Ireland. Women were eligible if they presented or were referred 
with symptoms or signs of suspected preeclampsia between 20+0 and 40+6 weeks of 
gestation, had a singleton or twin pregnancy, and were aged ≥16 years. Symptoms 
or signs included headache, visual disturbances, epigastric or right upper quadrant 
pain, increasing oedema, hypertension, dipstick proteinuria and/or suspected fetal 
growth restriction. Participants were included if the healthcare provider deemed that 
the woman required evaluation for suspected preeclampsia. Any woman already 
meeting diagnostic criteria for confirmed preeclampsia at enrolment was not eligible. 
Baseline demographic and pregnancy-specific information were entered onto the 
study database (finalised prior to the first participant being enrolled). Fifteen mls of 
blood (additional to routine blood samples) were drawn into ethylenediamine tetra-
acetic acid, transported to the laboratory within 1 hour, and plasma stored until 
analysis (-80oC). Pregnancy outcome details for the mother and infant were obtained 
from case note and electronic database review. 
 
Outcomes 
Definitions and outcomes were pre-specified in the study protocol. The primary 
analysis was of diagnostic accuracy of low plasma PlGF (<5th centile for gestational 
age) to predict need to deliver for preeclampsia within 14 days of testing, in women 
with suspected, but unconfirmed, preeclampsia before 35 weeks’ gestation. The pre-
specified secondary analyses included women presenting later (35+0 to 36+6; ≥37 
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weeks), or using a lower threshold (<12 pg/ml). All hypertensive disorders of 
pregnancy including superimposed and severe preeclampsia, were defined according 
to the American College of Obstetricians and Gynaecologists practice bulletin.(2002) 
Atypical preeclampsia was defined by the International and Australasian Societies for 
the Study of Hypertension in Pregnancy(Brown et al., 2001) as gestational 
hypertension without proteinuria but with other multi-organ involvement or fetal growth 
restriction (<10th customised birthweight centile). The latter(Gardosi and Francis, 
2009) was calculated using the Gestation Related Optimal Weight (GROW) method. 
 
Final adjudicated diagnosis of pregnancy outcome was the reference standard for 
evaluating PlGF test accuracy. This was determined by two independent senior 
obstetricians or obstetric physicians requiring documentation of endpoints required to 
fulfil the diagnostic criteria; disagreement was resolved by a third adjudicating 
physician. All adjudicators were masked to PlGF values when assigning a final 
diagnosis; PlGF measurements were not revealed until all subject adjudication was 
complete. 
 
PlGF measurement  
Plasma samples were tested, using the Triage®
 
PlGF Test (Alere, San Diego, 
California), at each study centre according to the manufacturer’s instructions. All 
meters were programmed for the study duration to produce a masked result, 
determining satisfactory test completion only, without revealing the value. All 
laboratory staff were unaware of clinical outcomes. To determine assay 
reproducibility, replicate samples were also tested at a central laboratory. The assay 
uses fluorescently-labelled recombinant murine monoclonal antibodies and detects 
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PlGF specifically and quantitatively, in the range of 12-3000 pg/mL, in approximately 
15 minutes. The Total Precision (coefficient of variation) on plasma controls at 
concentrations of 85 pg/mL and 1300 pg/mL is 12.8% and 13.2%, respectively.  
 
Statistical analysis  
Women were classified according to: the gestation of the test (<35, 35+0 to 36+6, and 
≥37 weeks); the test result: normal (≥5th centile for gestation), low (<5th centile but 
≥12 pg/ml), and very low (<12 pg/ml); and the principal outcome: preeclampsia-D14. 
A positive test was PlGF concentration <5th centile for gestational age for normal 
controls (calculated from a study of 247 women with normal pregnancies contributing 
1366 samples between 20 to 40 weeks’ gestation.(Saffer et al., 2013) Test 
performance was evaluated as sensitivity, specificity, positive and negative 
predictive values, positive and negative likelihood ratios, and ROC areas. Kaplan-
Meier survival curves of gestational age at delivery were produced. Median and 
inter-quartile ranges for the time from PlGF test to delivery were calculated. 
Comparison of PlGF with other standard tests for preeclampsia (systolic and 
diastolic blood pressure, uric acid, alanine transaminase) was carried out for the 
primary outcome using unadjusted PlGF concentrations; proteinuria was excluded as 
it forms a confirmatory component of that outcome. For implementation to clinical 
practice in women under 37 weeks’ gestation, an exploratory analysis was 
conducted for use of a single threshold (independent of gestation), with properties 
similar to 5th centile cut-off. We evaluated the biochemical reproducibility of the test 
by analysing all samples a second time in one central laboratory. The required 
sample sizes were calculated for accurate estimation of the sensitivity and specificity 
of PlGF in determining the primary endpoint. We assumed a sensitivity of 0.90, 
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specificity 0.90, and 95% confidence intervals (2-tailed), requiring 62 preeclampsia 
cases and 150 non-preeclamptic women. As adjudication of final diagnosis (some 
weeks after delivery) lagged behind enrolment, 287 women were recruited prior to 35 
weeks’ gestation before enrolment was stopped. 
 
3.1.3 Results 
Between January 2011 and February 2012, 649 women were recruited at 20+0 to 
40+6 weeks in seven centres across the UK and Ireland. Of consented women, 24 
did not have a valid baseline sample (17) or were lost to follow-up (7). The 
characteristics of the remaining 625 women are shown overleaf in table 3.1. 
 
There were 287 women recruited below 35 weeks gestation, 137 between 35+0 and 
36+6 weeks and 201 recruited over 37 weeks gestation. Women were recruited as a 
result of self-reported symptoms or due to signs observed at routine antenatal 
appointments, as shown in table 3.2 overleaf. 
 
Table 3.3 shows final adjudicated diagnoses, medical intervention, onset of delivery 
and outcome. Nearly a half of episodes of adverse maternal outcome occurred in 




Table 3.1: Characteristics at booking and enrolment, of all women 
Gestation at enrolment  < 35+0 35+0 to 36+6 ≥37+0 
 N=287 N=137 N=201 
Median (IQR) age (years) 31.9 (27.0 to 35.9) 32.4 (27.5 to 35.4) 32.1 (27.5 to 36.0) 
Median (IQR) body mass 
index (kg/m2) 
28.6 (24.2 to 33.6) 28.6 (24.4 to 32.7) 26.9 (23.1 to 31.2) 
Nulliparous 123 (43%) 60 (44%) 89 (44%) 

















Median (IQR) highest 1st 
trimester systolic BP (mmHg) 
120 (110 to 130) 118 (110 to 127) 120 (108 to 123) 
Median (IQR) highest 1st 
trimester diastolic BP (mmHg) 













Previous medical history    
Previous pre-eclampsia: 











12 (4.5%) 0 1 (0.6%) 
Pre-gestational diabetes 6 (2.2%) 4 (3.2%) 0 




Table 3.2: Characteristics at study enrolment, by gestational age 
Gestation at enrolment (weeks, days) < 35+0 35+0 to 36+6 ≥37+0 
 N=287 N=137 N=201 
At enrolment in assessment unit    
Median (IQR) gestational age 
(weeks) 
31.0 (27.9 to 33.4) 36.0 (35.4 to 
36.4) 
38.4 (37.6 to 
39.6) 
Signs/ symptoms of suspected 
pre-eclampsia (non- exclusive): 
New onset of hypertension 
Worsening of underlying 
hypertension 
New onset of dipstick proteinuria 
Persistent epigastric/ right upper 
quadrant pain 
Headaches 

























Median (IQR) highest systolic BP  144 (131 to 159) 144 (132 to 153) 145 (135 to 155) 
Median (IQR) highest  diastolic BP 92 (82 to 100) 94 (86 to 100) 95 (87 to 100) 
Dipstick proteinuria:  
Not done 
Negative  













Median (IQR) Alanine 
transaminase U/L  
14 (11 to 20) 
(n=248) 
15 (11 to 21) 
(n=123) 
14 (11 to 19) 
(n=177) 
Median (IQR) creatinine (µmol/ L) 51 (44 to 62) 
(n=267) 
55 (47 to 66) 
(n=128) 
55 (49 to 64) 
(n=194) 
Median (IQR) uric acid (µmol/ L) 257 (189 to 330) 
(n=188) 
315 (237 to 360) 
(n=96) 
310 (253 to 380) 
(n=149) 
Median (IQR) platelet count (109/L) 233 (196 to 271) 
(n=269) 
213 (175 to 263) 
(n=132) 




Table 3.3: Final diagnoses following expert adjudication 
Gestation at enrolment (weeks, days) < 35+0 35+0 to 36+6 ≥37+0 
Total number of women N=287 N=137 N=201 








Chronic hypertension only 
Isolated proteinuria only 































































Magnesium sulfate use 6 (2%) 4 (3%) 0 
Onset of labour: 
Spontaneous labour 
Induced labour 

















Using pre-specified thresholds of <5th centile (low PlGF) and <12 pg/ml (very low 
PlGF), low PlGF had high sensitivities and negative predictive values for women 
tested before 35 weeks, declining at later gestations. For implementation into clinical 
practice for women presenting before 37 weeks’ gestation, an exploratory analysis 
determined that a PlGF threshold of <100pg/mL predicted preeclampsia-D14 or 
before 37 weeks’ gestation (whichever was sooner) with sensitivity and negative 
predictive values similar to diagnostic accuracy estimates obtained using a <5th 
centile cut-off. PlGF <5th centile also had good test accuracy for predicting 
subsequent delivery of a small for gestational age infant <1st centile, at any time 
point after enrolment (not restricted to diagnosis within 14 days of testing). The 
majority of women recruited below 35 weeks delivered by caesarean section, 
whereas vaginal delivery was more likely at later gestations. Adverse perinatal 





Table 3.4: Mode of delivery and early pregnancy outcome 
Gestation at enrolment (weeks, days) < 35+0 35+0 to 36+6 ≥37+0 
Total number of women N=287 N=137 N=201 
Total number of babies N=299 N=151 N=204 
Median (IQR) gestation at delivery 
(weeks) 
36.7 (33.6 to 
38.6) 
37.3 (36.6 to 
38.4) 
39.4 (38.6 to 
40.3) 
Preterm delivery <37/40 158 (53%) 55 (36%) 0 
Mode of delivery: 
Spontaneous vaginal delivery 






















Median (IQR) birth weight (g) 2420 
(1620 to 3125) 
2820 
(2340 to 3340) 
3278 
(2980 to 3560) 
SGA (<10th customised birth weight 
centile) 
142 (47%) 57 (38%) 52 (25%) 
SGA (<3rd customised birth weight 
centile) 
108 (36%) 39 (26%) 25 (12%) 
SGA (<1st customised birth weight 
centile) 
78 (26%) 19 (13%) 15 (7.3%) 









For women presenting prior to 35 weeks’ gestation, there were three cases with false 
negative results (≥5th centile), all with an additional indication for early delivery; four 
cases with very low PlGF (<12pg/ml) were delivered after 37 weeks with severe 
preeclampsia, three of whom delivered infants 5th customised birthweight centile 
suggesting placental disease. PlGF was <5th centile in all cases and <12 pg/ml in 
four of the seven cases of antepartum fetal death. Low PlGF predicted intrauterine 
fetal death with sensitivity 1.00 (95% CI 0.71 to 1.00); specificity 0.48 (0.44 to 0.52); 
















Final adjudicated diagnosis 
and other details  
False negative (PlGF normal and delivered within 14 days of sampling with final diagnosis 
of pre-eclampsia) 
A 28+2 29+5 1224 1330 29 Superimposed pre-eclampsia; 
SPPROM, spontaneous 
labour, Caesarean section 
B 29+6 30+0 160 1095 1 Atypical pre-eclampsia; 
reduced fetal movements and 
pre-labour Caesarean section 
C 33+2 34+4 218 2020 5 Severe pre-eclampsia; 
previous history of early onset 
pre-eclampsia 
PlGF very low and not delivered pre-term <37/40 
D 33+6 37+5 <12 2900 34 Severe pre-eclampsia 
E 34+1 38+1 <12 2350 3 Severe pre-eclampsia 
F 34+2 37+0 <12 2310 5 Severe pre-eclampsia 













23+0 23+1 374 Severe pre-eclampsia  
25+3 26+6 690 Severe pre-eclampsia with placental 
abruption 
27+5 29+4 570 Superimposed pre-eclampsia 
28+0 30+2 480 Twin pregnancy; severe pre-eclampsia and 
discordant FGR 
28+0 35+4 2210 Chronic hypertension with increase in blood 
pressure; FGR not suspected antenatally  
30+4 35+5 2220 Chronic hypertension with placental abruption 
33+2 38+6 1900 Gestational hypertension; FGR not suspected 
antenatally  
 
The area under the ROC curve for low PlGF in predicting preeclampsia-D14 was 
greater than all other commonly utilised tests, either singly or in combination 
(p<0.001 for all comparisons). Addition of blood pressure or other blood tests 










Figure 3.1: ROC areas (standard error) for PlGF compared to five other signs/ tests 
(systolic and diastolic blood pressure, uric acid, alanine transaminase and 
proteinuria) in determining PE D14 in 176 women presenting <35+0 weeks gestation 
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The times (in days) to delivery for the three groups (very low, low and normal PlGF) are 
presented by Kaplan-Meier curves, below: 
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The following table shows PlGF concentrations according to final diagnosis, stratified 
by gestational age. It is apparent that PlGF concentrations were lower in cases with 
severe pre-eclampsia, than with mild and in pregnancy associated with adverse 
outcome. As discussed in chapter 1, PlGF concentrations are naturally lower with 




Table 3.6: PlGF concentrations (pg/ml) in women by final diagnosis and by adverse events 
 < 35+0 35+0 to 36+6 ≥37+0 
Number of women N=287 N=137 N=201 









By diagnosis    
Mild pre-eclampsia 51 (20 to 228) 
n=25 
29 (15 to 65) 
n=24 
20 (12 to 30) 
n =40 
Severe pre-eclampsia 10 (10 to 25) 
n =79 
16 (10 to 28) 
n =32 




43 (10 to 432) 
n =40 
54 (28 to 100) 
n =10 




29 (10 to 106) 
n =32 
14 (12 to 52) 
n =15 




153 (59 to 407) 
n =27 
29 (23 to 97) 
n =14 
27 (20 to 64) 
n =42 
All other diagnoses  291 (143 to 542) 
n =84 
104 (36 to 273) 
n =42 
52 (28 to 116) 
n =7 
By adverse events    
No event 107 (20 to 365) 
n=168 
40 (15 to 146) 
n=95 




32 (10 to 140) 
n=80 
25 (14 to 51) 
n=28 
21 (16 to 31) 
n=31 
All other adverse 
events 
19 (10 to 132) 
n=39 
36 (15 to 100) 
n=14 





Standard test performance statistics were calculated to evaluate the performance of 
PlGF and these are summarised in the table below, suggesting a low PlGF is a 
robust predictor of adverse outcome. 
Table 3.7: Test performance statistics for low PlGF in prediction of adverse outcomes 
Enrolment gestation (weeks) < 35+0 35+0 to 36+6 ≥37+0 
 N=287 N=137 N=201 
PlGF <5th centile for gestation Pre-eclampsia requiring delivery within 14 days 
Sensitivity  
n/N 
0.96 (0.89 to 0.99) 
73/76 
0.70 (0.58 to 0.81) 
47/67 




0.55 (0.48 to 0.61) 
115/211 
0.64 (0.52 to 0.75) 
45/70 
0.77 (0.68 to 0.84) 
88/115 
Positive Predictive Value 
n/N 
0.43 (0.36 to 0.51) 
73/169 
0.65 (0.53 to 0.76) 
47/72 
0.65 (0.53 to 0.75) 
49/76 
Negative Predictive Value 
n/N 
0.98 (0.93 to 0.995) 
115/118 
0.69 (0.57 to 0.80) 
45/65 
0.70 (0.62 to 0.78) 
88/125 
Positive Likelihood Ratio 2.1 (1.8 to 2.5) 2.0 (1.4 to 2.8) 2.4 (1.7 to 3.5) 
Negative Likelihood Ratio  0.07 (0.02 to 0.22) 0.46 (0.31 to 0.71) 0.56 (0.43 to 0.73) 
PlGF <12 pg/ml Pre-eclampsia requiring delivery within 14 days 
Sensitivity  
n/N 
0.63 (0.51 to 0.74) 
48/76 
0.22 (0.13 to 0.34) 
15/67 




0.90 (0.85 to 0.94) 
190/211 
0.91 (0.82 to 0.97) 
64/70 
0.89 (0.81 to 0.94) 
102/115 
Positive Predictive Value 
n/N 
0.70 (0.57 to 0.80) 
48/69 
0.71 (0.48 to 0.89) 
15/21 
0.63 (0.45 to 0.79) 
22/35 
Negative Predictive Value 
n/N 
0.87 (0.82 to 0.91) 
190/218 
0.55 (0.46 to 0.64) 
64/116 
0.61 (0.54 to 0.69) 
102/166 
Positive Likelihood Ratio 6.4 (4.1 to 9.9) 2.6 (1.1 to 6.3) 2.3 (1.2 to 42) 
Negative Likelihood Ratio  0.41 (0.30 to 0.55) 0.85 (0.73 to 0.98) 0.84 (0.73 to 0.97) 
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The following figure demonstrates that time from test to delivery was significantly lower in 
women with a very low PlGF. The difference is most marked in women under 35 weeks’ 
gestation. 
 
Figure 3.3: Time to delivery (median, IQR) stratified by PlGF concentration for all 
participants and for pre-eclampsia cases. Red line: very low PlGF (<12 pg/ml); orange 
line: low PlGF (<5th centile); green line normal PlGF (≥5th centile). The numbers in the 


























All pre-eclampsia cases (n=87)














This study suggests that PlGF testing presents a realistic and innovative adjunct to 
the management of women with suspected preeclampsia, especially those 
presenting preterm. Low PlGF concentration (<5th centile or 100pg/ml) has high 
sensitivity and negative predictive value, in determining which women presenting 
with suspected disease at less than 35 weeks’ gestation are likely to need delivery 
for preeclampsia within 14 days. Time to delivery is markedly different for women 
with very low, low and normal PlGF values, facilitating stratified management 
strategies with appropriate surveillance. PlGF was more predictive of need for 
delivery than other commonly utilised signs and tests, either singly or in combination, 
in current clinical practice. Sensitivity and negative predictive values were also high 
for delivery of an SGA infant <1st centile; this indicator is most likely to equate to fetal 
growth restriction of placental origin and be associated with adverse perinatal 
outcomes. Although diagnostic accuracy is greatest for women presenting before 35 
weeks’ gestation, the test may still benefit those presenting up to 37 weeks’ 
gestation (using a threshold of <100pg/ml) for whom stratified surveillance is also 
advantageous and the risks/benefits of delivery remain uncertain.  
 
The strengths of this study include use of multiple centres encompassing a wide 
demographic and ethnic profile and a pragmatic approach to enrolment with minimal 
exclusion criteria, enabling generalisability. The main research question was chosen 
to be clinically relevant, utilising a primary outcome where delivery was indicated for 
the mother or infant, despite being preterm. Final diagnoses were independently 
adjudicated by two senior clinicians following database record review, using strict 
criteria. PlGF concentrations were not revealed until all diagnoses had been 
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adjudicated, so that the test result could not influence decisions for delivery. 
Laboratory staff were also unaware of the diagnosis. The analysis followed pre-
specified methods and outcomes, with subsequent transparent evaluation of a single 
PlGF threshold (rather than using a variable 5th centile threshold dependent on 
gestational age) to enable easier adoption into clinical practice.  
 
The optimal choice of primary outcome was difficult. When the study was planned, 
there was no validated composite measure of adverse outcome for women with 
preeclampsia. The fullPIERS model subsequently published used a composite 
outcome determined by iterative Delphi consensus; (von Dadelszen et al., 2011a) 
components of this composite (other than blood transfusion) are reported in our 
study. Maternal plasma PlGF normally declines in the latter part of the third trimester, 
reducing test performance above 35 weeks’ gestation; an ideal test would maintain 
separation between preeclamptic cases and other women, which is probably 
unachievable using a single biomarker at all gestations. More accurate determination 
of very low PlGF values (less than the current limit of detection of 12 pg/ml) could be 
useful; however, the high clinical sensitivity reported in this study relates to the pre-
specified threshold of <5th centile (low PlGF, or PlGF 100 pg/ml) rather than very 
low PlGF.  
 
This is the largest, and the first prospective multicentre, study to evaluate PlGF in 
women with suspected preeclampsia. Other studies have evaluated PlGF and other 
factors including soluble Flt-1 (sFlt-1; soluble fms-like tyrosine kinase-1), a 
trophoblast derived anti-angiogenic factor that is increased in plasma from 
preeclamptic women. A retrospective study of 87 women gave promising results for 
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sensitivity (0.93) of the ratio, PlGF/sFlt-1 (R&D Systems immunoassay, Minneapolis, 
USA) in identifying need for delivery within two weeks; (Chaiworapongsa et al., 
2011b) however a more recent study using a different assay for sflt-1/ PlGF ratio 
(Elecsys platform, Roche, Penzburg, Germany), found considerably lower sensitivity 
(0.73) and negative predictive value (0.87) at high specificity (0.94) in predicting 
maternal adverse outcome in women presenting at less than 34 weeks’ gestation, 
(Rana et al., 2012b) a level of sensitivity which is unlikely to be useful in clinical 
practice. A case-control study (Knudsen et al., 2011) and a small prospective 
observational study (Sibiude et al., 2012) using the Triage assay reported promising 
test performance. Another report of a direct comparison of assays in 128 pregnant 
women (44 with preeclampsia) confirmed higher sensitivity of the Triage test than the 
sflt-1/ PlGF ratio (Elecsys) in diagnosing early-onset preeclampsia. (Benton et al., 
2011) This may relate to different target epitopes of PlGF used in the Triage test 
compared to others available. Other studies have not reported sensitivity and 
specificity (recommended measures of diagnostic accuracy), making direct 
comparison difficult, (Verlohren et al., 2012) but have compared assays in women 
with established disease (Sunderji et al., 2010) or have tested at a fixed time-point 
rather than at presentation. (Lai et al., 2013a)  
 
Suspected preeclampsia is the most frequent clinical presentation to obstetric day 
care assessment units, and those with early onset disease are at greatest risk. 
Current signs and tests do not perform well in predicting need for delivery or adverse 
outcomes. We hypothesise that adding PlGF measurement to current clinical 
assessment of women with suspected preeclampsia before 37 (and particularly 
before 35) weeks’ gestation could improve risk stratification, achieve an earlier 
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diagnosis based upon underlying pathophysiology, enable individualised 
management of women with the disease, with the potential to reduce associated 
maternal morbidity and reduce unnecessary health service usage. There may be 
double benefit: targeting of resources to those at highest risk, while minimising 
excessive assessment and intervention in women at lower risk. One decision-
analytic modelling analysis has estimated $1400 cost saving associated with 
introduction of PlGF testing (based on sensitivity of 0.82) for management of 
pregnant women in a United Kingdom setting. (Hadker et al., 2010) Cost savings 
may be greater when the Triage platform has been adapted to test whole blood at 
point-of-care. We would propose that further assessment of PlGF should be 
undertaken in the context of a randomised controlled trial, as recommended for all 
new diagnostic tests, to measure the impact on the health of mother and baby 
through changing diagnostic/ treatment decisions, time to treatment, as well as 
potential harms. (Ferrante di Ruffano et al., 2012)   
 
Hypertensive disorders of pregnancy remain a challenge worldwide, as indicated by 
the recent Global Burden of Disease Study; (Lozano et al., 2012) improved detection 
and management have also been strongly recommended for reduction of stillbirths. 
(Bhutta et al., 2011) Whilst current strategies focus on blood pressure measurement 
and assessment of end-organ damage, this study provides evidence for the recently 
proposed concept that better diagnosis results from measuring secondary rather 






















4.1 Biomarkers predicting pre-eclampsia requiring delivery within 14 days 
4.1.1 Introduction 
Presenting symptoms of pre-eclampsia are often subjective and non-specific with 
clinical findings based on features of advanced disease or markers of end organ 
involvement. (Gomez-Arriaga et al., 2013, Benton et al., 2012a, Conde-Agudelo et 
al., 2013) High blood pressure and urinary protein excretion are typically used to 
diagnose the disease but both are subject to error and poor test accuracy. (Menzies 
et al., 2007b, Benton et al., 2012a, Conde-Agudelo et al., 2013) It is currently difficult 
to distinguish pre-eclampsia of a severity that requires early delivery, from other less 
serious phenotypes (von Dadelszen et al., 2011b), nor is it possible to risk 
discriminate in the large number of women who present with suspected disease. An 
accurate biomarker (or panel of biomarkers) to enable diagnosis and prognosis of 
perinatal complications could have substantial impact on management strategies 
with the aim of minimising adverse maternal and fetal outcomes. (Myers et al., 2013) 
Recent research suggests an imbalance of placentally-derived factors could hold 
diagnostic potential in these women and encompass feto-placental involvement.  
 
Using samples from women recruited to the PELICAN study, this planned analysis 
evaluated the performance of a further 57 biomarkers, (including those prevalent in 
current medical literature and reflecting the heterogeneous components of the 
disease pathogenesis) in isolation, as a ratio or in combination with PlGF, to 
determine pre-eclampsia requiring delivery within 14 days in women presenting with 
suspected pre-eclampsia <35 weeks’ gestation, and presenting between 35+0 and 
36+6 as a secondary analysis. Plasma concentrations were obtained from 397 
women for measurement of a targeted biomarker panel. Factor analysis and 
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stepwise logistic regression were conducted to determine whether any biomarkers 
added to PlGF for the determination of subsequent pre-eclampsia requiring delivery 
within 14 days. 
 
4.1.2 Materials and Methods 
The PELICAN study was a prospective multicentre cohort study, undertaken 
between January 2011 and February 2012 in seven consultant-led maternity units in 
the United Kingdom and Ireland. Women were eligible for the study if they had signs 
or symptoms of pre-eclampsia, were over 20+0 weeks’ gestation with a singleton or 
twin pregnancy and were aged ≥16 years. Primary analysis (as pre-specified) was 
performed on those presenting prior to 35 weeks’ gestation, with analysis also 
reported for those between 35+0 and 36+6 weeks’ gestation.  
 
We undertook a planned analysis reported here on two groups of women: Group 1: 
presenting prior to 35 weeks of gestation, and Group 2: presenting between 35+0 and 
36+6 weeks of gestation. These gestational age groupings were pre-specified, based 
on known differences in pathophysiological pathways associated with preterm pre-
eclampsia and our prior knowledge of gestational changes of biomarker 
concentrations related to these pathways. Written informed consent was obtained 
and baseline demographic and pregnancy-specific information, including blood 
pressure readings, were entered onto the study database. Blood pressure was taken 
according to unit guidelines. Blood samples were drawn into ethylenediamine tetra-
acetic acid, with consent, at the time of enrolment. The samples were labelled, 
transported to the laboratory and the plasma was stored until analysis at -80oC. 
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Pregnancy outcomes were determined by case note review with independent 
adjudication (masked to all biomarker concentrations) for final maternal diagnosis. 
 
Independent adjudication was undertaken by two senior physicians, masked to 
biomarker measurements, requiring documentation of end points required to fulfil the 
diagnostic criteria; disagreement was resolved by a third adjudicator. All sites 
managed women (including decision for delivery) in line with the Hypertension in 
Pregnancy recommendations from the National Institute for Health and Care 
Excellence and local guidelines.  
 
Biomarker selection 
An initial panel of biomarkers was selected based on either a priori knowledge of an 
association with pre-eclampsia, a biological role in placentation or a role in cellular 
mechanisms involved in the pathogenesis of pre-eclampsia e.g., angiogenesis, 
inflammation, coagulation.(Myers et al., 2013) The full list of biomarkers (Table S1) 
was generated following a review of the literature, appraisal of selected 
bibliographies and consultation with medical experts. 
 
Biomarker measurement 
Plasma samples were tested for Placental Growth Factor (PlGF) using the Triage®
 
PlGF Test (Alere, San Diego, CA) by trained laboratory staff at the study site where 
the sample was taken (as previously published). Samples were labelled, and 
transported to the laboratory where they were spun at 3000 rpm for 10 minutes. The 
additional 57 biomarker assays were analysed in a central laboratory facility (Alere, 
San Diego, CA). A list of biomarker assay information (low and high cut-offs, assay 
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coefficient variable and assay format) is given in table S2. All laboratory staff were 
masked to clinical outcomes. Samples were stored at -80 ⁰C and thawed prior to the 
assays being performed at room temperature. 
 
Immunoassays utilizing human plasma were performed in 384-well microtitre plates 
using Perkin-Elmer Minitrak robotic liquid handling system for all liquid handling 
steps. Assays were variations of antibody sandwich assays or competitive assays 
using biotinylated antigen. All assays were heterogeneous and required multiple 
washes. Test samples were added to the 384-well plate, containing wells for a 
calibration curve consisting of multiple analyte concentrations and control samples. 
Calibration curves were prepared gravimetrically in plasma from healthy donors. For 
sandwich assays, one concentration in each set of calibrators included neutralizing 
antibody for correction of endogenous antigen present in the plasma pool. All 
participants had delivered and pregnancy outcomes recorded before biomarker 
concentrations were analysed and revealed. 
 
Statistical analysis 
Standard distributional checks showed high levels of skewness for all 57 additional 
biomarkers, which were consistent with underlying log normal distributions. Logged 
values of these biomarkers were therefore used. Before considering the pregnancy 
outcomes factor analysis of biomarker data from all the women enrolled was 
undertaken, reducing the 57 biomarkers into a smaller group of factors. 
Consideration of scree plots and Eigen-values (> two) identified the most important 
factors for further analysis.(Schnettler et al., 2013a) These factors were rotated 
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(orthogonal varimax method) so that each factor related strongly (correlation >0.6) to 
a small number of biomarkers only. 
 
The principal outcome for this analysis was pre-eclampsia requiring delivery within 
14 days and the factor scores were entered into a multiple logistic regression model 
for determination of this outcome. Two factors (and their biomarkers) were identified 
for further investigation. Stepwise logistic regression (a parametric method) was 
used to determine which of these biomarkers appeared to provide additional 
information beyond that derived from PlGF and prediction scores were extracted for 
the best combinations. A comparison of Receiver Operated Curves (ROC) areas (a 
non-parametric method) of individual biomarkers and combinations was made to see 
if any of the additional information was both consistent and large enough to be 
clinically useful. 
 
Some biomarkers, with high uniqueness scores, were not strongly associated with 
any factor. To investigate whether any of these biomarkers had diagnostic power in 
addition to that provided by PlGF and biomarkers identified earlier, stepwise logistic 
regression was undertaken. To avoid excluding a biomarker that may be of potential 
value, we did not use a standard multiple-testing correction to p-values, such as 
Bonferroni. However, for a biomarker to be considered useful, it had to pass a series 
of tests, so that the chance of a false positive was greatly reduced. These included: 
being a component of a significant factor, being a significant predictor in logistic 
regression both alone and after allowing for PlGF, having a ROC area for the 
combined score significantly greater than PlGF alone, being a useful determinant for 
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pre-eclampsia requiring delivery within 14 days and provide an improvement over 
PlGF alone that was judged to be clinically useful. 
 
4.1.3 Results 
423 women with enrolment samples and outcome data available were recruited to 
the study in seven centres across the UK and Ireland between January 2011 and 
February 2012; 286 women in Group 1 (presenting at 20+0 to 34+6 weeks of 
gestation) and 137 women in Group 2 (presenting at 35+0 to 36+6 weeks of 
gestation). 
 
For the 286 women who were enrolled prior to 35+0 weeks of gestation, 
characteristics of the study population at antenatal booking are shown in table 4.1, 
subdivided into those that met the primary outcome (pre-eclampsia requiring delivery 
within 14 days) and all others. Table 4.2 shows characteristics of delivery and 
maternal and neonatal outcome. Table 4.3 shows the test performance for the most 
promising individual biomarkers, depicted by ROC areas. PIGF had the highest ROC 
area (0.87) for determining preeclampsia requiring delivery within 14 days; the ROC 
areas for sflt-1 (0.83) and endoglin (0.83) were not significantly different. 
 
Addition of further biomarkers to PlGF increased the area under the ROC curve by a 
small, non-significant increment only. The highest test performance for preeclampsia 
requiring delivery within 14 days was found using a combination of PlGF, 
podocalyxin, soluble endoglin and procalcitonin, with a ROC area of 0.90, not 





For women presenting between 35+0 and 36+6 weeks of gestation (n=137), the 
results follow a similar pattern as for women presenting at earlier gestations. The 
ROC area for PlGF alone (0.75; 95% CI (0.67 to 0.83)) in determining need for 
delivery for preeclampsia within 14 days was lower than that achieved in earlier 
gestations. Integration of soluble fms-like tyrosine kinase-1 (sFlt-1) with PlGF (as a 
ratio) increased the ROC to 0.77 (95% CI (0.69 to 0.84). The combination of PlGF, 
pregnancy-associated plasma protein A and cystatin yielded the highest ROC area 
of 0.81 (95% CI (0.74 to 0.88) (table 4). Both increments were small and not 
significant.  





















within 14 days 
n=67 
All other participants 
n=70 
Total for analysis 20+0 to 
34+6 weeks gestation n=286 
Total recruited 35+0 to 36+6 
weeks gestation n=137 




Table 4.1: Characteristics of participants at booking and enrolment in women <35 weeks’ 
gestation (according to diagnosis of pre-eclampsia) Values given are median (quartiles) or n 
(%) as appropriate.  









31.1 (26.8 to 35.6) 
 




31.9 (27.0 to 35.8) 
BMI (kg/m2) 26.2 (22.8 to 30.1) 29.1 (25.0 to 34.7) <0.001 28.6 (24.2 to 33.6) 
White ethnicity 50 (65.8) 137 (65.2) 0.62 187 (65.4) 
Singleton 71 (93.4) 203 (96.7) 0.27 274 (95.8) 
Highest SBP 
(mmHg) 
120 (110 to 130) 121 (110 to 130) 0.32 120 (110 to 130) 
Highest DBP 
(mmHg) 
70 (65 to 80) 75 (66 to 84) 0.04 74 (66 to 81) 
Smoker at booking 11 (14.9) 42 (20.5) 0.30 58 (19.0) 
Quit smoking  7 (9.5) 27 (13.2) 0.41 34 (12.2) 
Previous medical 
history: 
    
Pre-eclampsia 
<34/40 
10 (13.3) 20 (9.7) 0.20 30 (10.7) 
Chronic 
hypertension 
7 (10.1) 38 (19.0) 0.08 45 (16.7) 
Known SLE or APS 2 (2.9) 10 (5.0) 0.44 12 (4.5) 
Pre-existing DM 2 (2.9) 4 (2.0) 0.71 6 (2.2) 
Renal disease 5 (7.2) 14 (7.0) 0.98 19 (7.1) 
 
SBP: systolic blood pressure in <12 weeks; DBP: diastolic blood pressure in <12 weeks;  




Characteristics Women with 




P value All women 
n=286 
At enrolment:     
New onset 
hypertension 
53 (70) 101 (48) 0.03 154 (54) 
Worsening of 
hypertension 
14 (18) 42 (20) <0.001 56 (20) 
Proteinuria (+1 or 
greater) 
51 (67) 94 (45) 0.77 145 (51) 
Highest systolic BP 
(mmHg) 
150 (140 to 165) 141 (129 to 156) <0.001 143 (131 to 159) 
Highest diastolic BP 
(mmHg) 




40 (42) 40 (31) <0.001 1 (1) 
Alanine transaminase 
(U/L) 
16 (12 to 21) 14 (11 to 19) 0.10 14 (11 to 20) 
Creatinine (mg/dl) 60 (50 to 73) 49 (42 to 57) <0.001 51 (44 to 62) 
Uric acid (mg/dl) 327 (256 to 410) 240 (180 to 289) <0.001 257 (190 to 330) 




Table 4.2: Characteristics of delivery and maternal and neonatal outcome. Values 
given are median (quartiles) or n (%) as appropriate. 
Characteristics Women with PE-





All women n=286 
Onset of labour     
Spontaneous 3 (4%) 38 (18%) 0.01 41 (14%) 
Induced 13 (17%) 95 (45%) <0.001 108 (38%) 
Pre-labour 
caesarean section 
59 (78%) 75 (36%) <0.001 134 (47%) 
Mode of delivery     
Spontaneous 3 (4%) 67 (32%) <0.001 70 (25%) 
Assisted vaginal 
delivery 
4 (5%) 27 (13%) <0.001 31 (11%) 
Caesarean 
section 
67 (91%) 116 (55%) <0.001 183 (64%) 
Adverse maternal 
outcome* 
37 (49%) 84 (40%) 0.11 121 (42%) 
Gestation (weeks) 32.9 (30 to 34.4) 37.9 (36 to 39.3) <0.001 36.9 (33.6 to 38. 7) 
Neonatal 
outcomes 
n=71 n=203  n=274 
Fetal death 3 (4) 3 (2) 0.19 6 (2) 
Neonatal death 2 (3) 0 (0) <0.001 2 (1) 
Birth weight (g) 1460 
(1030 to 1740) 
2900 
 (2320 to 3350) 
<0.001 2500 
(1620 to 3170) 
SGA  55 (78) 75 (37) <0.001 130 (47) 
Adverse perinatal 
outcome† 
34 (48) 26 (13) <0.001 60 (22) 
* Adverse maternal outcome defined as presence of any of the following complications: Maternal 
death, Eclampsia, Stroke, Cortical blindness or retinal detachment, Hypertensive encephalopathy, 
118 
 
Systolic blood pressure ≥160mmHg, Myocardial infarction, Intubation (other than for caesarean 
section), Pulmonary oedema, Platelets <50×10⁹/L (without transfusion), Disseminated intravascular 
coagulation, Thrombotic thrombocytopenic purpura/ haemolytic uraemic syndrome, Hepatic 
Dysfunction (Alanine transaminase ≥70IU/L), Hepatic haematoma or rupture, Acute fatty liver of 
pregnancy, Creatinine >150 μmol/L, Renal dialysis, Placental abruption, Major postpartum 
haemorrhage, Major infection. 
SGA: small for gestational age (<10th centile for birth weight) 
† Adverse perinatal outcome defined as: presence of any of the following complications: Antepartum/ 
intrapartum fetal or neonatal death, Neonatal unit admission for >48 hrs at term, Intraventricular 
haemorrhage, Periventricular leucomalacia, seizure, retinopathy of prematurity, respiratory distress 




Table 4.3: ROC areas (95% confidence intervals) for individual biomarkers and 
combinations (derived from logistic regression) to determine pre-eclampsia requiring 
delivery within 14 days of sampling in women presenting before 35 weeks’ gestation.  
[ ] indicates low concentration of biomarker/ratio correlated to disease. 
Biomarkers or combinations ROC areas (95% 
confidence intervals)  
P value (vs. PlGF 
alone) 
[PAPP-A] 0.65 (0.57 to 0.72) <0.001 
NGAL  0.67 (0.61 to 0.74) <0.001 
Cystatin 0.68 (0.61 to 0.75) <0.001 
BNP 0.75 (0.69 to 0.82) <0.001 
ST2 0.76 (0.70 to 0.82) <0.001 
sFlt-1 0.83 (0.78 to 0.88) 0.08 
Endoglin  0.83 (0.79 to 0.88) 0.07 
[PlGF] 0.87 (0.83 to 0.92)  -   
Combinations   
[PlGF/sFlt-1 ratio] 0.88 (0.83 to 0.91) 1.00 
PlGF, C-Met  0.88 (0.83 to 0.91) 1.00 
[PlGF/sEng ratio] 0.88 (0.84 to 0.92) 1.00 
[PlGF], sEng  0.88 (0.84 to 0.92) 1.00 
[PlGF], [CPA-4], [C-Met] 0.88 (0.84 to 0.92) 1.00 
[PlGF], [CPA-4] 0.89 (0.84 to 0.92) 0.86 
[PlGF], Cystatin, PAPP-A  0.89 (0.85 to 0.93) 1.00 
[PlGF], Podocalyxin, BNP, [CPA-4] 0.90 (0.86 to 0.93) 0.23 




Table 4.4: ROC areas (95% confidence intervals) for individual biomarkers and 
combinations (derived from logistic regression) to determine preeclampsia requiring 
delivery within 14 days of sampling in women presenting between 35+0 and 36+6 
weeks’ gestation. [ ] indicates low concentrations of biomarker correlated to disease. 
Biomarkers or combinations ROC areas (95% 
confidence intervals) 
P value (vs. 
PlGF alone) 
Cystatin 0.64 (0.55 - 0.73) 0.11 
[Pregnancy specific plasma protein A] 
(PAPP-A) 
0.66 (0.58 - 0.75) 0.12 
Neutrophil gelatinase-associated lipocalin 
(NGAL) 
0.67 (0.59 - 0.76) 0.22 
Brain natriuretic peptide (BNP) 0.70 (0.61 - 0.78) 0.35 
Interleukin-1 receptor-like 1 (ST2) 0.71 (0.63 - 0.79) 0.50 
Endoglin  0.71 (0.63 - 0.80) 0.60 
Soluble fms-like tyrosine kinase-1 (sFlt-1) 0.75 (0.67 - 0.83) 0.88 
[Placental growth factor] (PlGF) 0.75 (0.67 - 0.83) -  
Combinations   
[PlGF], procalcitonin 0.73 (0.65 - 0.81) 1.00 
[PlGF], endoglin 0.75 (0.67 - 0.83) 1.00 
[PlGF], Podocalyxin, BNP, procalcitonin 0.76 (0.68 - 0.84) 1.00 
[PlGF], Podocalyxin, sEng, procalcitonin 0.76 (0.68 - 0.83) 1.00 
[PlGF/sFlt-1 ratio] 0.77 (0.69 - 0.84) 1.00 
[PlGF/endoglin ratio] 0.77 (0.66 - 0.82) 1.00 







This prospective multicentre study is a comprehensive direct comparison of 
diagnostic biomarkers for preeclampsia. The results demonstrate that in women with 
suspected preeclampsia presenting preterm, use of a single angiogenesis-related 
biomarker (PlGF, sflt-1 or endoglin) alone represents a useful diagnostic test for 
determining preeclampsia requiring delivery within 14 days, a relevant endpoint 
indicating that a clinician has considered that the risks of adverse outcomes 
associated with ongoing expectant management are outweighed by the risks of 
delivery.  
 
Suspected hypertensive disorders in pregnancy are the commonest reason for 
presentation for obstetric assessment in the third trimester of pregnancy. Diagnostic 
uncertainty is common when women present to obstetric assessment units with one 
or more signs suggestive of preeclampsia. Women undergo a series of 
investigations, many of which are poor predictors of the need for delivery or likely 
adverse outcome. In practice, obstetricians require a test that enables a woman to 
be triaged, to determine those that require increased surveillance, and those where 
the likelihood of needing delivery for preeclampsia within fourteen days is very low 
and outpatient care may be appropriate. Such a test would enable development of 
safe clinical algorithms and avoid inappropriate intervention or unnecessary maternal 
anxiety. 
 
PlGF is an angiogenic factor synthesised by the trophoblast, a marker of associated 
placental dysfunction in pre-eclampsia, with known low plasma concentrations in the 
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disease. Whilst combining PlGF with some of the other 46 biologically plausible 
biomarkers marginally improved the ROC area, the combinations added little to the 
diagnostic performance of PlGF alone. This important negative result demonstrates 
the diagnostic option of using a single biomarker (over and above a combination of 
biomarkers) in preterm preeclampsia. These findings are more marked in women 
presenting prior to 35 weeks of gestation, and are similar, with lesser diagnostic 
efficacy, in women presenting between 35+0 and 36+6 weeks of gestation. This 
probably reflects the inclusion of women who meet the primary outcome definition 
(preeclampsia with delivery within 14 days) who were delivered routinely at 37 weeks 
of gestation following national guideline recommendations and not because of a 
clinician concern over a potential placentally-mediated adverse event. 
 
Strengths of this study include use of seven study sites and a large participant 
cohort, encompassing a wide demographic and ethnic profile including women with 
underlying maternal disease. Plasma testing was carried out in a central laboratory 
ensuring that results were obtained with rigorous quality control. Progressive 
statistical analysis explored single biomarker predictive power, and compared the 
impact of combining groups of markers, or using biomarker ratios. A limitation was 
that test results were not validated in a repeat sample or by comparative testing at a 
second laboratory.  
 
Previous studies have described other pathophysiologically relevant third trimester 
markers, including soluble endoglin (Rana et al., 2012a), or measurement of a ratio 
such as PlGF/sFlt-1. (Chaiworapongsa et al., 2011a, Rana et al., 2012b) However, 
studies have usually been small or from a single centre, in established disease, 
123 
 
using a case-control design and have shown lower sensitivity for a clinically relevant 
endpoint. Several additional biomarkers, in combination with PlGF yielded the 
highest ROC area, but the increase in test performance was only marginal. 
 
Pre-eclampsia and its related conditions represent a diagnostic challenge for 
clinicians. The lack of a reliable diagnostic test results in poorly targeted antenatal 
monitoring and hospitalisation. (Conde-Agudelo et al., 2004b, Schnettler et al., 
2013a, von Dadelszen et al., 2011b) Women with pre-eclampsia and a viable fetus 
present difficult management decisions; iatrogenic preterm delivery may avoid 
further maternal complications but may result in morbidity for the infant. Previous 
studies have suggested that individual biomarkers for diagnosis are promising, but 
often in case-control studies in which women with established pre-eclampsia are 
compared to healthy women with uncomplicated pregnancies, leading to inevitable 
over-fitting. We are not aware of previous reports of this size in a clinically relevant 
cohort (women with suspected pre-eclampsia) that has included such a panel of 
biomarkers that reflects the heterogeneity of the disease. 
 
Development of a diagnostic test, using pathophysiologically relevant biomarkers 
where concentrations correlate with need for imminent delivery, and therefore with 
clinically relevant disease severity, may have advantages over traditional diagnostic 
measures. (Anumba et al., 2010, Steegers et al., 2010a) Early onset pre-eclampsia 
is associated with greater maternal and perinatal risks; a test that predates signs of 
established disease would be advantageous allowing targeted surveillance and 
facilitating appropriate reassurance. Systematic reviews have indicated that currently 
utilised tests such as proteinuria, (Thangaratinam et al., 2009a) transaminases 
124 
 
(Thangaratinam et al., 2011c) and uric acid (Thangaratinam et al., 2006a) are not 
good predictors of maternal or fetal complications in women with suspected pre-
eclampsia.  
 
This study supports the utility of PlGF (without additional biomarkers) for diagnostic 
use in women with suspected pre-eclampsia and confirms other smaller or single-
centre studies. (Chaiworapongsa et al., 2013b, Meis et al., 1998b, von Dadelszen et 
al., 2011b, Moore et al., 2012) Women with low or very low PlGF concentrations 
experienced adverse perinatal outcomes (Chappell et al., 2013b) and suggest that 
increased surveillance should be considered for these women. Evidence now 
supports the use of PlGF across a range of demographic settings (Thangaratinam et 
al., 2009a) in the prediction of pre-eclampsia, (Chappell et al., 2013b, 
Thangaratinam et al., 2011c) adverse outcome (Conde-Agudelo et al., 2013) and 
placentally related stillbirth. (Moore et al., 2012) 
 
Suspected hypertension in pregnancy is the commonest reason for presentation for 
obstetric assessment in the third trimester of pregnancy. This study demonstrates 
that PlGF measurement alone is a very good diagnostic biomarker for determining 
need for imminent delivery for pre-eclampsia and that other biomarkers add minimal 
increment to its performance. Improved risk stratification would facilitate diagnosis 
and subsequent management decisions, allowing appropriate intervention and timely 
delivery. We suggest that PlGF measurement, as an adjunct to physical assessment 
and existing markers of disease, could improve outcomes for women and their 
babies. We further hypothesise that testing of this kind may improve the experience 
of women and the allocation of health resources. Improved detection of placental 
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disease remains a global health priority. Further research is essential to assess 
revealed PlGF measurements in real-time management of women with suspected 
pre-eclampsia through appropriate clinical algorithms, with the scope to determine 
disease prior to tertiary features of end organ damage.(Stepan et al., 2007, Staff et 
al., 2013c) 
 
The lack of reliable diagnostic tests results in poorly targeted antenatal monitoring 
and hospitalisation. A test performed at presentation that enables targeted 
surveillance for those at increased risk of maternal or fetal complications and 
provides appropriate reassurance to those who test negative has the potential to 
assist in the allocation of health resources. Biomarkers such as PlGF can be 
analysed quickly, representing a test that could aid risk stratification of women with 
suspected preterm preeclampsia. Further research, through randomised controlled 
trials, is essential to assess how these biomarker measurements can assist in 
determining (or refuting) diagnosis in preeclampsia, and how this can improve 
outcomes for mother and baby through optimal tailored clinical management. Further 







Improved detection of placental disease remains a global health priority. In women 
presenting with suspected pre-eclampsia before 37 weeks’ gestation, use of a single 
angiogenesis-related biomarker may be clinically useful as a diagnostic test without 
the need for combinations (which entail additional cost and complexity). Biomarkers 
such as PlGF can be analyzed quickly, representing a test that could aid risk 
stratification of women with suspected preterm preeclampsia. PlGF represents a 
























5.1 Placental Growth Factor (PlGF) in women with suspected pre-eclampsia 
prior to 35 weeks’ gestation: a budget impact analysis. 
 
The aim of a budget impact analysis is to estimate the financial consequences to a 
health-care decision maker of implementing a new technology, including the number 
of patients treated, the effectiveness of the new technology, the costs and rate of 
implementation and the overall impact on resource use compared to the current 
technology. In the NHS, national policy and clinical practice is influenced by clinical 
guidelines published by the National Institute for Health and Clinical Excellence 
(NICE) and guidelines by specialist groups, such as the Pre-eclampsia Community 
Guideline (PRECOG) (Milne et al 2005). Providers have the responsibility of 
ensuring that they provide evidence based health care, including diagnostic and 
screening tests. The NHS Clinical Commissioning Groups (CCGs) are responsible 
for improving practice in their respective area so as to ensure the best patient 
outcomes within the resource envelope available. 
 
One of the biggest challenges for the management of pre-eclampsia is early, reliable 
identification, and risk stratification. The current method for identifying pre-eclampsia 
is based on insensitive and unspecific clinical markers: 20% of women who have 
suspected pre-eclampsia do not meet the criteria for a clinical diagnosis prior to 
developing the end-stage, eclampsia (Altman et al., 2002) and only 0.7 to 5% of 
those who meet the diagnostic criteria will go on to experience any pre-eclampsia 
related adverse outcome. (Menzies et al., 2007a)  A diagnostic test that could 
reliably aid clinical diagnosis and direct clinical management by risk stratifying 
women into low-, intermediate-, and high-risk groups for adverse outcome would 
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facilitate clinical management. Such a test would need very high sensitivity and 
Negative Predictive Value (NPV), allowing better differentiation of those women who 
could benefit from more intensive management, from women who often receive 
inappropriate and resource-intensive management, but do not progress to a clinical 
diagnosis of pre-eclampsia or an adverse. 
 
Establishing a diagnosis of pre-eclampsia can be time consuming and resource 
intensive. In women with suspected pre-eclampsia, current clinical management 
requires high-cost monitoring, fetal surveillance, (Steegers et al., 2010b) and medical 
management, which increases the likelihood of antenatal admission and possible 
iatrogenic preterm delivery. (Meis et al., 1998a) In the US in 1992, $20 billion was 
spent on managing women with pre-eclampsia and their babies.(Schnettler et al., 
2013b) The next chapter of this thesis describes the development of a management 
algorithm, modelling the resource implications of PlGF testing in women with 






In the absence of a reliable test, clinical uncertainty leads to over-utilisation of 
ancillary testing and intervention, with associated expense of antenatal monitoring 
and in-patient admissions, placing considerable burden on pregnant women and 
their families. While biomarkers and imaging techniques have been evaluated, none 
have adequate sensitivity, specificity, and convenience for diagnosis or prediction of 
pre-eclampsia or its complications, (Meads et al., 2008) the majority identifying 
advanced disease with established end-organ damage. The PELICAN study 
identified PlGF as an important and reliable predictor of pre-eclampsia, in women 
below 35 weeks’ gestation. Test performance statistics revealed high sensitivity 
(0.96) and negative predictive value (0.98). The introduction of PlGF could target 
those women at greatest risk for increased surveillance, whilst avoiding unnecessary 
intervention and resource use in those with subsequent normal outcomes. 
 
Current clinical guidelines (American College of Obstetricians and Gynecologists. 
Task Force on Hypertension in Pregnancy and American College of Obstetricians 
and Gynecologists, National Institute for Health and Clinical Excellence, 2010) 
support the differentiation of pre-eclampsia into mild and severe categories; entities 
which are treated differently, particularly at preterm gestations. Diagnostic 
uncertainty and imperfect risk stratification leads to treatment delays and poorer 
outcomes (for women at high risk of disease who may need imminent delivery), or 
over-management and high costs for the health service and women (through 





Time to delivery is markedly different for women with <12, ≥12<100, and ≥100 pg/mL 
PlGF values, (9 days, 23 days and 62 days respectively), (Chappell et al., 2013a) 
facilitating stratified management strategies with appropriate surveillance. Pre-
eclampsia is diagnosed by the presence of hypertension and new onset proteinuria. 
Clinical management, according to the NICE Guideline CG107 (August 2010), is 
determined by the severity of hypertension (mild, moderate, and severe) and by the 
presence of other concerning findings (e.g., small for gestation age foetus or 
concerning maternal blood anomalies).  
 
Performing a budget impact evaluation provided an opportunity to supplement data 
from the literature with actual resource use to calculate the cost of current practice 
and model the savings if PlGF were used in management decisions. A treatment 
algorithm, to be used alongside the PlGF test, allowed us to hypothesise how 
pregnant women might be managed based on PlGF and other clinical 
characteristics. The aim of this analysis was to evaluate the cost impact on local 
NHS budgets of introducing PlGF testing in this cohort of women if management 
were based on revealed PlGF results. Costs for current treatment, without PlGF, are 
taken from women recruited as part of the PELICAN study. The cost of PlGF plus a 






We undertook a prospective observational, cohort study investigating the role of 
PlGF testing in women with suspected pre-eclampsia, between January 2011 and 
February 2012, in seven centres across the UK and Ireland (PELICAN study). 
(Chappell et al., 2013a) Women were eligible for the study if they had signs and/or 
symptoms of suspected pre-eclampsia, were between 20+0 and 40+6 weeks of 
gestation with a singleton or twin pregnancy and were aged ≥16 years. Women with 
confirmed pre-eclampsia at the time of presentation were not eligible. Written 
informed consent was obtained and baseline demographic and pregnancy-specific 
information were entered onto the study database. As part of the budget impact 
analysis we conducted a detailed case note review of the resource use and 
pregnancy outcomes of 132 women enrolled in the PELICAN study prior to 35 
weeks’ gestation from two sites (London and Oxford), selected from the 625 women 
enrolled in the PELICAN study. A sample of women presenting prior to 35 weeks’ 
gestation was based on (i) a random sample of 109 women from a large inner city 
hospital so that all 18 diagnostic groups associated with hypertension and proteinuria 
were represented in the model, and all women with no hypertension, no proteinuria 
(protein: creatinine ratio <30mg/mmol) and with no diagnosis of pre-eclampsia prior 
to delivery were included and (ii) 23 women from a smaller site. Detailed 
retrospective case note review was carried out to record health service usage, 
including outpatient appointments, day assessment attendance, hospital admissions 
and ultrasound surveillance during the two week period after their enrolment to the 





Plasma samples were tested for PlGF using the Triage®
 
PlGF Test (Alere, San 
Diego, California) by trained laboratory staff at the UK site where the sample was 
taken. All participants had delivered and had pregnancy outcomes recorded before 
biomarker concentrations were analysed and revealed. Using a threshold cut-off of 
the 5th centile, a PlGF concentration below this was classed as ‘low PlGF’. A PlGF 
concentration above 100pg/ml (equivalent to the 5th centile) was classed as ‘normal 
PlGF’. A PlGF concentration below 12pg/ml was categorised as ‘very low PlGF’. 
Diagnoses of mild, moderate, and severe hypertension were made using criteria 
dictated by National Institute for Health and Care Excellence guidelines for the 
management of hypertension in pregnancy; (National Institute for Health and Clinical 
Excellence, 2010) diagnosis of preeclampsia was made through adjudication by 
senior physicians using international definitions. (Brown et al., 2001) 
 
PlGF treatment algorithm 
The National Institute for Health and Care Excellence guidelines on the management 
of hypertensive disorders in pregnancy advocate admission for all women diagnosed 
with pre-eclampsia, with severity of hypertension and fetal well-being directing 
management and timing of delivery; timing of delivery is dependent on maternal and 
fetal condition and neonatal intensive care availability. (National Institute for Health 
and Clinical Excellence, 2010) This guideline was used to inform the ‘current 
treatment’ algorithm. 
 
Actual resource use, extracted from retrospective case note review, was applied to 
the treatment model, allowing theoretical comparison of economic burden. We 
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hypothesised that additional measurement of PlGF could aid clinical decision-making 
as to appropriate place of care and frequency of monitoring. Figure 1 shows a 
clinical management pathway, based on data from the PELICAN study, that uses 
measurement of PlGF alongside blood pressure and proteinuria to risk stratify 
women with suspected pre-eclampsia.  
 
Decision analytic model 
A decision model was developed to assess the budget impact of introducing PlGF 
testing as a prognostic adjunct compared with current practice. The model used a 
hypothetical cohort of 1,000 women who are assumed to have the same 
characteristics as 1,000 consecutive pregnant women presenting to an antenatal 
service in England. Using the proportions derived from our study data we calculated 
(i) the number of women who would be tested for pre-eclampsia using PlGF (ii) the 
number of women who fall into each of the three PlGF categories (iii) the number of 
women who will eventually have a diagnosis of pre-eclampsia or not in each of the 
resulting branches (iv) the number of women with no, mild to moderate or severe 
hypertension in each of the resulting branches. Of the 1,000 women, it is assumed 
that only women presenting with suspected pre-eclampsia undergo PlGF testing. 
Given that the treatment for women who do not present with suspected pre-
eclampsia remains the same in both arms of the model their costs have not been 








Health care resource use 
Health care resource use for the current treatment group presenting with suspected 
pre-eclampsia prior to 35 weeks’ gestation was calculated from women in the case 
note review. Women were divided by the three different PlGF test thresholds: <12 
pg/ml PlGF; PlGF ≥12<100 pg/ml; or PlGF ≥100 pg/ml and into three different groups 
of hypertension: normotensive or mild hypertension; moderate hypertension; or 
severe hypertension for a total of nine groups. As clinicians in the study were not 
aware of the PlGF test result the resource use for each group represents current 
practice based on clinical impression only, with no knowledge of PlGF 
concentrations. 
 
Resource use was evaluated by (i) percentage of women that accessed the service 
(ii) the mean number (and standard deviation) of times women accessed the service 
or average length of stay in the case of inpatient admissions (sub-divided into those 
that had fewer than five days length of stay and those with greater length of stay to 
reflect the different tariff payments for long and short stay women). 
 
Health care resource use for the ‘PlGF test plus treatment’ algorithm was based on 
the current treatment algorithm (figure 1) and the National Institute for Health and 
Care Excellence Hypertension in Pregnancy Guideline. (National Institute for Health 
and Clinical Excellence, 2010) Health care resource use was calculated in the same 
way as for the ‘current treatment’ arms, except that a weighted average was included 
for the proportion of women in each group with proteinuria (given that this would 
increase the likelihood of women being admitted). The proportion of women in each 
group with proteinuria was calculated from the 288 records in the PELICAN study 
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where the baseline measurement of PlGF, proteinuria and blood pressure was taken 
prior to 35 weeks’ gestation (table 2). 
 
The cost of routine diagnostic tests (such as serum transaminases, urinary protein 
estimation) and medication was not included as they represent a negligible 
proportion of total cost of care and reliable recorded data were not readily available. 
Most of these costs would be included in the tariff and hence would not represent an 
additional cost to the payer. 
 
Cost Perspective 
The model is from the budget perspective of a commissioner, the organisation 
responsible for buying health care, within the National Health Service (NHS) in 
England. All costs are for the 2013/2014 financial year. Costs were obtained from 
2013-2014 NHS tariffs and 2011-2012 reference costs (table 3). Reference costs 
were converted to 2013-2014 values using the average last two years (2011/12 and 




Confidence intervals were calculated using Monte Carlo simulation for 1,000 
iterations of the model to calculate the Monte Carlo error and associated 95% 
confidence intervals. The percentage of iterations where the model reported a cost 
saving are also reported. All percentages were modelled using a beta distribution 
and health care resource using a gamma distribution. Point estimates only were 
used for health care resource use associated with the treatment algorithm. The 
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impact of different assumptions about health care resource use for the treatment 
algorithm on cost savings was tested as part of the deterministic sensitivity analysis. 
It was assumed that tariff, reference and PlGF costs were constant and hence these 
were also not varied. 
 
Sensitivity Analysis 
Studies have reported different point estimates for the incidence of pre-eclampsia 
and the presentation of risk factors indicative of pre-eclampsia in a pregnant 
population. We conducted two sensitivity analyses using the point estimates reported 
by Hadker et al (2010)(Hadker et al., 2010) and Meads et al (2008).(Meads et al., 
2008) The ‘PlGF plus treatment’ algorithm is based on guidelines for women 
presenting with suspected pre-eclampsia in whom there was additional information 
available on PlGF concentrations. There are no data directly available for actual 
resource use following implementation of the PlGF test and treatment algorithm as 
no trial has been conducted and formal implementation of the test has not been 
comprehensively reported. As a result we tested a range of best and worst case 
scenarios of health care resource use to assess the impact on potential cost savings 
from the PlGF test and treatment algorithm. The final price for PlGF test has not 










The resource cost (per 1,000 women) for two weeks following the PlGF test, 
according to diagnostic group, is summarised in Tables 5.1 and 5.2. Of 1,000 
women, 60 presented with suspected pre-eclampsia prior to 35 weeks’ gestation and 
18 (30%) had a final diagnosis of pre-eclampsia.  In the model, one woman with a 
final diagnosis of pre-eclampsia had a PlGF concentration greater than 100 pg/ml 
(false negative). 19 women without pre-eclampsia had a PlGF concentration below 
100 pg/ml PlGF threshold (false positives) and hence were managed using the PlGF 
algorithm even though they did not have a final diagnosis related to pre-eclampsia. 
 
The mean cost saving associated with the PlGF test (in the PlGF plus treatment arm) 
was £35,087 (95% CI -£33,181 to -£36,992) per 1,000 women. For each woman 
tested this equated to a cost saving of £582 (95% CI -£552 to -£613). In 94% of 
iterations, PlGF testing was associated with cost saving compared to current 
practice. (Hadker et al., 2010) used an incidence of pre-eclampsia of 4.0% with 15% 
of pregnant women presenting with symptoms indicative of pre-eclampsia. If these 
figures are used in the model, holding all other variables at the baseline values, the 
mean cost saving per 1,000 women is £24,324 (95% CI -£22,876 to -£27,785) with 
77% of the iterations of the model demonstrating a cost saving. 
 
These assumptions produce a mean cost saving per woman, (with inclusion of the 
PlGF test), of £543 (95% CI -£493 to -£594), with the assumption that 45 pregnant 
women will present with suspected pre-eclampsia prior to 35 weeks’ gestation and 
hence PlGF concentrations will be measured. If the incidence of pre-eclampsia 
reported previously (Meads et al., 2008) is used, the result is similar to the baseline 
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result at a cost-saving of £22,342 (95% CI -£20,320 to -£24,362) and 78% of 
iterations of the model are cost saving. Most cost savings were found in the 
moderate hypertension diagnostic group with a saving of £37,413 across 35 women. 
Women with a PlGF of ≥12<100 pg/ml had a total cost saving of £33,491 (across 21 
women). In the ‘current treatment’ group, 60% of women were admitted, 28% for 
longer than five days. This was high compared to women with no to mild 
hypertension, where 39% were admitted, with 4% being admitted for fewer than 5 
days. 
 
The following diagram represents these assumptions, showing final diagnosis in 60 





Figure 5.2: Algorithm (+PlGF) showing hypothetical diagnostic outcome for 60 women 














































Table 5.1: Two-week costs of PlGF plus treatment algorithm compared to current practice for 1,000 pregnant women, based on 
correct identification of women with a final diagnosis of pre-eclampsia (deterministic). 
PlGF (pg/ml) Hypertension No. of Women PlGF +  Algorithm Total Cost Current Practice Total Cost Difference 
PlGF≥100 No to mild hypertension 0.2 £139 £135 £4 
 
Moderate hypertension 0.5 £395 £576 -£181 
 
Severe hypertension 0.1 £103 £35 £68 
Total PlGF≥100 Total 0.7 £637 £747 -£110 
PlGF≥12<100 No to mild hypertension 1.5 £1,334 £1,523 -£190 
 
Moderate hypertension 4 £5,678 £17,001 -£11,323 
 
Severe hypertension 0.5 £1,764 £1,099 £665 
Total PlGF≥12<100 Total 6 £8,775 £19,623 -£10,848 
PlGF<12 No to mild hypertension 2.7 £2,898 £5,101 -£2,203 
 
Moderate hypertension 7.7 £20,888 £19,764 £1,125 
 
Severe hypertension 0.9 £4,425 £1,950 £2,475 
Total PlGF<12 Total 11.3 £28,212 £26,815 £1,397 





Table 5.2: Two-week costs of PlGF cost plus treatment algorithm compared to current practice for 1,000 pregnant women based on 
correct identification of women without a final diagnosis of pre-eclampsia (deterministic). 
PlGF (pg/ml) Hypertension Number of Patients PlGF +  Algorithm Total Cost Current Practice Total Cost Difference 
PlGF≥100 No to mild hypertension 9.5 £7,634 £6,858 £775 
 
Moderate hypertension 12.7 £10,240 £14,946 -£4,706 
 
Severe hypertension 0.9 £1,652 £566 £1,085 
Total PlGF≥100 Total 23 £19,525 £22,370 -£2,845 
PlGF≥12<100 No to mild hypertension 6 £5,638 £6,439 £801 
 
Moderate hypertension 8 £11,365 £34,029 -£22,664 
 
Severe hypertension 1 £2,183 £1,360 £822 
Total 
PlGF≥12<100 Total 15 £19,186 £41,829 -£22,643 
PlGF<12 No to mild hypertension 1.7 £1,834 £3,228 -£1,394 
 
Moderate hypertension 2.3 £6,257 £5,920 £337 
 
Severe hypertension 0.2 £819 £361 £458 
Total PlGF<12 Total 4.2 £8,911 £9,509 -£599 
TOTAL  42 £47,622 £73,709 -£26,087 
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The following tables show presumed parameters inputted into the model. 
Table 5.3: Presumed population parameters 
Diagnosis per 1000 women Percentage (95% CI) Source 
Suspected pre-eclampsia 20% (10%-30%) Clinical expert 
Suspected pre-eclampsia <35 weeks 6% (4%-8%) Clinical expert 
Disease Incidence   
Incidence of pre-eclampsia 1.8% (0.8%-2.5%)* Clinical expert 
Percentage with moderate hypertension in 
women diagnosed with pre-eclampsia 
68% (60%-76%) Anumba et al (2010) 
Percentage with severe hypertension in 
women diagnosed with pre-eclampsia 
8% (4%-12%) Anumba et al (2010) 
Percentage with moderate hypertension in 
women without a diagnosis of pre-eclampsia 
55% (50%-60%) Anumba et al (2010) 
Percentage with severe hypertension in 
women without a diagnosis of pre-eclampsia 
4% (2%-6%) Anumba et al (2010) 
PlGF test characteristics (<35 weeks 
predictive for the next two weeks) 
  
Sensitivity PlGF>100pg/ml 96% (89%-99%) Chappell et al (2013) 
Specificity PlGF>100pg/ml 55% (48%-61%) Chappell et al (2013) 
Sensitivity PlGF<12pg/ml 63% (51%-74%) Chappell et al (2013) 
Specificity PlGF<12pg/ml 90% (85%-94%) Chappell et al (2013) 
Cost of PlGF test £50 Alere  
*There is no good estimate of the prevalence of pre-eclampsia in women <35 weeks’ gestation with estimations varying 
widely. We have used a conservative estimate at the lower end of the potential prevalence based on clinical opinion, as 





Table 5.4: Percentage of pregnant women with PCR>30 mg/mmol by hypertensive 
category, on all 625 PELICAN pregnant women 
Hypertension Normotensive to mild Moderate Severe 
PlGF≥100 pg/ml 26% 27% 29% 
PlGF≥12<100 
pg/ml 
42% 30% 59% 
PlGF<12 pg/ml 76% 64% 70% 
 
Table 5.5: Cost parameters 
 Cost per unit Reference 
Hospital admission – length of stay up to 5 
days 
£789 NHS PbR Tariff 
Hospital admission – cost per day after 5 days £377 NHS PbR Tariff 
Outpatient appointments £284 NHS PbR Tariff 
Additional specialised ultrasound 















Table 5.6: Sensitivities using Monte Carlo simulation (1000 women) 
Analysis Cost of PlGF 
plus algorithm 
Cost of current 
treatment 




Algorithm admits all women with 
PlGF<100 pg/ml (assumes 
length of stay <5 days) 
£106,261 £120,894 -£14,633 71% 
Increase length of stay for all 
women admitted PlGF + 
algorithm by 3 days 
£95,132 £120,894 -£25,761 81% 
Algorithm admits all women with 
PCR> 30 mg/mmol 
£95,182 £120,894 -£25,712 87% 
Admission to inpatient ward 
costs 50% more 
£92,403 £147,320 -£54,917 97% 
Admission to inpatient ward 
costs 50% less 
£78,089 £94,467 -£16,378 85% 
PlGF test costs £30 per test £84,046 £120,894 -£36,847 95% 







The results of the decision analytic model suggest that, based on the best 
information available, there is a greater than 90% chance that PlGF testing plus a 
treatment algorithm represents a cost saving for a commissioner’s budget compared 
to current practice. This cost saving is likely to be around £582 per woman 
presenting prior to 35 weeks’ gestation with clinical characteristics indicative of pre-
eclampsia over two weeks or £35,087 per 1,000 pregnant women. These results are 
relatively robust to changes made to the assumptions in the model, although 
changes in the incidence of pre-eclampsia reduce the probability that PlGF plus a 
treatment algorithm is cost-saving.   
 
Strengths and limitations 
The main strength of this study is the comprehensive comparison of resource use in 
women undergoing PlGF testing for suspected pre-eclampsia. With most savings 
associated with pregnant women presenting with moderate hypertension, the ‘PlGF 
plus management’ algorithm potentially provides clinicians with the ability to stratify 
these women into risk groups more appropriately. Data were extracted from our 
recent prospective study, including participants encompassing a wide demographic 
and ethnic profile and a pragmatic approach to enrolment with minimal exclusion 
criteria, enabling generalisability. Final diagnoses were independently adjudicated by 
two senior clinicians following database record review, using strict criteria. PlGF 




The model has a number of limitations. PlGF has not yet been tested as part of a 
randomised controlled trial, meaning that there is uncertainty about what resource 
use pregnant women with suspected pre-eclampsia, tested with PlGF and managed 
using the treatment algorithm, would actually use. An improvement in health 
outcomes for women and their infants is not yet proven, although results of our study 
suggest that PlGF has the potential to aid diagnosis and assist decision-making, with 
subsequent impact on maternal and perinatal outcomes. Resource use may have 
varied costs in different settings, and so the cost savings presented here need to be 
reproduced in other settings.   
 
The predictive potential of PlGF testing is optimal below 35 weeks’ gestation, with 
outcomes reliably predicted in the two week period after testing (the primary 
outcome of our study). For the purposes of this analysis, therefore, we did not 
evaluate women presenting after 35 weeks’ gestation or assess resource use 
beyond the two week test period. It is now common practice to routinely deliver 
women with pre-eclampsia at 37 weeks. (Koopmans et al., 2009) This implies costs 
are likely to decline towards term, as hospital admission demands the greatest 
economic burden. (American College of Obstetricians and Gynecologists and Task 
Force on Hypertension in Pregnancy, 2013) It was not possible to include additional 
diagnostic tests and therapeutic medications in the model, due to the lack of 
availability of this information. We believe, however, that this would produce a 





The results suggest that PlGF plus a treatment algorithm presents a realistic and 
innovative adjunct to the management of women with suspected pre-eclampsia. 
Previous decision analytical models of screening tests for pre-eclampsia have 
demonstrated cost savings as a result of better identification of true positives and 
negatives. (Hadker et al., 2013) The weakness of these previous models is that 
health care resource use data were not reported with PlGF test results, and hence 




PlGF testing is associated with improved predictive performance, in the diagnosis of 
preeclampsia, compared with current diagnostic practice in high risk women. It is 
likely that PlGF testing with linked treatment algorithm is cost-saving compared to 
current practice from the perspective of a health care commissioner over a two week 
period. Some uncertainties still remain that warrant further research with a 













Figure 5.3: Schematic findings of budget impact analysis, suggesting how PlGF could be 


























6.1 Patient reported outcome measures (PROMs) in obstetrics 
The application of patient reported measures of health outcome is becoming 
increasingly relevant in the evaluation of health care and outcomes in clinical trials. 
The use of such measures in obstetrics, particularly pre-eclampsia, remains 
developmental but could represent an important step in understanding the issues 
important to women throughout their care pathway. 
 
6.1.1 Introduction 
Patient reported outcome measures (PROMs) assess the health, functional status 
and quality of life of an individual patient, usually via a standardised, validated 
questionnaire or survey. (Darzi, 2008) The initial design enabled comparative 
feedback following elective surgery. Their use is now commonplace in intervention-
specific surgical specialities and chronic disease (Devlin NJ and Appleby J, 2010). 
Over the last decade, PROMs have been used in a number of ways: as a diagnostic 
tool,(Kroenke et al., 2001) to assess burden of disease (Snyder and Aaronson, 
2009), or as means of measuring healthcare provider performance. (Devlin NJ and 
Appleby J, 2010) The short form 36 (SF-36) health survey, for example, is a generic 
questionnaire that assesses self perceived health status by using 36 questions 
relating to eight broad areas (or “domains”) of wellbeing. (Dawson et al., 2010) The 
European Quality of Life index (EQ-5D) is another generic health questionnaire that 
uses five domains and a visual analogue scale to calculate a ‘utility’ value of health 
status. There are also several examples of disease-specific questionnaires, allowing 





There is a paucity of these tools within obstetrics, but their development could 
provide useful information to guide future commissioning (Tyler S, 2012) and 
enhance understanding of perceived outcomes and experiences in clinical practice. 
(Ismail et al., 2013) There has been a marked shift internationally, towards 
acknowledging the patient’s perspective when monitoring health and health-related 
intervention, (Devlin NJ and Appleby J, 2010) which recognises the patient’s agenda 
may not match that of the clinician involved with their medical care. PROMs may 
elicit a more accurate reflection of the issues important to service users and ensure 
their inclusion in future management tools. For this part of the project, we used both 
the SF-36 and EQ-5D as a starting point from which to develop a PROM focussing 
on obstetric care. These survey formats had been used to introduce PROMs in other 
clinical domains; their development in obstetrics seemed feasible.  
 
Trials evaluating clinical interventions across all fields often report a wide range of 
outcomes, potentially leading to reporter bias or difficulty in reliably comparing 
results across trials. One response has been to produce and use a core outcome 
set, an agreed minimum set of outcomes to be measured and reported in trials. Work 
is currently underway to develop this idea further and provide recommendations, for 
researchers, on how these outcomes should be recorded and assessed. Such 
information was not available at the time of conception of the PELICAN study. Core 
outcome sets may variably include PROMS, and it remains unclear whether 
outcomes chosen truly represent those pertinent to pregnant women. It is likely that 
events such as preterm delivery, admission to hospital or neonatal unit admission 
are also likely to be important to women, but this aspect of the work explored the 
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development of PROMs from an alternative perspective previously utilised and 
recommended in the generation of PROMs in other fields of medicine. 
 
6.1.2 Methods 
A first draft survey, created by obstetric clinicians and social scientists, was 
circulated among twenty pregnant women. These women were recruited from 
antenatal clinics, the antenatal day assessment unit, hospital antenatal classes and 
the inpatient antenatal ward. All participants were (i) over the age of 16 years, (ii) 
able and willing to give consent, and (iii) over twenty weeks’ gestation. The only 
exclusion criterion was known lethal fetal abnormality. Their feedback was used to 
amend the initial survey, before it was distributed to a wider cohort of 100 women: 51 
pregnant women with hypertensive pregnancy disorders (forty-six pre-eclampsia or 
suspected pre-eclampsia, three gestational hypertension and one chronic 
hypertension) and 49 pregnant women with no significant medical disorder in the 
second half of pregnancy. 
 
The resulting questionnaire was based on the 36-item short-form health survey (SF-
36) and EuroQol EQ-5D. Following collection of one hundred surveys, data were 
anonymised. All questions had answers on numerical scales (a five or six point 
Lickert scale) or were attributed numerical values for the purposes of analysis. It was 
pre-specified that the report would include the two most extreme values (1 and 2, 
compared with 5 and 6 on the scale). Initial analysis led to the production of a five 
question survey, using an unpaired student t-test, based on the questions that 
yielded the most comparative scores. For the small number of missing data and 
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questions that were unanswered were given the median score for the group (cases 
or controls). The results of these questions were isolated and analysed to provide a 
simplified overview of the psychosocial impact of pre-eclampsia. All answers were 
allocated a score of 1 to 5 or 6, with a low score indicating minimal disruption.  
 
6.1.3 Results 
Results were analysed to enable the research group to draw comparison between 
hypertensive women (women with a diagnosis of suspected or confirmed pre-
eclampsia) and healthy pregnant women. 
 
6.1.3.1 Development work 
The first draft questionnaire comprised of thirty-two questions; only eight domains 
were found to be significantly associated with hypertension during pregnancy. Three 
of these related to reported symptoms during pregnancy (swelling), two to 
demographic characteristics (parity, children living with participant, and fulltime 
employment), one to perceived quality of life (ability to continue usual employment), 
and one’s attitudes towards pregnancy (desire for subsequent pregnancy). The early 
developmental stages highlighted the following survey domains as generating the 
most divergent scores: 
 quality of life 
 mood 
 attitude towards pregnancy 
Early results suggested that women with a diagnosis of hypertension during 
pregnancy were more likely to report difficulty in maintaining employment and a 
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reduced desire for subsequent pregnancy than healthy controls. There was a trend 
towards reduced enjoyment of life but no significant differences between mood in 
women with pre-eclampsia compared with healthy pregnancy. However, there were 
increased numbers of women responding negatively to questions relating to sleep 




6.1.3.2 Demographics of 100 women 
Table 6.1: Demographic characteristics of participants [percentage] 
Demographic Characteristic Controls [%] (n=50) Hypertensive women 
[%] (n=50) 


































Full time employment 
































6.1.3.3 Results of 100 women 
Overall, 75% of hypertensive women reported deterioration in how they rated their 
current health compared to 59% of healthy women (not significant). Hypertensive 
disease correlated with a significantly lower number of hypertensive women (18%) 
returning to employment as compared with healthy controls (45%; p=0.003). There 
were no differences reported in relationship status, mood, or anxiety, with similar 
incidence recorded in hypertensive and healthy women. 39% of healthy women 
stated that they were enjoying being pregnant compared to 41% of hypertensive 
women. Financial concerns were more prevalent in the control group, perhaps 
representative of expected parental concern at times of domestic change, in the 
absence of overriding physical health concerns. The similarity between hypertensive 
and healthy women was unexpected. This possibly indicates the high baseline 
anxiety and uncertainty experienced even in healthy pregnancy, or perhaps that 
hypertension in pregnancy does not have a striking negative impact on most self-
reported pregnancy outcomes. Compared to normal pregnancy, women with a 
diagnosis of hypertension in pregnancy were more likely to report a past medical 
history of hypertension (6% of controls and 46% of cases, p<0.001) and previous 
pre-eclampsia (0 controls and 10% of cases, p=0.001). However, they were no more 
likely to report a history of diabetes (p=0.118) or renal disease (p=1). Women with 
hypertension during pregnancy were also more likely to report inpatient stays during 
their current pregnancy as compared to controls (p<0.001); but were not more likely 





Table 6.2: Health before and during pregnancy [percentage] 




Pre-existing hypertension 3 [6] 23 [46] 
Pre-existing diabetes 0 [0] 4 [8] 
Pre-existing renal disease 1 [2] 2 [4] 
Previous pre-eclampsia 0 [0] 10 [10] 
Under care of consultant 18 [36] 28 [56] 
Inpatient stay during current 
pregnancy 
4 [8] 35 [70] 
 
The majority of healthy women were recruited to the study between 33 and 35 
weeks’ gestation, perhaps because this represents the stage in normal pregnancy 
when women are most likely to engage with hospital services, such as antenatal 
classes. The hypertensive cases were recruited across a range of gestational ages, 





Figure 6.1: Number of weeks' gestation of participants 
 
 
Women with hypertension in pregnancy were significantly more likely to report 
swelling (p=0.001), and in particular hand and foot swelling (p=0.026) or facial 
swelling (p=0.006) than controls. They were no more likely to report sickness, back 
pain, urinary problems, hip or pelvis pain, bleeding, abdominal pain, headaches or 
visual disturbances than healthy controls. Cases were more likely to report that they 
had suffered disruption to their employment as a result of their pregnancy (16% of 








































counterparts. However, they were less likely to report increased financial concerns 




Table 6.3: Perceived quality of life among participants [percentage] 





How would you rate your current health? 
A little worse – worse ever 
12 [24] 29 [58] 0.09 
Compared with one month ago, how often have you felt unwell? 
Almost all of the time –about half of the time  
13 [26] 18 [36] 0.39 
How has this pregnancy affected your ability to continue your 
usual employment? 
A lot of disruption – stopped working  
8 [16] 16 [32] 0.03 
How has pregnancy affected your relationship with your partner? 
Suffering – ended relationship  
9 [18] 4 [8] 0.23 
How has pregnancy affected your relationship with family? 
Suffering – ended relationship 
3 [6] 2 [4] 0.68 
Please record how this pregnancy has affected your relationship 
with your children. 
Suffering – ended relationship  
2 [4] 4 [8] 0.61 
Please record how this pregnancy has affected your ability to 
enjoy being pregnant. 
Reduced moderately – no longer want to be pregnant  
14 [28] 14 [28] 0.58 
How has this pregnancy affected your ability to enjoy life? 
Reduced slightly – extremely unhappy  
28 [56] 38 [76] 0.37 
Please record how this pregnancy has affected your ability to 
manage your finances. 
Moderate impact – cannot afford pregnancy 
18 [36] 8 [16] 0.04 
Please record how this pregnancy has affected your ability to 
prepare for a new baby. 
Much harder to prepare  - completely unprepared  




Table 6.3 above includes some of the questions included in the final draft of the 
study survey. Women were asked to choose an answer from a defined scale (eg. 
ranging from ‘not affected at all’ to ‘extremely unhappy’). Selections of the answers 
are included in bold, with the question above. The table highlights the difference 
between hypertensive and healthy women; the presence of pre-eclampsia led to a 
76% of cases reporting reduced enjoyment of life compared with 56% of healthy 
controls and demonstrates difficulty continuing normal function and employment. 
Interestingly, many more healthy women revealed difficulties in their relationship 
during pregnancy than pre-eclamptic women. Hypertensive women did not report 
any significant differences in mood as compared with healthy controls, in terms of 
sadness, tearfulness or anxiety (p=1, p=1 and p=0.624 respectively), although 18% 
of healthy and 24% of hypertensive women reported feeling anxious at least half the 
time. 
 
There was no significant difference in ability to sleep (p=0.512). Women with pre-
eclampsia were not more likely to use anti-depressants (p=0.362) or alcohol than 
healthy women (p=0.617) and admission to hospital was found not to reduce anxiety 
in either cohort. Furthermore, admission to hospital did not improve women’s 
understanding of pre-eclampsia with 38% of healthy and 54% of hypertensive 
women reporting that their knowledge was either unchanged or only slightly 
improved (p=0.816). Women with hypertensive disease of pregnancy were more 
likely to report that their disease experience had reduced their desire to be pregnant 
again, with 14% of controls and 44% of cases stating less inclination towards 
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subsequent pregnancy (p=0.002). Overall, there was less difference between 




Table 6.4: Perceived mood among participants 
Quality of life indicator (showing negative 







How has this pregnancy affected your anxiety? 
I feel anxious half of the time – I have 
anxiety attacks 
9 [18] 12 [24] 0.62 
How has this pregnancy affected how sad you 
feel? 
I feel sad all of the time – I am depressed 
4 [8] 3 [6] 1 
How has this pregnancy affected your 
sleeping? 
I have problems sleeping half of the time – I 
never sleep well  
18 [36] 12 [24] 0.51 
How has this pregnancy affected how often you 
feel tearful? 
I feel tearful most of the time – I cry every 
day  
3 [6] 3 [6] 1 
How often do you take medications for low 
mood?  
Occasionally – when not pregnant  
4 [8] 1 [2] 0.36 
How often do you use alcohol or other 
substances to improve your mood? 
Occasionally – when not pregnant (answers 
2-6) 
3 [6] 1 [2] 0.62 
Has being seen at hospital improved our 
anxiety?  
Not at all – improved a little 
20 [40] 27 [54] 0.76 
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How has your understanding of pre-eclampsia 
changed? 
Unchanged – a bit better  
19 [38] 27 [54] 0.82 
Has this pregnancy made you less likely to 
want another? 
Somewhat – I will never have another 
pregnancy  






The lack of significant difference in findings between hypertensive women and their 
healthy counterparts suggests that, although the ED-5Q and SP-30 have proven to 
be an effective basis to develop PROMs for orthopaedics and other surgical 
specialities, they may not adequately capture clinical picture of pregnancy. 
 
6.1.4.1 Strengths and weaknesses 
The main strengths of the study lie in its novelty including its use of healthy controls 
with co-morbidities, rather than pre-selected healthy controls and its objective to 
establish a PROM in pregnancy. Limitations of the study include the small sample 
size and the fact women were selected from a demographic that was unlikely to be 
representative of the wider population due to the high number of primiparous women 
in the control group and the fact the study was single centred. The inclusion of 
women with hypertensive diseases of pregnancy other than pre-eclampsia may have 
skewed the results further. The questionnaire itself faced limitations given that 
several of the answers provided were subjective and did not relate directly to the 
questions asked. Further development of questions would be required to allow 
reliable statistical conclusions, without bias according to accepted norms (eg the 
presumption that women are likely to wish to pursue further pregnancy). 
 
6.1.4.2 Future development 
PROMs are a patient-centric way of assessing the effectiveness of care from the 
patient’s perspective. Their use has been advocated by the NHS to encourage public 
involvement. The Francis report highlighted a magnitude of deficiencies in patient-
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centered care including; neglect of patients and poor standards of care, inadequacy 
of regulatory systems, issues of negative culture, tolerance of poor standards and 
disengagement from managerial and leadership responsibilities. The inclusion of 
service user experience as a means of reporting clinical performance represents a 
unique opportunity to provide holistic feedback at individual trust level. PROMs have 
been becoming more widespread across many medical specialities over the last five 
years, including early pregnancy, anal sphincter injury and pregnancy-associated 
surgery. At the time of writing, however, PROMs had not been described in obstetric 
literature. Maternity services are used by over 650,000 women each year (Sandall et 
al., 2014) and generate over £3 billion annually in litigation cases (NHS Litigation 
Authority 2012) highlighting the potential of woman-centric quality indicators to 
standardise care and improve cost effectiveness. 
 
The development of innovative data gathering techniques and performance 
monitoring opportunities are key aspects of healthcare management and should take 
into account the views of patients. Current measures of satisfaction lack validity and 
specificity (Devlin NJ and Appleby J, 2010) leading to the introduction of 
questionnaires that are defined by patients, as well as informed by them. The 
relevance of PROMs is underpinned by the methodology used for their development. 
Rising costs and the need for funding in line with the growing number of births in the 
UK and patients’ expectations of quality of care mean PROMs have a role in policy 
making and allocation of healthcare resources. (Dawson et al., 2010) Development 
of PROMs in maternity services could provide a quality assessment tool that can link 
women’s health status to outcomes and allow funds and services to be tailored 
according to user needs. The CQC Maternity Surveys have shown that bench-
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marking services against each other is a driver for improvement and maternity 
PROMS provide a much more potent benchmark that is derived entirely from the 
woman’s perspective. Strategies to aid the deployment of openness, transparency 
and candour, especially in the case of deliveries that have not gone well may help 
with mitigating the impact of litigation. 
 
6.1.5 Conclusion 
To our knowledge, this is the first patient reported outcome measure specifically 
designed for use in pre-eclampsia. Patient reported outcomes also give an 
opportunity for scientists and clinicians to align their research with patients’ interest. 
Pregnancy is a complex emotional and physical time for most women and its impact 
if influenced on both physical wellbeing and individual psychosocial circumstances. 
Development of tools to assess patient perspectives in the evaluation of health care 
is an area of interest that requires further research to better direct support services 
and recording of outcomes in women with pregnancy complicated by hypertensive 
disease. 
 
PROMs link the effect of different treatments to women’s health status to deliver 
compassionate, patient-centric care. Development of PROMs in maternity services 
will provide a novel quality assessment tool that can direct resources appropriately 
and support tailored service development. Recognising the women’s perspectives of 
health care delivery could improve empathy and organisational structure to support 
an individual focus whilst ensuring the most effective use of NHS resources. 
However, it seems unlikely that existing PROMs would translate effectively into use 






















Pre-eclampsia remains an important cause of maternal and perinatal mortality. The 
ability to predict the disease, particularly the more severe phenotypes, at earlier 
gestations, would allow clinically relevant surveillance and appropriate intervention to 
improve outcomes. Recent advances in understanding of its pathogenesis have led 
to new predictive, diagnostic and prognostic tests being evaluated. The research 
contained in this thesis suggests that PlGF represents a practical, point of care test, 
with high sensitivity and negative predictive value with the potential to better direct 
management strategies in high risk women below 37 weeks’ gestation. Furthermore, 
our evidence suggests it could be effectively funded within an NHS setting. 
Additional research is required to assess its position in clinical practice. 
 
7.2 Summary of findings 
The initial PELICAN Study paper (chapter 3) reported high sensitivity (95-96%) and 
negative predictive value (95-98%) for low PlGF in determining need for delivery for 
confirmed pre-eclampsia within 14 days. The need for a test with high sensitivity is 
paramount in this setting because there is greater preference for minimizing false 
negatives when considering overall benefits and harms and in ensuring appropriate 
resource use. The clinical utility of PlGF in facilitating stratified management 
strategies with appropriate surveillance is further apparent by the markedly different 
times to delivery demonstrated in the PELICAN study for women with very low, low 
and normal PlGF values; as PlGF measurements were masked to the clinicians in 
the study, women were delivered because of deteriorating maternal or fetal 




We have also shown that PlGF is considerably better than current markers, even 
when currently utilised test are combined, as in clinical practice. The area under the 
receiver operating characteristic curve for low PlGF (0.87, standard error 0.03) for 
predicting pre-eclampsia within 14 days was greater than all other commonly used 
tests, singly or in combination (range, 0.58–0.76), in women presenting with 
suspected pre-eclampsia (P<0.001 for all comparisons). We hypothesised that 
adding PlGF measurement to current clinical assessment of women with suspected 
pre-eclampsia before 37 (and particularly before 35) weeks’ gestation could improve 
risk stratification, achieve an earlier diagnosis and enable individualised 
management, with the potential to reduce associated maternal morbidity and 
unnecessary health service usage. 
 
One of the key research recommendations of the NICE Hypertension in Pregnancy 
guidelines was “What is the role of assessing haematological or biochemical 
parameters at diagnosis of gestational hypertension and during surveillance of 
gestational hypertension?” and the logical extension of this is to consider novel 
diagnostic tests once prospective observational studies had identified suitable 
candidate biomarkers (i.e. beyond current conventional haematological and 
biochemical parameters). A decision analytical model using data from the PELICAN 
study to establish the budget impact of treating women with suspected pre-
eclampsia for two weeks from the date of PlGF testing demonstrated a mean cost 
saving associated with the clinical algorithm integrating PlGF of £34,447 per 1,000 
pregnant women or a cost saving of £574 per woman given a PlGF test. Most of the 
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cost savings for the clinical algorithm integrating PlGF were for pregnant women with 
moderate hypertension, with a cost saving of £36,706. 
 
7.3 Clinical application of main findings 
Pre-eclampsia remains a leading cause of iatrogenic pre-term delivery and perinatal 
adverse outcome. Diagnostic deliberations are common when women present to 
obstetric assessment units with one or more signs suggestive of pre-eclampsia. 
Women undergo a series of investigations, many of which are poor predictors of the 
need for delivery or likely adverse outcome. In practice, obstetricians require a test 
that identifies women requiring enhanced surveillance with possible intervention and 
those where the likelihood of needing imminent delivery is low, meaning outpatient 
care is appropriate. The development of safe clinical algorithms to direct care and 
avoid inappropriate admission, over-utilisation of stretched resources and 
unnecessary maternal anxiety would be a useful outcome. Current expectant 
management protocols demand considerable resource input and require clinicians to 
make treatment decisions around mode and time of delivery without a reliable means 
of assessing likely maternal outcome. 
 
PlGF analysis represents a test for pre-eclampsia that uses a biomarker implicated 
in its pathophysiology and has attraction over the traditional measurement of blood 
pressure, urinary protein and assessment of established haematological and 
biochemical markers which are end-organ consequences of established disease. 
Accurate biomarker tests will potentially have greater impact at earlier gestations on 
decisions for surveillance and intervention by iatrogenic delivery (currently the only 
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definitive treatment). The difference in PlGF concentrations is greatest between 
normal and pre-eclamptic pregnancies prior to 37 weeks. Using PlGF as a test 
therefore offers a rational and reliable method to aid the diagnosis of hypertensive 
disorders of pregnancy for women presenting at earlier gestations. PlGF provides a 
point-of-care diagnostic advantage in women presenting with suspected pre-
eclampsia and out-performs other biologically plausible biomarkers of disease. 
 
The development of a PROM questionnaire in hypertensive pregnancy demonstrates 
its potential to improve the patient-doctor relationship and better direct support 
services. It is, however, difficult at this stage to confirm whether our findings reflect 
women’s views on a larger scale and further work and validation is required to 
assess its suitability for clinical use. Wider public and patient involvement (PPI) 
would ensure the inclusion of outcome measures that matter to women. 
 
7.4 Future research 
The PELICAN Study adds to an increasing body of research recommending early 
biomarker testing in the risk stratification of women with suspected pre-eclampsia 
and contributes substantial evidence to support the next phase of clinical trials. 
There is a window of opportunity to define its impact and role in directing clinical 
decision making in a real-time setting, with a view to introducing it as a test across 
the NHS. Given the substantial health resource use associated with assessment of 
women with suspected pre-eclampsia, PlGF testing has potential to provide 




PlGF should be assessed by means of a randomised controlled trial, to explore its 
potential as a functional clinical test. This could be undertaken by investigating the 
capability of PlGF to diagnose a clinically relevant endpoint (such as need for 
delivery within 7 or 14 days). Timely diagnosis allows appropriate surveillance level 
and potential prevention of adverse outcome. Currently, a consensus based 
definition of ‘adverse outcome’ does not exist. It is uncertain whether PlGF could 
predict a composite measure of maternal adverse outcomes, as events such as 
pulmonary oedema or post-partum haemorrhage (that are commonly included in 
such composite measures) are not directly linked to disease pathophysiology. A 
randomised controlled trial directly comparing PlGF testing (in addition to currently 
used variables) against current normal practice would provide useful data as to 
whether PlGF represents a cost effective diagnostic test. It is worth noting, however, 
that most diagnostic tests, including measurement of proteinuria, have been 
implemented without the benefit of an evidence base from randomised controlled 
trials, and therefore the ‘gold standard’ or ‘referent’ may be imperfect. A study of this 
kind could also be used to carry out a robust health economic evaluation 
demonstrating resource use and associated cost implications of introducing PlGF as 
a diagnostic adjunct. 
 
A randomised controlled trial of a diagnostic test may have several components: 
(Ferrante di Ruffano et al., 2012) evaluating whether knowledge of the novel 
diagnostic test (e.g. PlGF) compares against usual care within a trial setting (e.g. 
whether knowledge of revealed PlGF results in a shorter time to confirmed diagnosis 
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compared to usual care) and/ or whether a diagnostic test impacts on outcomes 
further downstream in the disease process. This latter step is dependent on 
implementation of a management pathway related to the diagnostic test and is far 
more dependent on other factors such as clinician and patient behaviour in response 
to the diagnostic test result.  
 
Since the PELICAN study was undertaken and the initial results published, grant 
funding has been secured to undertake a stepped wedge randomised controlled trial 
of PlGF testing in women with suspected pre-eclampsia (the PARROT trial). The 
main objectives of this trial are to test the hypothesis that knowledge of plasma PlGF 
measurement will reduce the time to diagnosis of confirmed pre-eclampsia, 
compared to current management, and to evaluate whether knowledge of plasma 
PIGF measurement identifies women with an increased likelihood of clinically 
indicated need for delivery within 14 days for diagnosed pre-eclampsia and has a 






















8.1 My contribution to the project 
I was the Project Co-ordinator for the PELICAN Study and was involved in every 
aspect of the study that produced the three papers included in this thesis (chapters 
3, 4 and 5). I developed the initial study protocol (see appendix) and produced the 
majority of the study literature, including participant information leaflets, consent 
forms and awareness posters. I wrote the application for ethical approval and 
ensured information submitted to the Ethics and Research and Development 
Committees was updated as the study progressed. At the start of the project, I 
formed links with selected trusts and conducted induction meetings, whereby I 
presented the concept and requirements of the study, to identify units that would be 
suitable to take part. 
 
Once maternity units had agreed to participate, I managed the distribution and 
administration of contracts between the trusts and the sponsor. Throughout the 
project, I regularly attended meetings with the staff at all the trusts involved, 
presenting information to ensure awareness of the project and trouble-shooting as 
issues arose. I ensured that all aspects of the project were being managed and 
monitored uniformly and in line with the protocol instructions. 
 
I was based at St Thomas’ Hospital and recruited the majority of participants at this 
site, meaning that I was able to explain the project to the women taking part and gain 
a useful insight into their experience. I designed and managed the database used to 
collate anonymous demographic details of each participant, in a meaningful way, as 
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well as overseeing laboratory sampling using unique numerical identifiers. I trained 
appropriate members of the study team at each site as to how to use the database 
and record necessary information. 
 
The Triage testing kit, used to measure PlGF, was produced by Alere, San Diego. All 
plasma samples were sent for repeat testing and storage in San Diego. I participated 
in regular teleconferences between UK Project Leads and stakeholders in the US, to 
resolve problems and ensure a unified, coordinated approach to all aspects of the 
project. I remained research active throughout the duration of the project and was 
able to share in the team’s achievement once the study reached completion and 
results were ready for analysis. Alongside the main PELICAN study, I led on 
development of a questionnaire survey, used to develop a Patient Reported 
Outcome Measure for pregnancy. This piece of work provided me with a useful 
perspective which, I hope, is reflected in the discussion, as a powerful reminder of 
the potential of a point of care test, such as PlGF. 
 
The first paper, published in Circulation, presented the initial findings from the 
PELICAN Study. I contributed by writing the first draft of the introduction and 
methods but went on maternity leave during the final stages of PELICAN and for 
some of the results writing phase of this paper. As such, I am the second author and 
my supervisor, the first. On my return, I played a major role in the required revisions 
of the final version and presented this work at various national and international 
obstetric and maternal medicine conferences. I was then closely involved with the in 
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depth statistical analysis and production of the second paper included in this thesis 
(for which I am the primary author). 
 
The budget impact analysis was an important and carefully planned further analysis. 
I worked closely with a Health Economist to plan its design and structure. I 
conducted the data extraction at both participating sites, requiring me to produce a 
robust database and collect all necessary information in an appropriate format. After 
attending a training course in Health Economics, I wrote the paper with the Health 
Economist, which has since been presented at a national conference. 
 
8.2 Associated publications 
8.2.1 Oral presentations 
2012: Blair Bell scientific meeting, London 
2013: BMFMS international conference, Dublin 
2013: Registrars’ academic meeting, Cambridge 
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accuracy of placental growth factor in women with suspected preeclampsia: A 
prospective multicenter study. Circulation. 2013;128:2121-2131. 
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PRE-ECLAMPSIA: CLINICAL APPLICATION OF 
PlGF 
Assessment of the Clinical Utility of Placental Growth Factor in 
Women Presenting with Signs and Symptoms of Pre-eclampsia 
13 May 2010-Amendment 1 November 2010 
Version 4 (July 2011) 
 Synopsis 
PELICAN is a multi-center, prospective, observational study to support the development of clinical 
management guidelines for the interpretation and use of Placental Growth Factor (PlGF) in pregnant 
women with clinical signs and/or symptoms of pre-eclampsia (measured in EDTA anti-coagulated 
human plasma.)  
 
The goals of the study are to validate PlGF as an aid to the diagnosis of pre-eclampsia and as a 
predictor of final pregnancy outcome.  The results of this study will be used to develop clinical 
management guidelines, to be validated by a follow-up study.  The primary analysis will use the 
Triage PlGF Test.  
 
Pregnant women over 16 years of age and between 20 to 37 weeks of gestation with signs or 
symptoms of pre-eclampsia will be enrolled.  Baseline demographics and medical/gestational history 
will be recorded, as well as the participant’s symptoms, signs and laboratory data relevant to the 
evaluation of pre-eclampsia. 
Study blood samples will be collected for the measurement of PLGF on the Triage system at the 
following timepoints:  
 Upon initial study enrollment with signs or symptoms of pre-eclampsia; 
 If the participant is not believed to have pre-eclampsia upon the initial evaluation but 





 At follow up consultations as appropriate, (samples more than a week apart); 
 At the time of hospital admission for further diagnostic testing or for expectant 
management; 
 
EDTA-anti-coagulated venous whole blood (~10-20ml) will be collected at each of the 
aforementioned time points, processed to plasma and evaluated on the Triage PLGF assay.  
All measurements of PLGF in plasma samples will be performed at the enrolling sites. PlGF 
measurements will be blinded to all attending clinicians and not used in the routine clinical 
management of participants. 
1 Background and Rationale 
1.1 Pre-eclampsia 
 
While most pregnancies are reassuringly healthy, up to 20% of women have obstetric or medical 
complications requiring additional treatment and evaluation. The most common obstetric 
complication is preterm labour, followed closely by the various hypertensive disorders of pregnancy.  
 
Hypertension complicates 6-12% of all pregnancies[3], and includes two relatively benign conditions 
(namely, chronic and gestational hypertension), and the more severe conditions of pre-eclampsia or 
eclampsia. Pre-eclampsia complicates 3-5% of all pregnancies, and is characterized by placental and 
maternal vascular dysfunction which may lead to adverse outcomes such as severe hypertension, 
stroke, seizure (eclampsia), renal and hepatic injury, hemorrhage, fetal growth restriction, or even 
death.[4] Pre-eclampsia may develop from 20 weeks gestation through six weeks post-partum. 
 
The diagnosis of pre-eclampsia, and hence the prediction of adverse events, is based on traditional 
but unreliable and nonspecific clinical markers such as blood pressure, urine protein excretion, and 
symptoms. For example, more than 20% of women who have eclampsia will fail to meet the 
common diagnostic criteria of pre-eclampsia prior to their event, making the prediction of this 
adverse outcome extremely difficult.[5] Conversely, only 0.7 to 5.0% of women with classically 
defined pre-eclampsia will experience any composite adverse outcomes.[6] Thus, the traditional 
criteria for pre-eclampsia perform poorly in identifying women and infants at risk of adverse 
outcome, and consequently this clinical uncertainty leads to significant overutilization of ancillary 
testing and intervention. Not surprisingly, the suspicion of pre-eclampsia is the most common 
reason for iatrogenic preterm delivery and labour induction in the U.S.[7, 8] Multiplied by 4 million 
births per year, the potential for unintentional harm and economic waste is obvious. 
 
There is a clear need for rational improvement in the diagnosis of pre-eclampsia to 1) improve the 
evaluation of women and infants at risk for adverse outcomes, and 2) reduce unnecessary testing, 
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intervention, and expense in cases with a benign prognosis. While many biomarkers and imaging 
techniques have been evaluated for this purpose, none have adequate sensitivity, specificity, and 
convenience for the diagnosis or prediction of pre-eclampsia.[9,10] Furthermore, very few of these 
markers have been independently evaluated for their ability to separately predict the timing or 
severity of specific adverse outcomes such as placental abruption, severe hypertension, neurological 
injury, fetal growth restriction, etc. The reason for these disappointing results is that, until recently, 
the unique pathophysiology of pre-eclampsia was not understood, and the biomarkers previously 
studied were mostly generic indicators of vascular activation and dysfunction which arise late in the 
disease process, and which are not specific to pre-eclampsia - or even to pregnancy. However, 
recent advances have identified a class of pregnancy-specific angiogenic and anti-angiogenic factors 
which are produced by the placenta, and which closely correlate with the preclinical and clinical 
stages of pre-eclampsia.[11,12] The possibility now exists to develop assays for these biomarkers 
that would finally offer a rational and reliable way to aid in the diagnosis of the hypertensive 
disorders of pregnancy. 
1.2 PlGF as a Marker of Pre-eclampsia 
The placenta plays a central role in the pathogenesis of pre-eclampsia [13], as evidenced by the 
rapid disappearance of clinical signs or symptoms following delivery of the placenta.  
 
The maternal syndrome of hypertension, proteinuria and oedema is part of a severe systemic 
inflammatory response that includes leukocyte and endothelial cell activation. Although the origins 
of pre-eclampsia remain unclear, a major cause is the failure to develop an adequate blood supply to 
the placenta, leading to placental oxidative stress.[14] 
 
Current evidence suggests that the clinical signs or symptoms of pre-eclampsia may be mediated, in 
part, by an imbalance of circulating angiogenic factors of placental origin. Placental growth factor 
(PlGF) is made by the placenta and circulates at high concentration in normal pregnancy. In pre-
eclampsia, there is increased expression of soluble fms-like tyrosine kinase-1 (sFlt1) which binds to 
circulating PlGF.[15-17] Consequently, concentrations of plasma PlGF are found to be decreased in 
pre-eclampsia.[18-20]  
 
Gestational age also affects circulating levels of PlGF. PlGF concentrations peak at 26 to 30 weeks 
and then decline as term approaches.[21] PlGF levels are abnormally low in patients with pre-
eclampsia compared to controls of approximately the same gestational age and PlGF is lower in 
severe pre-eclampsia compared with mild pre-eclampsia.[22] Thus, a diagnostic test utilizing PlGF to 
aid in the diagnosis of pre-eclampsia may be optimized by the use of different PlGF cut-off levels at 




1.3 The Triage® PlGF Test 
The Triage® PlGF Test is a fluorescence immunoassay to be used with the Triage® Meter for the 
quantitative determination of Placental Growth Factor (PlGF) in EDTA anti-coagulated plasma 
specimens. The test is intended for use as an aid in the diagnosis of pre-eclampsia in conjunction 
with other diagnostic and clinical information. 
 
The Triage® PlGF Test device is designed to be compatible with EDTA plasma samples for measuring 
the concentration of PlGF present in the sample. The results (PlGF pg/ml concentration) can be 
displayed, printed, and temporarily stored. The test device contains a positive and negative internal 
control mechanism. The system is provided with compatible external liquid QC controls which are 
supplied separately.    
 
The test procedure involves the addition of a specified volume of EDTA anti-coagulated plasma to 
the test device using a disposable transfer pipette, insertion of the inoculated device into the Meter, 
reading of the result from the display screen or printout, and storage of the result. Results are 
typically obtained within 15 minutes. 
 
2 Study Objectives 
2.1 Primary Study Objective 
The primary study objective is to assess the clinical utility of plasma PlGF in the diagnosis and 
management of pre-eclampsia.  
3 Study Design 
3.1 Intended Use 
The Triage® PlGF Test is a fluorescence immunoassay to be used with the Triage® Meter for the 
quantitative determination of Placental Growth Factor (PlGF) in EDTA anti-coagulated plasma 
specimens. The test is intended for use as an aid in the diagnosis of pre-eclampsia in conjunction 
with other diagnostic and clinical information. 
3.2 Overview of Study Design 
Pregnant women over 16 years of age and between 20 to 37 weeks of gestation with signs or 
symptoms of pre-eclampsia will be enrolled. Baseline demographics and medical and gestational 
history will be recorded, as well as the participant’s symptoms, signs and laboratory data relevant to 
the evaluation of pre-eclampsia.  
 
Study blood samples can be collected for the measurement of PLGF on the Triage system at the 
following timepoints:  
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 Upon initial study enrollment with signs or symptoms of pre-eclampsia; 
 If the participant is not believed to have pre-eclampsia upon the initial evaluation but 
returns with new or worsening symptoms or signs of pre-eclampsia; 
 At follow up consultations as appropriate, (samples more than a week apart); 
 At the time of hospital admission for further diagnostic testing or for expectant 
management); 
 
EDTA-anti-coagulated venous whole blood (~20ml) can be collected at any/each of the 
aforementioned time points; these blood draws will occur in parallel with other clinical testing being 
performed as routine standard care. These study blood samples will be processed to plasma and 
tested on the Triage System.  
 
The final diagnosis and adverse maternal, fetal and neonatal outcomes will be recorded. 
 
The utilization of healthcare resources associated with the diagnosis and management of pre-
eclampsia will also be recorded. 
 
3.3 Blinding 
The results of the Triage PlGF Tests will be blinded to the medical personnel at the site involved in 
care of the participant during the study and will not impact medical management of the participants. 
 
3.4 Study Duration 
Each participant’s involvement in the study will last from enrollment to delivery.  Post delivery 
outcome data will also be recorded. 
4 Study Participants 
4.1 Number of Participants 
Approximately 500 pregnant women between 20 and 40 weeks gestation will be initially enrolled, 
during a pilot phase, at multiple clinical centers in the UK and Ireland.  Further women (20-37 weeks 
gestation) will be recruited across an additional five UK centres from July 2011.  
 
The table below shows the breakdown, per gestational age, of the expected and targeted groups of 




Assumptions for UK Training Study       
PE Rate 30.0%        
Total Patients 500        
GA Bin %Population non-PE PE Total (in Bin)     




(target)     
24-29 13.0% 46 20 65     
29-32 20.0% 70 30 100     
32-35 20.0% 70 30 100     
35-37 20.0% 70 30 100     
37-40 20.0% 70 30 100     
Total 100.0% 350 150 500     
         
Minimum Enrollment Criteria        
(1) target of 10 PE cases per GA bin.       
(2) minimum of 60 PE cases for GA < 35 weeks.      
(3) minimum of 40 PE cases for GA >= 35 weeks.      
(4) minimum of 25 non-PE cases per GA bin.      
(5) minimum of 150 non-PE cases for GA < 35 weeks.     
(6) minimum of 100 non-PE cases for GA >= 35 weeks.      
         
Sample Size         
For a sensitivity of 0.90 and a sample size of 60 PE, the 95% confidence interval is 0.795 to 0.962. 
For a specificity of 0.90 and a sample size of 150 non-PE, the 95% confidence interval is 0.840 to 0.943. 
(Further breakdown of statistical considerations can be seen in section 7.) 
4.2 Inclusion / Exclusion Criteria 
To be enrolled in the study, each participant must meet all of the following inclusion criteria and 
none of the following exclusion criteria: 
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4.2.1 Inclusion Criteria 
a. Age 16 or over at enrollment; 
b. Pregnancy at  20+0 to 40+6  weeks gestation; 
c. Signs or symptoms of pre-eclampsia.  
d. Able to give informed consent 
e. Singleton or twin pregnancy 
4.2.2 Exclusion Criterion 
a. Unable to give informed consent 
b. Gestation with 3 or more viable fetuses at the time of enrollment 
 
4.3 Targeted Participants for Enrollment 
Any woman suspected of having pre-eclampsia may be included. The following section is a guide as 
to who this may include. 
 
Sites are encouraged to enroll participants with a variety of presenting symptoms, signs and findings 
suggestive of the diagnosis of pre-eclampsia, or where there is clinical uncertainty. 
 
Appropriate study participants include women with signs or symptoms suggestive of the presence of 
pre-eclampsia with onset after gestational week 20+0, such as: 
 New onset of increases in blood pressure – such as:  
o Resting systolic BP ≥ 140 mmHg and/or diastolic BP ≥ 90; or  
o ≥ 30 mmHg increase in systolic and/or ≥ 15 mmHg increase in diastolic BP compared 
to average of 1st trimester values (≤ 14+0 weeks). 
 Worsening of underlying hypertension – defined as pre-existing hypertension now with any 
one of the following: 
o New onset of resting systolic BP ≥ 160 mmHg or diastolic BP ≥ 105 mmHg; or 
o Need for doubling of pre-20 week dose of antihypertensive; or 
o Need for addition of second antihypertensive agent. 
 New onset of protein in urine – defined as any one of the following: 
o ≥ 1+ proteinuria by dipstick in the absence of urinary tract infection 
o ≥ PCR 30mg/mmol 
o 24 hour collection ≥300 mg (or 165mg/12hr collection) 
 New onset symptoms including: 
o Persistent epigastric or right upper quadrant pain; 
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o Nausea and vomiting;   
o Headaches, visual disturbances or migraines (in participant without a history of 
migraines). 
 Unexplained laboratory anomalies including: 
o Thrombocytopenia (platelets ≤ 100,000); 
o Aspartate aminotransferase (AST) ≥ ULN; 
o Alanine aminotransferase (ALT) ≥ ULN; 
o Lactate dehydrogenase ≥ ULN; 
o Serum creatinine ≥ 80 IU/dL; 
o Uric acid ≥ 4 mg/dL; 
 Evidence of abnormal fetal growth or placental function: 
o Fetal growth restriction – defined as ultrasound estimated fetal weight ≤ 3rd 
percentile  for gestational age; 
o Fetal or placental hydrops; 
o Uterine artery Doppler notching or increased resistance; 
o Suspected placental abruption. 
 Other unexplained clinical events:  
o Suspected pulmonary oedema; 
o Suspected or possible seizure activity. 
 
As PlGF levels vary with gestational age, it is desired that enrolled participants span the entire range 
of gestational ages from 20 to 37 weeks, with participants enrolled in each of the following strata: 
 
 Gestational age 20+0 to 23+6 weeks; 
 Gestational age 24+0 to 28+6 weeks; 
 Gestational age 29+0 to 31+6 weeks; 
 Gestational age 32+0 to 34+6 weeks; 
 Gestational age 35+0 to 36+6 weeks; 
 
Participants with twins may be enrolled.  
 
Enrollment of participants with signs or symptoms of pre-eclampsia with underlying chronic 
hypertension and gestational hypertension (mild and severe) who meet study criteria are also 




Enrollment of participants with signs or symptoms of pre-eclampsia where either the diagnosis is 
unclear or the future risk to the mother or fetus remains unclear is encouraged. 
 
Similarly, enrollment of participants with signs or symptoms of pre-eclampsia plus co-morbid 
conditions which can confound the diagnosis of pre-eclampsia is also encouraged, such as: 
 
 Chronic hypertension; 
 Renal disease; 
 Diabetes (gestational or pre-existing); 
 Lupus erythematosus; 
 Anti-phospholipid antibodies; 
 Solid organ transplantation. 
 
4.4 Participant Withdrawal and Replacement 
A participant will be considered inappropriate for evaluation, for the primary purposes of this study, 
if she: 
 Withdraws consent for study participation or is lost to follow-up before information on the 
final diagnosis and adverse maternal and fetal outcomes can be obtained.  
 
Participants who are inappropriate may be withdrawn from the study.  
 
Participants may voluntarily choose to withdraw from the clinical study at any time. Participants may 
also be withdrawn by the Investigator due to noncompliance with study procedures.  
 
4.5 Screening 
The study must be explained to each potential study participant and written informed consent 
obtained prior to enrollment. All participants will be offered at least 24 hours to consider 
enrollment, but can choose to participate the same day if they wish.  
 
Prior to enrollment, the potential participant’s medical history and status should be reviewed to 
assure they meet the study inclusion/exclusion criteria based upon available information.  
 
No study-specific procedures should be performed (i.e. study-related blood draws) until after 
written informed consent has been obtained for that participant.  
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4.6 At Enrollment (Initial Study Visit) 
Screening and enrollment may occur at the same clinic visit.  Once it has been determined that the 
participant meets the study enrollment criteria (including signs or symptom of pre-eclampsia) and 
written informed consent has been obtained, the following procedures will be performed: 
 
Demographics and baseline medical / gestational history will be recorded on the CRF, including: 
 History of chronic co-morbid conditions (such as hypertension, diabetes, renal disease [including 
proteinuria] and auto-immune diseases) or solid organ transplantation; 
 Information related to risk factors for pre-eclampsia, such as: 
o Gravidity and parity; 
o Previous history of pre-eclampsia; 
o Family history in first degree female relatives of pre-eclampsia; 
o Number of viable fetuses at enrollment; 
o Interval since previous pregnancy; 
o Anti-phospholipids antibodies; 
o Polycystic ovarian syndrome; 
o BMI >30 prior to pregnancy; 
o Tobacco use/Nicotine patch use; 
 Available information on blood pressure or proteinuria prior to this pregnancy, in the first 
trimester, and in the second trimester, prior to gestational week 20+0. 
 
Concomitant medications will be recorded, including any anti-hypertensive agents, aspirin, heparin, 
insulin and corticosteroids (with dosage).  
 
Blood pressure obtained by the clinical staff will be recorded following local practice.  
 
Clinical Blood Samples:  
 
These will be taken at the discretion of the attending clinicians following local guidelines. 
 
NB: The clinical team will be blinded to all results from the Triage System. 
If any other laboratory assessments are performed to assess for possible pre-eclampsia (uric acid, 




Research Blood Sample: 
 
Approximately 10-20 ml of blood will be collected in “lavender top” Vacutainer tubes with EDTA 
anti-coagulant.  One aliquot will be tested at the study site on Triage PlGF and the result recorded.  
 
The remaining, unused, plasma sample will be stored, in accordance with local hospital policy.  
Storage will be at local hospital sample laboratory, for a period of less than 12 months.  The 
remaining frozen, plasma aliquots (each 2ml) will be shipped to The Alere Research Centre, in San 
Diego, United States.  This transfer is to enable possible further analysis, and/or validation, co-
ordinated by our international, commercial collaborators, in the event that future pre-eclampsia, (or 
other hypertensive disorders of pregnancy,) biomarkers are identified.  The Alere Research Centre 
will hold the plasma samples for a period in of 25 years.  The Research Centre is FDA compliant and 
will hold and dispose of the samples accordingly. 
 
Clinical sites will evaluate and treat participants with signs or symptoms of pre-eclampsia according 
to their usual medical and institutional standards.  
 
The decision to proceed immediately to delivery, admit the participant to the hospital for further 
diagnostic evaluations, or expectant management, or to manage the participant as an outpatient, 
will be at the discretion of the attending physician and should not be affected by study participation.  
 
The initial disposition of the participant will be recorded.  
 
Once the results of the initial assessments are available, the Investigator will record the participant’s 
initial diagnosis at the time of the enrollment assessment using the definitions as delineated in 
Section 5.  
 
4.7 During the Pregnancy 
If the participant did not meet diagnostic criteria for pre-eclampsia at the initial study visit but this 
diagnosis is again suspected at least one week later during the pregnancy due to new or worsening 
symptoms, signs or findings, the assessments will be repeated and recorded.  
The signs, symptoms and findings suggestive of pre-eclampsia at this return visit will be recorded. 
 
If the participant is admitted to the hospital for further diagnostic testing or expectant management 
for pre-eclampsia after the initial study visit, an additional biomarker blood sample (~20ml each) will 




The sample will be processed to plasma and PlGF will be measured using the Triage System.   
NB: The clinical team will be blinded to all results from the Triage System. 
 
Results of additional tests performed to monitor for pre-eclampsia as usual care during the 
remainder of the pregnancy will also be recorded. 
 
All hospital admissions/discharges and any interventions (dialysis, intubation, etc) will be recorded.  
This information will be used to inform health economic analysis, to demonstrate the following: 
 Day Unit attendances 
 Ante-partum bed nights 
 Post-partum bed nights 
 Fetal monitoring by ultrasound 
 Special Care Baby Unit bed nights 
 Neonatal Intensive Care Unit bed nights 
 Administration of corticosteroids and magnesium 
 Biochemical analysis of serum and/or urine 
4.8 Post-partum 
Information about the delivery and neonate will be recorded, such as: 
 The date/time of onset of labor and date/time of delivery; 
 Mode of delivery (e.g., spontaneous or induced, labor, C-section or vaginal delivery); 
 Whether epidural anesthesia was used; 
 Neonatal birth weight; 
 Neonatal birth defects and genetic abnormalities;  
 Placental weight and pathology (infarcts, etc), if available. 
 
The use of any medications for the treatment of hypertension, antenatal steroid or IV magnesium 
during the pregnancy / peripartum period will be recorded.    
 
If any subsequent information has led to a revision of the estimated gestational age at the time the 
initial visit study blood samples were obtained, the revised gestational age at initial assessment will 
be recorded.   
 





Each participant’s clinical course and test results during the entire pregnancy (and peri-natal period, 
where appropriate) will be reviewed by the Investigator. The Investigator will then record the final 
diagnoses for each participant using the diagnostic definitions described below (with the dates 
diagnostic criteria were first met), taking into account the entire clinical course of the participant’s 
pregnancy.   
 
Assessments of blood pressure, urine protein and other laboratory assessments to support the 






For the purposes of this study, the following definitions will be utilised for diagnoses, based upon the 




Systolic BP ≥ 140 mm Hg and/or DBP ≥ 90 mm Hg on two occasions 4 hours to 1 
week apart; 
Severe hypertension: 
Systolic BP ≥ 160 mm Hg or DBP ≥ 110 mm Hg on two occasions at least 4 hours 
apart while the patient is on bed rest; 
De novo hypertension: 
New onset of hypertension after 20+0 weeks gestation (with documented non-
hypertensive blood pressures prior to 20+0 weeks gestation); 
Chronic hypertension: 
Documented presence of chronic non-gestational hypertension prior to this 
pregnancy, or 
De novo hypertension that does not resolve by 6 weeks postpartum, or  





De novo hypertension after gestational week 20+0 or hypertension that resolves by 6 weeks 




Mild gestational hypertension: 
SBP 140-159 mm Hg and/or DBP 90-109 mmHg on two occasions 4 hours to 1 week 
apart presenting de novo after gestational week 20 without proteinuria or markers of 
severe pre-eclampsia.  
Severe gestational hypertension 
SBP ≥ 160 and/or DBP ≥ 110 mm hg on two occasions 4 hours to 1 week apart presenting 





Any of the following*: 
 Urine protein ≥ 300 mg/24 hours (or 165mg/12hr) from a timed urine collection 
(preferred definition, if results from 24-hour timed urine collection available); 
 Urinary protein 1+ on dipstick on two occasions at least 4 hours apart; 
 Urinary protein ≥2+ on dipstick on one occasion. 
 Protein: Creatinine ratio ≥ 30 (mg/mmol). 
*In the absence of a symptomatic urinary tract infection. 
 
Gestational proteinuria: 
De novo proteinuria after 20+0 weeks gestation (with a negative proteinuria assessment 
prior to 20+0 weeks gestation). 
 
Chronic proteinuria: 
Proteinuria noted prior to 20+0 weeks; or proteinuria that fails to resolve by 6 weeks 
postpartum. 
 
Pre-eclampsia (Traditional Definition): 
 






Mild gestational hypertension plus gestational proteinuria that does not meet the criteria for 




Presence of pre-eclampsia as defined above plus one or more of the following: 
 Systolic BP ≥ 160 mm Hg or DBP ≥ 110 mm Hg on two occasions at least 6 hours 
apart while the patient is on bed rest;  
 Proteinuria of 5 g or higher in a 24-hour urine specimen or 3+ or greater on two 
random urine dipstick assessments collected at least 4 hours apart; 
 Oliguria of less than 500 mL urine output in 24 hours; 
 Cerebral or visual disturbances; 
 Pulmonary edema or cyanosis; 
 Epigastric or RUQ pain; 
 Impaired liver function (2X ULN for AST and/or ALT); 
 Thrombocytopenia (platelet count <100,000/mm3); 
 Fetal growth restriction (fetal weight <5th percentile for gestational age). 
 
Superimposed pre-eclampsia (Traditional definition): 
 
 Chronic hypertension plus new onset proteinuria (defined as urine protein ≥ 300 
mg/24 hours from a timed urine collection) 
 
Superimposed pre-eclampsia (Atypical)[24]: 
 
Any of the following: 
 Chronic hypertension plus new onset and persistent symptom(s) (e.g., headache 
and/or scotomata and/or epigastric pain); 






The presence of new-onset grand mal seizures in a woman with pre-eclampsia or gestational 
hypertension in the absence of all of the following: 
 Known seizure disorder; 
 Chronic treatment with anti-seizure medications; 
 Known intra-cerebral pathology. 
 
Atypical pre-eclampsia:[25] 
In the absence of proteinuria: 
Gestational hypertension plus any of the following: 
 Presence of symptoms of pre-eclampsia: epigastric pain, headache, nausea and 
vomiting, visual changes (see definitions in Section 6.2); 
 Hemolysis; 
 Thrombocytopenia (platelet count <100,000/mm3); 
 Elevated liver function tests (2X ULN for AST and/or ALT). 
 IUGR fetal weight <10% 
 
In the absence of hypertension:        
Gestational proteinuria plus any of the following: 
 Presence of symptoms: epigastric pain, headache, nausea and vomiting, visual changes 
(see definitions in Section 6.2).  
 Hemolysis; 
 Thrombocytopenia (platelet count <100,000/mm3); 
 Elevated liver function tests (2X ULN for AST and/or ALT). 
 IUGR fetal weight <10% 
 
HELLP syndrome: 
Gestational hypertension or gestational proteinuria plus elevated liver enzymes (2X ULN), 





The following definitions of symptoms will be utilized for this study: 
Epigastric pain: 
Right upper quadrant to mid upper abdominal deep pain that is persistent and not related to 
dietary intake. 
Headache: 
Moderate to severe headache that persists following appropriate medication in a participant 
without a prior history of chronic headaches.  
Nausea and vomiting: 
Persistent, unexplained nausea or emesis unresponsive to treatment. 
Visual changes: 
Participant complains of visual impairment that is persistent. 
 
5.3 Other Prior / Concomitant Conditions 
History of pre-eclampsia: 
Participant recalls a prior pregnancy affected by pre-eclampsia, toxemia, eclampsia, HELLP 
syndrome, or 
 
Participant can not recall name of condition but reports a prior that was  
o induced for hypertension, or  
o treated with magnesium sulphate 
Any known family history of the above, for a first degree relative (mother or sister.) 
 
Pre-existing proteinuria: 
o ≥ 1+ proteinuria by dipstick in the absence of urinary tract infection 
o P:C Ratio ≥ 30mg/mmol 
o ≥ 165 mg/12 hour collection or ≥300 mg /24 hours urine protein collection  
 
History of diabetes: 
Pre-gestational diabetes 
o Type I – insulin-requiring diabetes 
 Participant taking (or prescribed) insulin prior to pregnancy  
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o Type II – non-insulin requiring diabetes 
 Participant taking (or prescribed) oral diabetic agents prior to pregnancy 
 
Gestational diabetes 
o Prior pregnancy affected by gestational diabetes 
 No interval diagnosis of diabetes 
o Current pregnancy affected by gestational diabetes 
 
History of renal disease: 
Participant reports any history of kidney disease and documented serum Cr ≥ 80 to 20+0 
weeks 
 
History of lupus or arthritis: 
Participant reports history of  
o Lupus 
o Arthritis 
o Unspecified autoimmune disease 
and 
Documented abnormality of rheumatologic laboratory test prior to, or during 
pregnancy 
 
History of anti-phospholipid antibody syndrome: 
 
Participant reports history of antiphospholipid syndrome 
and 
Documented laboratory abnormality by any of the following (2 occasions, 12 weeks 
apart): 
o Anticardiolipin IgG  
o Anticardiolipin IGM  
o Presence of lupus anticoagulant 
Gravidity: 
Total number of pregnancies, including current pregnancy 
Parity:  
Number of birth events, categorised as: 
o Term births (≥ 37+0 weeks), 
o Preterm births (between 20+0 and 36+6 weeks), and 
o Pregnancy loss or termination less than 20+0 weeks 
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5.4 Adverse Maternal, Fetal and Neonatal Outcomes 
Any maternal, fetal and neonatal adverse outcomes (with date of onset) will be recorded, including 
the following:  
Adverse maternal outcomes: 
 Acute renal failure (≥100 micromol/L AN, or ≥130 PN) 
o Need for dialysis 
 Acute myocardial ischemia 
 Need for third IV agent to control blood pressure (e.g., in addition to labetolol and 
hydralazine) 
 Hypertensive encephalopathy  
      (Altered mental status with characteristic cerebral imaging) 
 Cortical blindness 
 Retinal detachment 
 Stroke (ischemic or hemorrhagic)  
     (Focal motor impairment of a sustained or permanent nature) 
 Pulmonary edema/Adult respiratory distress syndrome (ARDS) 
(Characteristic pulmonary imaging in addition to oxygen requirement) 
o Need for mechanical ventilatory support (other than for Cesarean section) 
 Disseminated intravascular coagulation (DIC) 
 Thrombotic thrombocytopenic purpura (TTP)/hemolytic uremic syndrome (HUS) 
 Acute fatty liver 
 Liver hematoma or rupture 
 Placental abruption  
      (Retroplacental clot or associated with pre-term delivery or fetal demise) 
 Death 
Adverse Fetal Outcomes: 
 Preterm delivery (prior to 37+0 weeks gestation) 
 Fetal growth restriction (fetal weight below 10th percentile for gestational age) 
 Severe fetal growth restriction (fetal weight below 5th percentile for gestational age) 
 Antepartum / intrapartum fetal death 
 Customized SGA <10th centile 
Adverse Neonatal Outcomes: 
 Neonatal death 
 Respiratory distress syndrome 
 Intraventricular hemorrhage* 
 Necrotising enterocolitis 
 Bronchopulmonary dysplasia 
 Periventricular leulomalacia* 
 Retinopathy of prematurity* 
 Seizure 
 NICU admission for >48 hrs (for full-term infant). 




Severe adverse outcomes are those that result in major organ failure or death. Non-severe adverse 
outcomes are those that do not result in major organ failure or death. 
 
5.5 Health Outcome Data/Health Economics   
Data on the utilisation of health resources will be recorded including the following; 
 
Maternal: (Bed night is defined as a day with an overnight stay) 
 Number of out-patient visits / healthcare contact associated with the diagnosis of suspected 
pre-eclampsia; 
 Number of out-patient visits associated with the monitoring of confirmed pre-eclampsia; 
 Number of bed nights for  “diagnostic testing” including investigations performed (urinalysis 
and serum analysis); 
 Number of bed nights for “expectant management and delivery”; 
 Total number of day assessment bed days; 
 Intervention provision as a result of suspected pre-eclampsia eg. administration of 
corticosteroids or IV magnesium; 
 Adverse maternal outcome and subsequent treatment; 
 
Fetal: 
 Need for admission into neonatal care; 
 Need for admission for Special Care Baby Unit 
 Number of bed nights in neonatal care associated with delivery for PE; 
 Neonatal complications in post-natal period including seizures, intraventricular 
haemorrhage, respiratory distress; 
 
6 Biomarker Blood Sample Collection Procedures 
6.1 Collection of Biomarker Blood Samples 
6.1.1 Study-specific venous blood samples must be obtained via direct venepuncture or via an 
existing central venous line, peripheral intravenous line or hep-lock (as long as the hospital 
staff follows their protocol for first withdrawing blood to flush the line). The route by which 
each blood sample was obtained and the actual date/time it was obtained must be recorded 




6.1.2 Gently invert each blood collection tube at least 8 – 10 times to allow for dissolution of the 
additive (if any). It is very important that the blood sample is mixed properly to ensure 
adequate handling and improved quality of the samples in subsequent steps.  
 
6.1.3 Using a single sheet of barcode labels for each time point, affix: 
 
 one barcode label from the sheet to the blood collection tube(s) and  
 one barcode label from the same sheet to each of the appropriate area(s) on the Sample 
Collection Form.   
 
The labels on each sheet have the same 6-digit number and are followed by a unique letter 
(Example: 001234A, 001234B, 001234C, etc). 
 
Each blood draw time point should be associated with a different 6-digit number obtained 
from a new (unused) single sheet of barcode labels. 
 
6.1.4 The blood sample tubes should be transported promptly (with the corresponding used 
sheets of barcode labels) for processing. 
6.2 Processing of Blood Samples 
Study blood biomarker samples from all time points will be analysed at the site for PlGF. Leftover 
sample will be processed to plasma, aliquoted and frozen.  
 
Sample Replacement 
A blood sample will be considered inappropriate for assessment for this study if: 
 It contains an insufficient volume to perform the PlGF measurements; 
 A plasma sample is grossly hemolysed; 
 It was not collected in the proper type of collection tube; 
 It is not properly labeled with a barcode label; 
 It is not properly frozen at the site.  
 
If the site personnel become aware that a sample is inappropriate, a replacement sample can be 




6.3 Disposition of Plasma Samples after Study Completion 
After completion of this study, the remaining unused plasma from each sample will be stored at the 
relevant laboratory, according to local guidelines.   These samples will NOT be submitted to a 
cell/DNA bank and will NOT be used for genetic testing.  Each sample will be identified only by its 
barcode number and will not be individually identifiable. 
 
6.4 Possible Risks & Benefits Associated with Study Procedures 
There is no health benefit to participants by participating in this study. The Triage PlGF Test results 
will not be used in the management of patients.  
 
The only parts of this protocol that are experimental are the measurement of biomarkers in blood 
specimens. All other aspects of this protocol are considered routine care. 
 
The only study-related procedures that could impact participant safety are the blood draws to obtain 
blood samples required for the measurement of PlGF and other biomarkers.  
 
The risks of drawing blood via venepuncture may include pain, bleeding, bruising or swelling at the 
site of the blood draw or lightheadedness or syncope.  Infection at the site of the blood draw is also 
a rare complication. Whenever possible, study-specific blood samples will be drawn at the same 
time as routine blood draws to minimise the need for multiple venepunctures.  
 
There is no risk to the participant associated with running the Triage PlGF Test, as these tests are 
performed in vitro on blood samples. 
 
Also, as the results of the study-related tests will be blinded to the medical team during the study, 
the results of these tests will not alter participant care.  
 





7 Statistical Considerations (PELICAN study) 
7.1 Objectives 
The primary objective is to measure PlGF levels in samples of EDTA-anti-coagulated plasma collected 
from pregnant women with signs or symptoms of pre-eclampsia to determine whether PlGF levels 
predict maternal and fetal adverse outcomes and might be useful as a safe and reliable parameter to 
guide clinical management. 
7.2 Normal and abnormal values of PlGF 
PlGF levels are known to vary with gestation in normal pregnancies (Krauss 2004, Levine 2006, 
Romero 2008).  The reference values for the PELICAN study are not defined in the protocol.  
 
Two approaches to defining Normal ranges will be used  
(i) Predefined standard values  
(ii) Gestation-adjusted centiles  
 
7.2.1 Predefined standard values  
Standard values of PlGF are by Alere with the Triage ® machine, corresponding to the 5th centile in a 








95%LCI 95%UCI Test Neg Test Pos 
19 ≤ GA < 24 62.9 1.000 0.025 1.000 0 1 
24 ≤ GA< 29 130 1.000 0.664 1.000 0 9 
29 ≤ GA < 32 128 0.889 0.518 0.997 1 8 
32 ≤ GA < 35 70.4 0.944 0.727 0.999 1 17 
GA ≥ 35 14.6 0.535 0.377 0.688 20 23 
19 ≤ GA < 35 Variable 
as above 
0.946 0.818 0.993 2 35  
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Assessment of test performance.   
Using these two systems, all PlGF measurements will be assessed as normal or abnormal. 
Measurements are to be repeated up to 5 times per woman, depening on gestation at trial entry.  
The first measurement is taken at the earliest worrying sign for preeclampsia (abnormal proteinuria 
or blood tests, hypertension or severe symptoms as detailed in the protocol).  For analysis purposes, 
measurements will be grouped as: first, maximum/most abnormal, and by gestational age bands. 
The boundaries of the gestational age bands will be as defined above (19 ≤ GA < 24, 24 ≤ GA< 29, 29 
≤ GA < 32, 32 ≤ GA < 35, GA ≥ 35, 19 ≤ GA < 35 weeks). 
 
Test performance will be evaluated separately for each group of tests.  This will allow us to 
investigate whether the test is valid only at certain gestations, and whether repeated testing is 
useful.   
 
Critical values will be assessed using sensitivity, specificity, positive and negative predictive values 
and ROC areas. 95% confidence intervals will be produced using standard techniques (the Clopper-
Pearson (1934) exact method for percentages, Normal approximation for ROC areas).  Analysis will 
be carried out in Stata (version 11.2 or later; StataCorp, College Station, Texas, USA). 
 
8 Investigator Obligations 
8.1 Guidelines for the Conduct of the Study 
The investigator is responsible for ensuring that the study is conducted in accordance with the 
clinical protocol and is in full compliance with FDA regulatory requirements.  The basic 
principles outlined in 21 CFR Parts 50, 54, 56 & 312, the ICH-Guidelines for Good Clinical 
Practice as published in the Federal Register on May 9, 1997 and the Declaration of Helsinki. 
The investigator is also responsible for protecting the rights, safety and welfare of patients 
under the investigator’s care.   
 
8.2 Informed Consent   
The investigator or designee will inform the participant of the nature, risks and purpose of the study.  
A written informed consent form will be provided to each participant describing this information.  
This form must be reviewed and approved by the Sponsor and the Institutional Review Board/Ethics 
Committee (IRB/EC) before its use in the study.  Each participant must sign and date this form prior 
to their participation in the study.  A signed original consent form for each participant will be kept on 
file at the clinical site.  A copy will also be given to the participant signing the form. 
 
For patients who are sedated and/or hemodynamically unstable, surrogate consent from a family 
member or legal representative will be required and may be obtained if permitted by the clinical 
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site’s policies and IRB/EC.  In such cases, the participant will be informed of their enrollment in this 
study when they have become fully alert: they will be told who gave surrogate consent for their 
participation and that they have the right to withdraw from the study. 
8.3 Confidentiality 
The Principal Investigator and designees, employees and agents involved with this study will 
comply with relevant state and federal laws relating to the confidentiality, privacy and 
security of participant’s health information.  They will only create, maintain, use or disclose 
any data that is generated by this study or other information disclosed to the Principal 
Investigator or their employees or agents during the course of the study to the Sponsor, 
IRB/EC, FDA or other authorised recipients as appropriate for the execution, analysis, review 
and reporting of this study.  Such information shall not be used for any other purposes and 
will remain confidential.   
 
8.4 Protocol Modification/Amendments 
If preliminary or interim review indicates that modification should be made in the experimental 
design, study parameters, participant selection, etc, these changes will be made after appropriate 
amendment(s) to this protocol with the mutual approval of the Sponsor and the investigator.  Any 
protocol change that may significantly affect the safety of study patients must also be submitted for 
review and approval by the IRB/EC and may also require FDA review and approval. 
 
8.5 Recording & Monitoring of Study Data 
All required study data will be recorded on the internet based the Case Report Forms (CRFs).  The 
data recorded on the CRFs is derived from study specific database currently used in the department.   
8.6 Direct Access to Source Data & Study Documents 
The investigator and study center will permit trial-related monitoring, audits, IRB/EC review 
and regulatory inspection by providing authorised personnel from the Sponsor, its 
representatives, the IRB/EC, other appropriate regulatory agency direct access to all trial 
related data. 
Direct access is the permission to examine, analyse, verify and reproduce any records, source 
documents or reports that are important to the evaluation of a clinical study.  Any party with 
direct access should take reasonable precautions to maintain the confidentiality of the study 
participants. 
8.7 Record Retention 
Case Report Forms, ICFs, original source documents, study records, and reports must be 






Patient Participation Leaflet 
 
 
PELICAN: PRE-ECLAMPSIA: CLINICAL 
APPLICATION OF PlGF 
Participation Information Leaflet 
1. Study Title 
Pre-Eclampsia: Clinical Application of PlGF 
2. Background 
You have been asked to take part in this study because you are being investigated 
for hypertensive disorders (high blood pressure) of pregnancy, or suspected ‘pre-
eclampsia’.  You will be having blood tests in hospital and we would like to add one 
extra test, to use for this study.  Please read the following information. Ask us if 
there is anything that is not clear. You do not have to take part.  
 What is the purpose of the study? 
A substance called Placental Growth Factor (PlGF) is produced by the placenta in 
normal pregnancy but the levels of PlGF are reduced in pre-eclampsia.  By carrying 
out this study, we are hoping to provide evidence that the test can be used to 
improve diagnosis of the disease. 
3. What will happen to me if I take part? 
You will be seen by a doctor or midwife, who will explain the study, answer questions 
and obtain your consent to take part.  There will be no change to your current 
treatment and the result will not be revealed to those caring for you.  Your blood 
sample will be tested for Placental Growth Factor (PlGF) and the findings will be used 
to help women in the future.   
What do I have to do? 
All you have to do is allow us to analyse an additional blood test, taken together with 
your necessary samples.  Later, the hospital team will collect information from your 
hospital notes about you and your baby’s birth.  This information will help us to work 
out the relationship between PlGF levels and pre-eclampsia. 
4. What are the other possible disadvantages and risks of taking part? 
There are no known side effects of taking part, as you will be having blood tests 




5. What are the potential benefits of taking part? 
None for you, but you may help future mothers at risk of pre-eclampsia. 
6. What if there is a problem? 
Any complaint about the research will be dealt with. Please speak to any of the 
researchers or midwives/doctors looking after you. If you remain unhappy and wish 
to complain formally, you can do this through the NHS complaints procedure. 
7. Will my taking part in the study be kept confidential? 
Yes. All the information about your participation in the study will be kept confidential. 
The data will be stored following NHS guidelines for 25 years.  Only the clinical 
research team and independent monitor will have access to this information. 
8. What will happen if I don’t want to carry on with the study? 
You are free to withdraw from the study at any time.  Just let one of the doctors or 
midwives looking after you know. 
9. What will happen to any samples I give? 
The PlGF test will be done using the blood sample. The sample may be stored 
afterwards, for at least 25 years.  Part of this sample will be stored in the USA.  The 
same sample may be used during this time, for future studies into the same disease. 
This will not require you to provide any further samples. 
10. What will happen to the results of the research study? 
The results of the study will be published in a medical journal. You will not be 
identified in any report/publication. 
11. Who has reviewed the study? 
This study was reviewed by the Proportionate Review Sub-Committee of the East 
London 3 
Research Ethics Committee. 
12. Who should I contact? 
If you are interested in taking part or would like further information, please contact: 
Dr Suzy Duckworth (Study Co-ordinator) 
Maternal and Fetal Research Unit 
St Thomas’ Hospital 
Telephone: 07976 951634 
 
 








First draft patient questionnaire in the development of obstetric PROMs 
        
         
 
Date of completion  
      
         Background Information 
       1 Age   
      
         
         2 Ethnicity 
























other   other   chinese 
   
     
other 
   





       
 
arab  
      
 
other   
      
         
         
3 
How many children have you 
had?   
      
 
4 
How many children (<18 years) live with 
you?   
      
227 
 
         
         5 Employment status: Working full-time 37 hours/week or more  
  
 






















         
         
6 





















   
  
Higher degree/professional   
   
         
         Medical History 
       
         7 Have you ever been told you had: High blood pressure  





    
  
Kidney disease   
    
  
Previous 
Preeclampsia   





    
  
Other, please state    
   
         
         8 How many weeks pregnant are you?  
      
         
228 
 
         9 How is your pregnancy being cared for? Please tick all that apply 
    
 
I am attending the ante-natal day unit   
      
 
I have been admitted to the antenatal ward   
      
 
I am under routine midwife-led care   
      
 
I am being seen by my GP   
      
 
I am being seen in a consultant-led 
antenatal clinic   
      
         
         Health in current pregnancy 
       
         
10 
Do you currently have a diagnosis of any of the 
following: 
      
 
Pre-eclampsia (high blood pressure and protein in urine)  
     
 
High blood pressure only 
 
  
     
 
Protein in urine only 
 
  










     
         
         11 During this pregnancy have you suffered from any of the following: 




















     
 
Hip or pelvic pain 
 
  










     
         
229 
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12 During this pregnancy have you experienced any of the following problems: 




















     
 
Hand and foot swelling 
 
  





     
         
         
13 
Compared with one month ago, how would you rate your current
health? 
     
 
Excellent, better than usual 
 
   




    
    
 
About the same as usual 
 
    
    
 
A little worse  
 
    




    
    
 
The worst I have ever felt 
 
    
    
         
         
14 
Compared with one month ago, how often have you felt 
unwell? 
      
 
Almost all of the time 
 
  
    
 
A lot of the time 
 
    
    
 
About half the time 
 
    
    
 
Less than half the time 
 
    




    




    
    
         




Please record how this pregnancy has affected the following aspects of your 
normal life. 
    a Ability to continue usual employment 
       
 
Not at all 
 
 
     
 
A little disruption 
 
  
     
 
Pregnancy has caused a lot of problems 
 
  
     
 
Most of the time 
 
  
     
 
I have had to stop working 
 
  
     
 
Not applicable/would rather not answer 
 
  
     
         
         b Relationship with partner 
       
 
Our relationship has not changed 
 
 
     
 
Our relationship is suffering 
 
  
     
 
Pregnancy has caused some problems 
 
  
     
 
Pregnancy has caused a lot of problems 
 
  
     
 
Pregnancy has ended my relationship 
 
  
     
 
Not applicable/would rather not answer 
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         c Relationship with family 
       
 
Our relationship has not changed 
 
 
     
 
Our relationship is suffering 
 
  
     
 
Pregnancy has caused some problems 
 
  
     
 
Pregnancy has caused a lot of problems 
 
  
     
 
Pregnancy has ended a relationship 
 
  
     
 
Not applicable/would rather not answer 
 
  
     
         
         d Relationship with existing children 
       
 
Our relationship has not changed 
 
 
     
 
Our relationship is suffering 
 
  
     
 
Pregnancy has caused some problems 
 
  
     
 
Pregnancy has caused a lot of problems 
 
  
     
 
Pregnancy has ended a relationship 
 
  
     
 
Not applicable/would rather not answer 
 
  
     
         
         e Ability to enjoy being pregnant 
       
 
No effect, I am enjoying pregnancy 
 
 
     
 
Enjoyment reduced slightly 
 
  
     
 
Enjoyment reduced moderately 
 
  
     
 
Enjoyment reduced greatly 
 
  
     
 
I am not enjoying this pregnancy 
 
  
     
 
I no longer want to be pregnant 
 
  
     
         
         f Ability to enjoy life 




No effect, I am enjoying life 
 
  
     
 
Enjoyment reduced slightly 
 
  
     
 
Enjoyment reduced moderately 
 
  
     
 
Enjoyment reduced greatly 
 
  
     
 
I am not enjoying my life currently 
 
  
     
 
I am feeling extremely unhappy 
 
  
     
         
         g Ability to manage finances 
       
 
No effect, I have no financial concerns 
 
 
     
 
Pregnancy has had a small impact 
 
  
     
 
Pregnancy has had a moderate impact 
 
  
     
 
Pregnancy has had a large impact 
 
  
     
 
I am very  worried about finances 
 
  
     
 
I feel I cannot afford this pregnancy 
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         h Ability to prepare for new baby 
       
 
No effect, I feel prepared 
 
 
     
 
I have found it a bit harder to prepare 
 
  
     
 
I have found it somewhat harder to prepare 
 
  
     
 
I have found it a lot harder to prepare 
 
  
     
 
I have not been able to prepare at all 
 
  
     
 
I feel completely unprepared 
 
  
     
         
         16 How has this pregnancy effected your mood 
       
         a I feel anxious....... 
       
 
None of the time 
 
 
     
 
Some of the time 
 
  
     
 
Half the time 
 
  
     
 
Most of the time 
 
  
     
 
All of the time 
 
  
     
 
I have anxiety attacks 
 
  
     
         
         b I feel sad........ 
       
 
None of the time 
 
 
     
 
Some of the time 
 
  
     
 
Half the time 
 
  
     
 
Most of the time 
 
  
     
 
All of the time 
 
  
     
 
I am depressed 
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c I have problems sleeping....... 
       
 
None of the time 
 
 
     
 
Some of the time 
 
  
     
 
Half the time 
 
  
     
 
Most of the time 
 
  
     
 
All of the time 
 
  
     
 
I never sleep well 
 
  
     
         
         d I feel tearful....... 
       
 
None of the time 
 
 
     
 
Some of the time 
 
  
     
 
Half the time 
 
  
     
 
Most of the time 
 
  
     
 
All of the time 
 
  
     
 
I cry every day 
 
  
     
         
         e I take medication for low mood..... 

























     
 
When I'm not pregnant 
 
  
     
         
         f I use alcohol/other substances to improve mood...... 



























     
 
When I'm not pregnant 
 
  
     
         
         g I would describe my diet as........ 
       
 
Better than usual 
 
 















     
 
Worse than usual 
 
  





     
         
         
h 
Has being seen at hospital improved your 
anxiety? 





     
 
Not at all 
 
  
     
 
Improved a little 
 
  










     
 
I feel much better now 
 
  
     
         
         i My understanding of pre-eclampsia is....... 





     
 
A bit better 
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         j This pregnancy has made me less likely to want another 
      
 
Not at all 
 
 
     
 
Agree a little bit 
 
  










     
 
Not for a long time 
 
  
     
 
I will never do it again 
 
  
     
         
         
 
Any comments 
       
          
*Appendix 2 
 Questions Included in Likert Scale 
Questions Included in Likert Scale 
How has this pregnancy affected your ability to continue usual employment? 
Not at all  
A little disruption  
Pregnancy has caused a lot of problems 
Unable to work most of the time 
I have had to stop working 
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Not applicable/would rather not answer 
I feel anxious... 
None of the time 
Some of the time 
Half of the time 
Most of the time 
All of the time 
I have anxiety attacks 
I have problems sleeping... 
None of the time 
Some of the time 
Half of the time 
Most of the time 
I never sleep well 
How has this pregnancy affected your ability to enjoy life? 
No effect, I am enjoying life 
Enjoyment reduced slightly 
Enjoyment reduced moderately 
Enjoyment reduced greatly 
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I am not enjoying my life currently 
I am feeling extremely unhappy 
This pregnancy has made me less likely to want another... 
Not at all 
Agree a little bit 
Somewhat agree 
Definitely agree 
Not for a long time 
I will never do it again 
 
 
